Tricyclic compound

ABSTRACT

A novel compound represented by the formula (1):  
                 
 
[R 1  represents hydrogen atom, chlorine atom, or hydroxyl group; X 1  . . . X 2  represents —CH(R 2 )—CH(R 3 )—, —CH(R 2 )—CH(R 3 )—CH(R 4 )—, etc.; R 2 to R 4 represent hydrogen atom, or an alkyl group; A 1 , A 11 , A 2 , and A 21  represent hydrogen atom, or an alkyl group; Y represents —CH(A 3 )-, —CH(A 3 )-C(A 4 )(A 41 )-, —CH(A 3 )-C(A 4 )(A 41 )-C(A 5 )(A 51 )-, or a single bond; A 3 , A 4 , A 41 , A 5 , and A 51  represent hydrogen atom, or an alkyl group; Z represents hydroxyl group, or —N(A 6 )(A 61 ); A 6  represents hydrogen atom, or an alkyl group, A 61  represents hydrogen atom, an alkyl group, an aralkyl group, etc.; and groups in each of one or more combinations selected from the group consisting of combinations of A 6  and A 3 , A 6  and A 4 , A 6  and A 1 , A 6  and A 2 , A 2  and A 3 , A 2  and A 4 , A 6  and A 5 , A 3  and A 1 , and A 5  and A 1  may bind to each other to form a 5- or 6-membered ring], or a salt thereof, which potently inhibits the phosphorylation of myosin regulatory light chain.

TECHNICAL FIELD

The present invention relates to a novel tricyclic compound or a saltthereof, and a medicament comprising said tricyclic compound or a saltthereof as an active ingredient.

BACKGROUND ART

Movements of cells include contraction, migration, release, aggregationand the like, and phosphorylation of the myosin regulatory light chainis important for these cell movements. The myosin regulatory light chainis a subunit having a molecular weight of 20 kDa and constitutingmyosin, which exists in smooth muscle cells and various non-muscle cellssuch as neutrophils, leukocytes, platelets and nerve cells ofwarm-blooded animals (Barany, K., et al., Biochemistry of Smooth MuscleContraction, pp. 21-35, 1996). Myosin existing in smooth muscle cellsand various non-muscle cells such as neutrophils, leukocytes, plateletsand nerve cells of warm-blooded animals is constituted by a myosin heavychain subunit having a molecular weight of about 200 kDa, the myosinregulatory light chain subunit having a molecular weight of about 20kDa, and a myosin constitutive light chain subunit having a molecularweight of about 17 kDa. The myosin regulatory light chain is mainlyphosphorylated by the myosin light chain kinase to increase the activityof myosin ATPase existing in the myosin heavy chain subunit (Barany, M.,et al., Biochemistry of Smooth Muscle Contraction, pp. 321-339, 1996).It is known that the activated myosin having the increased ATPaseactivity becomes possible to interact with actin and activates movementapparatuses of cytoskeleton to activate cell movements. That is, it isknown that activation of myosin relates to cell contraction (Kamm, K.,et al., Annu. Rev. Physiol., 51, pp. 299-313, 1989). It is also knownthat activation of myosin relates to change of cell morphology (Schmidt,J. T. et al., J, Neurobiol., 52 (3), pp. 175-188, 2002). It is knownthat activation of myosin relates to cell migration (Niggli, V., FEBSLett., 445, pp. 69-72, 1999). Further, it is known that activation ofmyosin relates to cell release (Kitani, S., et al., Biochem. Biophys.Res. Commun., 183, pp. 48-54, 1992). It is further known that activationof myosin relates to cell aggregation (Itoh, K., et al., Biochim.Biophys. Acta., 1136, pp. 52-56, 1992). It is also known that activationof myosin relates to cell apoptosis (Mills, J. C. et al., J. Cell Biol.,Vol. 140, No. 3, pp. 627-636, 1998). Based on these findings, it isconsidered that an agent which inhibits the phosphorylation of themyosin regulatory light chain suppresses cell contraction, regulateschange of cell morphology, suppresses cell migration, suppresses cellrelease, suppresses cell aggregation and suppresses cell apoptosis.

Cell contraction is deeply involved in diseases relating to contractionof various smooth muscle layers. Examples of such diseases include, forexample, hypertension (Samlyo, A. P., et al., Rev. Physiol. Biochem.Pharmacol., Vol. 134, pp. 209-34, 1999), angina pectoris (Shimokawa etal., Cardiovasc. Res., Vol. 43, No. 4, pp. 1029-39, 1999; Satoh, H., etal., Jpn. J. Pharmacol., 79 (suppl.), p. 211, 1999), cerebral vascularspasm (M. Satoh et al., the 57th General Meeting of Japan NeurosurgicalSociety, Collection of Abstracts, 153, 1998; N. Ono et al., Pharmacol.Ther., Vol. 82, No. 2-3, pp. 123-31, 1991; Shimokawa et al., Cardiovasc.Res., Vol. 43, No. 4, pp. 1029-39, 1999), erectile dysfunction(Andersson, K E. et al., World J. Vrol., 15, pp. 14-20, 1997), bronchialasthma (K. Iidzuka, Allergy, 47, 943, 1998; K. Iidzuka et al., Jpn. J.Respirology Society, 37, 196, 1999) and the like.

Change of cell morphology is deeply involved in diseases relating tomorphological change of various cells. Examples of the diseases relatingto change of cell morphology include, for example, various nervedysfunctions as those relating to nerve cells. As the nervedysfunctions, for example, neural damages caused by trauma,neurodegenerative diseases such as Alzheimer's disease, Parkinson'sdisease, diabetic retinopathy, glaucoma and the like can be exemplified(Arakawa, Y., et al., BIO Clinica, 17 (13), pp. 26-28, 2002). Further,cell migration is deeply involved in diseases relating to migration ofvarious cells. Examples of such diseases include, for example, cancerinvasion and metastasis (Itoh, K. et al., Nat. Med., Vol. 5, No. 2, pp.221-5, 1999; Keely, P. et al., Trends Cell Biol., Vol. 8, No. 3, pp.101-6, 1998), nephritis (Fujimoto, O. et al., Journal of JapaneseSociety of Internal Medicine, 88 (1), pp. 148-58, 1998) and the like.

Furthermore, it is considered that cell release is deeply involved invarious allergies and the like (Keane-Myers A. et al., Curr. AllergyAsthma Rep., 1(6):550-557, 2001), and further, cell aggregation isconsidered to be deeply involved in thrombosis and the like (Nakai, K.et al., Blood, Vol. 90, No. 10, pp. 3736-42., 1997). Further, it isknown that cell apoptosis is involved in neurodegenerative diseases suchas Alzheimer's disease, Parkinson's disease and glaucoma, viraldiseases, hepatic diseases and the like (Thompson, C. B., Science, Vol.267, pp. 1456-1462, 1995).

Based on these findings, it is considered that the inhibitor of thephosphorylation of myosin regulatory light chain of the presentinvention, which is an agent inhibiting the phosphorylation of themyosin regulatory light chain, is useful as an active ingredient of amedicament for prophylactic and/or therapeutic treatment of a diseaserelating to cell contraction, disease relating to change of cellmorphology, disease relating to cell migration, disease relating to cellrelease, disease relating to cell aggregation, and/or disease relatingto cell apoptosis.

It has been reported that 1-(5-isoquinolinesulfonyl)-2-methylpiperazine(H-7), which is an isoquinoline derivative, inhibits phosphorylation ofthe myosin regulatory light chain of mesenteric artery (Suzuki, A. etal., Br. J. Pharmacol., 109, pp. 703-712, 1993), iris smooth muscle(Howe, P. H. et al., Biochem J., 255, pp. 423-429, 1988), and astrocyte(Mobley P.L., et al., Exp. Cell Res., 214, pp. 55-66, 1994).

DISCLOSURE OF THE INVENTION

Conventionally, it has been desired to provide a novel compound havingan action of strongly inhibiting the phosphorylation of myosinregulatory light chain. The inventors of the present inventionsynthesized various novel compounds and studied pharmacological actionsthereof. As a result, it was found that the compounds represented by thefollowing formula (1) and salts thereof had the desired pharmacologicalaction, and were useful as an active ingredient of a medicament forprophylactic and/or therapeutic treatment of diseases relating to cellcontraction, those relating to change of cell morphology, those relatingto cell migration, those relating to cell release, those relating tocell aggregation, and those relating to cell apoptosis. The presentinvention was achieved on the basis of these findings.

The present invention thus provides a compound represented by thefollowing formula (1) or a salt thereof:

wherein R¹ represents hydrogen atom, chlorine atom, or hydroxyl group;

X¹ . . . X² represents —CH(R²)—CH(R³)—, —CH(R²)—CH(R³)—CH(R⁴)—,—C(R²)═C(R³)—, or —C(R²)═C(R³)—CH(R⁴)—;

R², R³, and R⁴ independently represent hydrogen atom, or an alkyl group;

A¹, A¹¹, A², and A²¹ independently represent hydrogen atom, or an alkylgroup;

Y represents —CH(A³)-, —CH(A³)-C(A⁴)(A⁴¹)-,—CH(A³)-C(A⁴)(A⁴¹)-C(A⁵)(A⁵¹)-, or a single bond;

A³, A⁴, A⁴¹, A⁵, and A⁵¹ independently represent hydrogen atom, or analkyl group;

Z represents hydroxyl group, or —N(A⁶)(A⁶¹);

A⁶ represents hydrogen atom, or an alkyl group, A⁶¹ represents hydrogenatom, an alkyl group, an aralkyl group, an alkyl group substituted withcarboxyl group, an alkyl group substituted with cyano group, an alkylgroup substituted with hydroxyl group, an alkyl group substituted withan alkoxyl group, an alkyl group substituted with an amino group, analkyl group substituted with aminocarbonyl group, or an alkyl group ofwhich end is substituted with N(A⁷)(—X³-A⁷¹), where —X³— representscarbonyl group, A⁷ represents hydrogen atom, or an alkyl group, and A⁷¹represents an alkyl group, an aralkyl group, or an aryl group, or A⁷ andA⁷¹ may combine together to form an alkylene group, or an alkylene groupsubstituted with an alkyl group to form a ring; and

groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ may bindto each other to form a 5- or 6-membered ring.

From another aspect, the present invention provides a medicamentcontaining a compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient. Theaforementioned medicament has an inhibitory action on phosphorylation ofmyosin regulatory light chain, and is useful as a medicament forprophylactic and/or therapeutic treatment of, for example, a diseaserelating to cell contraction, disease relating to change of cellmorphology, disease relating to cell migration, disease relating to cellrelease, disease relating to cell aggregation, and/or disease relatingto cell apoptosis, and the like.

More specifically, there are provided a medicament for decreasingphosphorylation amount of myosin regulatory light chain in a cell, whichcomprises a compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having a cell contraction inhibitory action, which comprisesa compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having an action to regulate change of cell morphology, whichcomprises a compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having a cell migration inhibitory action, which comprises acompound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having a cell release inhibitory action, which comprises acompound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having a cell aggregation inhibitory action, which comprisesa compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, amedicament having a cell apoptosis inhibitory action, which comprises acompound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient, and amedicament for inhibiting the Rho/Rho kinase pathway, which comprises acompound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof as an active ingredient.

The present invention also provides an inhibitor of the phosphorylationof myosin regulatory light chain containing a compound represented bythe aforementioned formula (1) or a physiologically acceptable saltthereof, and an inhibitor of the Rho/Rho kinase pathway comprising acompound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof.

From another aspect, the present invention provides use of a compoundrepresented by the aforementioned formula (1) or a physiologicallyacceptable salt thereof for manufacture of the aforementionedmedicaments. The present invention also provides a method forprophylactic and/or therapeutic treatment of a disease relating to cellcontraction, disease relating to change of cell morphology, diseaserelating to cell migration, disease relating to cell release, diseaserelating to cell aggregation, and/or disease relating to cell apoptosisand the like, which comprises the step of administrating aprophylactically and/or therapeutically effective amount of a compoundrepresented by the aforementioned formula (1) or a physiologicallyacceptable salt thereof to a mammal including human, a method fordecreasing phosphorylation amount of myosin regulatory light chain in acell, which comprises the step of administrating an effective amount ofa compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof to a mammal including human, amethod for inhibiting cell contraction, which comprises the step ofadministrating an effective amount of a compound represented by theaforementioned formula (1) or a physiologically acceptable salt thereofto a mammal including human, a method for regulating change of cellmorphology, which comprises the step of administrating an effectiveamount of a compound represented by the aforementioned formula (1) or aphysiologically acceptable salt thereof to a mammal including human, amethod for inhibiting cell migration, which comprises the step ofadministrating an effective amount of a compound represented by theaforementioned formula (1) or a physiologically acceptable salt thereofto a mammal including human, a method for inhibiting cell release, whichcomprises the step of administrating an effective amount of a compoundrepresented by the aforementioned formula (1) or a physiologicallyacceptable salt thereof to a mammal including human, a method forinhibiting cell aggregation, which comprises the step of administratingan effective amount of a compound represented by the aforementionedformula (1) or a physiologically acceptable salt thereof to a mammalincluding human, a method for inhibiting cell apoptosis, which comprisesthe step of administrating an effective amount of a compound representedby the aforementioned formula (1) or a physiologically acceptable saltthereof to a mammal including human, and a method for inhibiting theRho/Rho kinase pathway, which comprises the step of administrating aneffective amount of a compound represented by the aforementioned formula(1) or a physiologically acceptable salt thereof to a mammal includinghuman.

BEST MODE FOR CARRYING OUT THE INVENTION

The alkyl group mentioned in this specification may be a linear orbranched alkyl group, and for example, a lower alkyl group is preferred.The lower alkyl group include linear or branched alkyl groups having 1to 6 carbon atoms, and specific examples are, for example, methyl group,ethyl group, propyl group, isopropyl group, butyl group, secondary butylgroup, tertiary butyl group, pentyl group, 2-methylbutyl group, hexylgroup, and the like. As the lower alkyl group in R², R³, R⁴, A¹, A¹¹,A², A²¹, A³, A⁴, A⁴¹, A⁵, A⁵¹, A⁶, and A⁶¹, methyl group, or ethyl groupis independently preferred.

Examples of R¹ include hydrogen atom, chlorine atom, and hydroxyl group.Preferred examples of R¹ are hydrogen atom, and hydroxyl group. It ispreferable to choose these two as R¹, and it is also preferable tochoose each of hydrogen atom and hydroxyl group.

Examples of —X¹ . . . X²— include —CH(R²)—CH(R³)—,—CH(R²)—CH(R³)—CH(R⁴)—, —C(R²)═C(R³)—, and —C(R²)═C(R³)—CH(R⁴)—. As —X¹. . . X²—, —CH(R²)—CH(R³)—, —CH(R²)—CH(R³)—CH(R⁴)—, or —C(R²)═C(R³)— ispreferred, —CH(R²)—CH(R³)—, or —C(R²)═C(R³)— is particularly preferred.R², R³, and R⁴ may be the same or different, and they are preferablyrepresent hydrogen atom, or a lower alkyl group, more preferablyhydrogen atom, or methyl group. It is particularly preferred that all ofthese substituents are hydrogen atoms, and it is also preferred that anarbitrary one of these substituents is methyl group, and all of theremaining substituents are hydrogen atoms. Preferred example of—CH(R²)—CH(R³)— include —CH₂—CH₂—, —CH(CH₃)—CH₂—, and —CH₂—CH(CH₃)—, andpreferred examples of —C(R²)═C(R³)— include —CH═CH—, —C(CH₃)═CH—, and—CH═C(CH₃)—.

A¹, A¹¹, A², and A²¹ may be the same or different, and they preferablyrepresent hydrogen atom, or a lower alkyl group, more preferablyhydrogen atom, or methyl group. It is particularly preferred that all ofthese substituents are hydrogen atoms, and it is also preferred that anarbitrary one of these substituents is methyl group, and all of theremaining substituents are hydrogen atoms.

Y represents —CH(A³)-, —CH(A⁴)-C(A⁴)(A⁴¹)-,—CH(A³)-C(A⁴)(A⁴¹)-C(A⁵)(A⁵¹)-, or a single bond, and as for—CH(A³)-C(A⁴)(A⁴¹)-, and —CH(A³)-C(A⁴)(A⁴¹)-C(A⁵)(A⁵¹)-, —CH(A³)-bindsto N (nitrogen atom) bonding to X². As Y, —CH(A³)-, —CH(A³)-C(A⁴)(A⁴¹)-,or a single bond is preferred.

A³ preferably represents hydrogen atom, or a lower alkyl group, and amore preferred example is hydrogen atom. A³ is also preferably a loweralkyl group, and particularly preferred examples are methyl group, andethyl group.

It is preferred that A⁴ and A⁴¹ independently represent hydrogen atom,or a lower alkyl group, and it is preferred that, for example, both ofthem represent hydrogen atom. It is also preferred that either one of A⁴and A⁴¹ is hydrogen atom, and the other is a lower alkyl group. Further,it is also preferred that A⁴ and A⁴¹ are lower alkyl groups, which maybe the same or different. Preferred examples of the lower alkyl group asA⁴ or A⁴¹ are methyl group, and ethyl group.

It is preferred that A⁵ and A⁵¹ independently represent hydrogen atom,or a lower alkyl group, and it is preferred that, for example, both ofthem are hydrogen atoms. It is also preferred that either one of A⁵ andA⁵¹ is hydrogen atom, and the other is a lower alkyl group. Further, itis also preferred that A⁵ and A⁵¹ are lower alkyl groups, which may bethe same or different. Preferred examples of the lower alkyl group as A⁵or A⁵¹ are methyl group, and ethyl group.

Z represents hydroxyl group, or N(A⁶)(A⁶¹). Z is preferably hydroxylgroup. It is also preferred that Z is N(A⁶)(A⁶¹). In such a compound, A⁶is hydrogen atom or an alkyl group, preferably hydrogen atom, or a loweralkyl group, most preferably hydrogen atom, or methyl group. It is alsopreferred that, for example, A⁶ represents either one of them, or acombination of two of them.

As A⁶¹, hydrogen atom, an alkyl group, an aralkyl group, an alkyl groupsubstituted with carboxyl group, an alkyl group substituted with cyanogroup, an alkyl group substituted with hydroxyl group, an alkyl groupsubstituted with an alkoxyl group, an alkyl group substituted with anamino group, and an alkyl group substituted with aminocarbonyl group arepreferred. Alternatively, A⁶¹ is preferably an alkyl group of which endis substituted with N(A⁷)(—X³-A⁷¹). —X³— represents carbonyl group. A⁷preferably represents hydrogen atom, or an alkyl group. A⁷ is preferablyhydrogen atom. Further, it is also preferred that A⁷ is an alkyl group.Examples of this alkyl group include lower alkyl groups, and methylgroup is especially preferred. A⁷¹ preferably represents an alkyl group,an aralkyl group, or an aryl group. Among then, an alkyl group ispreferred as A⁷¹, and more preferred examples of this alkyl groupinclude lower alkyl groups. More preferred examples include methylgroup, ethyl group, propyl group, isopropyl group, and tert-butyl group,and A⁷¹ is most preferably methyl group among these. Furthermore, it isalso preferred that A⁷ and A⁷¹ combine together to form an alkylenegroup, or an alkylene group substituted with an alkyl group to form aring together with N to which A⁷ and A⁷¹ bind and —X³—. When A⁷ and A⁷¹combine together to become an alkylene group substituted with an alkylgroup to form a ring, the alkyl group is preferably a lower alkyl group.Examples of the lower alkyl group include methyl group and ethyl group,and a more preferred example is methyl group. Further, the ring formedby A⁷ and A⁷¹ is preferably a 4- to 7-membered ring, and preferredexamples include, in particular, 4-, 5-, and 6-membered rings.

Preferred examples of N(A⁷)(—X³-A⁷¹) mentioned above include acetylaminogroup, propionylamino group, butyrylamino group, isobutylylamino group,pivaloylamino group, (N-acetyl-N-methyl)amino group,(N-acetyl-N-ethyl)amino group, (N-propionyl-N-methyl)amino group,(N-propionyl-N-ethyl)amino group, (N-butyryl-N-methyl)amino group,(N-butyryl-N-ethyl)amino group, (N-isobutyryl-N-methyl)amino group,(N-isobutyryl-N-ethyl)amino group, (N-pivaloyl-N-methyl)amino group, and(N-pivaloyl-N-ethyl)amino group, and more preferred examples include, inparticular, acetylamino group, and (N-acetyl-N-methyl)amino group. Morepreferred examples further include propionylamino group, and(N-propionyl-N-methyl)amino group. More preferred examples still furtherinclude butyrylamino group, isobutyrylamino group, and pivaloylaminogroup. Furthermore, N(A⁷)(—X³-A⁷¹) is also preferably 2-oxo-1-azetidylgroup, 2-oxo-1-pyrrolidyl group, 2-oxo-1-piperidyl group, or2-oxo-1-azepanyl group, and more preferred examples are, in particular,2-oxo-1-azetidyl group, 2-oxo-1-pyrrolidyl group, and 2-oxo-1-piperidylgroup. Further, examples of A⁶¹ include hydrogen atom, a lower alkylgroup, an aralkyl group, a lower alkyl group substituted with carboxylgroup, a lower alkyl group substituted with aminocarbonyl group, a loweralkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, and a lower alkyl group substituted with an aminogroup, and preferred examples include an alkyl group of which end issubstituted with N(A⁷)(—X³-A⁷¹).

A⁶¹ is preferably hydrogen atom.

Further, A⁶¹ is also preferably a lower alkyl group, and this loweralkyl group is most preferably methyl group, or ethyl group. It is alsopreferred that, for example, A⁶ represents either one of them, or acombination of two of them.

A⁶¹ is also preferably an aralkyl group. Examples of the aralkyl groupherein referred to include benzyl group, and 2-phenylethyl group, and aparticularly preferred example is benzyl group. These groups may besubstituted with a lower alkyl group, or a halogen atom. Preferredexamples of this lower alkyl group include methyl group, and ethylgroup, and examples of the halogen atom include fluorine atom, chlorineatom, and bromine atom. As for the number of these substituents, thelower alkyl group and the halogen atom, the aryl ring preferably has oneor two of these substituents. When the aryl ring is substituted with twoor more substituents, these substituents are independently chosen, andeither a halogen atom, or a lower alkyl group may be chosen.

As A⁶¹, a lower alkyl group substituted with carboxyl group is alsopreferred. In this compound, the lower alkyl group may be substitutedwith one or more carboxyl groups, and a lower alkyl group substitutedwith one of carboxyl group is usually preferred. Preferred examplesinclude carboxymethyl group, 2-carboxyethyl group, 3-carboxypropylgroup, and 4-carboxybutyl group. In particular, carboxymethyl group and2-carboxyethyl group are preferred. Preferred examples also includeeither one of or a combination of any two of the aforementioned groups.

As A⁶¹, a lower alkyl group substituted with cyano group is alsopreferred. In this compound, the lower alkyl group may be substitutedwith one or more cyano groups. A lower alkyl group substituted with oneof cyano group is generally preferred, and preferred examples includecyanomethyl group, 2-cyanoethyl group, 3-cyanopropyl group, and4-cyanobutyl group.

As A⁶¹, a lower alkyl group substituted with hydroxyl group is alsopreferred. In this compound, the lower alkyl group may be substitutedwith one or more hydroxyl groups. A lower alkyl group substituted withone of hydroxyl group is generally preferred, and preferred examplesinclude 2-hydroxyethyl group, 3-hydroxypropyl group, and 4-hydroxybutylgroup. In particular, 2-hydroxyethyl group, and 3-hydroxypropyl groupare preferred. Preferred examples also include either one of or acombination of any two of these groups.

As A⁶¹, a lower alkyl group substituted with a lower alkoxyl group isalso preferred. The lower alkoxyl group include linear or branchedalkoxyl groups having 1 to 4 carbon atoms, and specific examplesinclude, for example, methoxy group, ethoxy group, propoxy group,isopropoxy group, and the like. Methoxy group and ethoxy group arepreferred. The lower alkyl group may be substituted with one or morelower alkoxyl groups. A lower alkyl group substituted with one of loweralkoxyl group is generally preferred, and preferred examples include2-methoxyethyl group, 3-methoxypropyl group, 2-ethoxyethyl group,3-ethoxypropyl group, and 4-methoxybutyl group. In particular,2-methoxyethyl group and 3-methoxypropyl group are preferred. Preferredexamples also include either one of or a combination of any two of thesegroups.

As A⁶¹, a lower alkyl group substituted with an amino group is alsopreferred. The amino group includes a monoalkyl amino group having oneof lower alkyl group as a substituent, and a dialkylamino group havingtwo of lower alkyl group as substituents. As for the dialkylamino group,the alkyl groups may be the same or different. Although the lower alkylgroup may be substituted with one or more amino groups, a lower alkylgroup substituted with one of amino group is usually preferred, andpreferred examples include, for example, 2-aminoethyl group,2-(methylamino)ethyl group, 2-(dimethylamino)ethyl group, 3-aminopropylgroup, 3-(methylamino)propyl group, 3-(dimethylamino)propyl group,4-aminobutyl group, 4-(methylamino)butyl group, and4-(dimethylamino)butyl. In particular, 2-aminoethyl group,2-(methylamino)ethyl group, 2-(dimethylamino)ethyl group, 3-aminopropylgroup, 3-(methylamino)propyl group, and 3-(dimethylamino)propyl groupare preferred.

As A⁶¹, a lower alkyl group substituted with aminocarbonyl group is alsopreferred. The lower alkyl group may be substituted with one or moreaminocarbonyl groups. A lower alkyl group substituted with one ofaminocarbonyl group is generally preferred, and preferred examplesinclude, for example, aminocarbonylmethyl group and aminocarbonylethylgroup. Preferred examples also include either one of or a combination ofany two of these groups.

Further, as A⁶¹, a lower alkyl group of which end is substituted withN(A⁷)(—X³-A⁷¹) is also preferred. —X³—, A⁷¹, and A⁷ have the samemeanings as defined above. As for substitution with N(A⁷)(—X³-A⁷¹), A⁶¹may be substituted with one or more N(A⁷)(—X³-A⁷¹). A⁶¹ substituted withone of N(A⁷)(—X³-A⁷¹) is usually preferred. Examples of the “alkyl groupof which end is substituted with N(A⁷)(—X³-A⁷¹)” include, for example,2-(acetylamino)ethyl group, 2-(propionylamino)ethyl group,2-(butyrylamino)ethyl group, 2-(isobutyrylamino)ethyl group,2-(pivaloylamino)ethyl group, 2-[(N-acetyl-N-methyl)amino]ethyl group,2-[(N-acetyl-N-ethyl)amino]ethyl group,2-[(N-propionyl-N-methyl)amino]ethyl group,2-[(N-propionyl-N-ethyl)amino]ethyl group,2-[(N-butyryl-N-methyl)amino]ethyl group,2-[(N-butyryl-N-ethyl)amino]ethyl group,2-[(N-isobutyryl-N-methyl)amino]ethyl group,2-[(N-isobutyryl-N-ethyl)amino]ethyl group,2-[(N-pivaloyl-N-methyl)amino]ethyl group,2-[(N-pivaloyl-N-ethyl)amino]ethyl group, 3-(acetylamino)propyl group,3-(propionylamino)propyl group, 3-(butyrylamino) propyl group,3-(isobutyrylamino)propyl group, 3-(pivaloylamino)propyl group,3-[(N-acetyl-N-methyl)amino]propyl group,3-[(N-acetyl-N-ethyl)amino]propyl group,3-[(N-propionyl-N-methyl)amino]propyl group,3-[(N-propionyl-N-ethyl)amino]propyl group,3-[(N-butyryl-N-methyl)amino]propyl group,3-[(N-butyryl-N-ethyl)amino]propyl group,3-[(N-isobutyryl-N-methyl)amino]propyl group,3-[(N-isobutyryl-N-ethyl)amino]propyl group,3-[(N-pivaloyl-N-methyl)amino]propyl group, and3-[(N-pivaloyl-N-ethyl)amino]propyl group, and preferred examplesinclude, in particular, 2-(acetylamino)ethyl group,3-(acetylamino)propyl group, 2-[(N-acetyl-N-methyl)amino]ethyl group,and 3-[(N-acetyl-N-methyl)amino]propyl group. Further, specific examplesof the “alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹)”where A⁷ and A⁷¹ combine together to become an alkylene group, or analkylene group substituted with an alkyl group to form a ring include2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 2-(2-oxo-1-azepanyl)ethyl group,3-(2-oxo-1-azetidyl)propyl group, 3-(2-oxo-1-pyrrolidyl)propyl group,3-(2-oxo-1-piperidyl)propyl group, and 3-(2-oxo-1-azepanyl)propyl, andpreferred examples include, in particular, 2-(2-oxo-1-azetidyl)ethylgroup, 2-(2-oxo-1-pyrrolidyl)ethyl group, 2-(2-oxo-1-piperidyl)ethylgroup, 3-(2-oxo-1-azetidyl)propyl group, 3-(2-oxo-1-pyrrolidyl)propylgroup, and 3-(2-oxo-1-piperidyl)propyl group.

In the present invention, groups in each of one or more combinationsselected from the group consisting of combinations of A⁶ and A³, A⁶ andA⁴, A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹,and A⁵ and A¹ may bind to each other to form a 5- or 6-membered ring,and a 6-membered ring is particularly preferred. In this compound, it isparticularly preferred that one 5- or 6-membered ring is formed with oneof the aforementioned combinations. The ring is preferably consists ofcarbon atoms except for the N atom to which A³ binds. When a ring isformed with A⁶ and A¹, A⁶ and A², or A⁶ and A³, or a ring is formed withA² and A³, A¹¹ and A²¹ are preferably hydrogen atoms, and the ring ismost preferably a saturated ring.

Further, when Y is a single bond, and Z is —N(A⁶)(A⁶¹), it is preferredthat, for example, the groups of A⁶ and A¹ bind to each other to form a5- or 6-membered ring.

Moreover, when Y is —CH(A³)-, and Z is —N(A⁶)(A⁶¹), it is preferredthat, for example, the groups of A⁶ and A³ bind to each other to form a6-membered ring.

Furthermore, when Y is —CH(A³)-C(A⁴)(A⁴¹), and Z is —N(A⁶)(A⁶¹), it ispreferred that, for example, the groups of A² and A³ bind to each otherto form a 6-membered ring.

Specifically, examples of the structure represented by the formula (2):

[the bond on the left of Y binds to N (nitrogen atom) bonding to X²],which is a partial structure in the formula (1), wherein a ring isformed with the aforementioned combinations, include the followingsstructures containing a 5- or 6-membered ring, i.e., groups representedby the formula, (2-1), formula (2-2), formula (2-3), formula (2-4-t),formula (2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), andformula (2-6-c):

wherein A⁶ represents hydrogen atom, or an alkyl group, A⁶¹ representshydrogen atom, an alkyl group, an aralkyl group, an alkyl groupsubstituted with carboxyl group, an alkyl group substituted withaminocarbonyl group, an alkyl group substituted with cyano group, analkyl group substituted with hydroxyl group, an alkyl group substitutedwith an alkoxyl group, an alkyl group substituted with an amino group,or an alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe leftmost single bond in each group binds to N (nitrogen atom)bonding to X² in the formula (1). In the groups of these formulas, thebonds in the cyclohexane ring are in the trans-conformation in thegroups represented by the formula (2-4-t), formula (2-5-t), and formula(2-6-t), or cis-conformation in the groups represented by the formula(2-4-c), formula (2-5-c), and formula (2-6-c).

Among them, the groups represented by the formula (2-1), formula (2-2),formula (2-4-t), and formula (2-4-c) are preferred, and the groupsrepresented by the formula (2-1), formula (2-2), and formula (2-4-t) areparticularly preferred. Preferred examples also include either one of ora combination of any two of these groups. Preferred examples of A⁶ andA⁶¹ are as mentioned above.

Preferred examples of the compounds represented by the formula (1) arementioned below.

Compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,and X¹ . . . X² is ethylene group, or 1,3-propylene group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, and X¹ . . .X² is ethylene group, or 1,3-propylene group;

compounds wherein R¹ is hydrogen atom, and X¹ . . . X² is ethylenegroup, or 1,3-propylene group;

compounds wherein R¹ is hydroxyl group, and X¹ . . . X² is ethylenegroup, or 1,3-propylene group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,and X¹ . . . X² is ethylene group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, and X¹ . . .X² is ethylene group;

compounds wherein R¹ is hydrogen atom, and X¹ . . . X² is ethylenegroup;

compounds wherein R¹ is hydroxyl group, and X¹ . . . X² is ethylenegroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, and A⁶ ishydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, and A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, and A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and A⁶ is hydrogen atom, or a lower alkylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, and A⁶ ishydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, and A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, and A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, and A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ ishydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is an aralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isan aralkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is an aralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is an aralkylgroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is anaralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is an aralkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is an aralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is an aralkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with carboxyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with carboxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with carboxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with carboxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with carboxyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with carboxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withcarboxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withcarboxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with cyano group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with cyano group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with cyano group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with cyano group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with cyano group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with cyano group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with cyanogroup;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withcyano group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with hydroxyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with hydroxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with hydroxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with hydroxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with hydroxyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with hydroxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withhydroxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withhydroxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with a lower alkoxylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with a lower alkoxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with a lower alkoxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with a lower alkoxyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with a lower alkoxyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with alower alkoxyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with alower alkoxyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with an amino group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with an amino group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with an amino group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with an amino group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with an amino group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with an amino group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with anamino group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with anamino group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group of which end is substituted withN(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupof which end is substituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group ofwhich end is substituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group of which end issubstituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group of which end issubstituted with N(A⁷)(—X³-A⁷¹);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with a loweralkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with a lower alkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with a lower alkylcarbonylamino group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with a lower alkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with a lower alkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with a lower alkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with alower alkylcarbonylamino group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted with alower alkylcarbonylamino group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, A⁶ is hydrogenatom, and A⁶¹ is a lower alkyl group substituted with aminocarbonylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ isa lower alkyl group substituted with aminocarbonyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with aminocarbonyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, A⁶ is hydrogen atom, and A⁶¹ is a loweralkyl group substituted with aminocarbonyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl groupsubstituted with aminocarbonyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withaminocarbonyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is a lower alkyl group substituted withaminocarbonyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is 1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² is1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is 1,3-propylenegroup, and Y is —CH(A³)-;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is 1,3-propylenegroup, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, and Y is—CH(A³)-;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and Y is —CH(A³)-;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is 1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² is1,3-propylene group, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is 1,3-propylenegroup, and Y is —CH(A³)-;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is 1,3-propylenegroup, and Y is —CH(A³)-;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, or 1,3-propylene group, and Y ismethylene group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, or 1,3-propylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, or1,3-propylene group, and Y is methylene group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,or 1,3-propylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and Y is methylene group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and Y is methylene group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is 1,3-propylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² is1,3-propylene group, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is 1,3-propylenegroup, and Y is methylene group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is 1,3-propylenegroup, and Y is methylene group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and groups in each of one or morecombinations selected from the group consisting of combinations of A⁶and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ andA⁵, A³ and A¹, and A⁵ and A¹ bind to each other to form a 5- or6-membered ring;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and groups in each of one or more combinations selectedfrom the group consisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ bind to each other to form a 5- or 6-membered ring;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 5- or 6-membered ring;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 5- or 6-membered ring;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and groups in each of one or morecombinations selected from the group consisting of combinations of A⁶and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ andA⁵, A³ and A¹, and A⁵ and A¹ bind to each other to form a 5-memberedring;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and groups in each of one or more combinations selectedfrom the group consisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ bind to each other to form a 5-membered ring;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 5-membered ring;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 5-membered ring;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and groups in each of one or morecombinations selected from the group consisting of combinations of A⁶and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ andA⁵, A³ and A¹, and A⁵ and A¹ bind to each other to form a 6-memberedring;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and groups in each of one or more combinations selectedfrom the group consisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ bind to each other to form a 6-membered ring;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 6-membered ring;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and groups in each of one or more combinations selected from the groupconsisting of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ bind toeach other to form a 6-membered ring;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-3), formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-3), formula (2-4-t), formula(2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula(2-6-c);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, and the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, and the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,and the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,and the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-3), formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group,an aralkyl group, a lower alkyl group substituted with carboxyl group, alower alkyl group substituted with aminocarbonyl group, a lower alkylgroup substituted with cyano group, a lower alkyl group substituted withhydroxyl group, a lower alkyl group substituted with a lower alkoxylgroup, or a lower alkyl group substituted with an amino group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t),formula (2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), orformula (2-6-c), A⁶ is hydrogen atom, or a lower alkyl group (preferredexamples also include compounds wherein A⁶¹ is a lower alkyl group ofwhich end is substituted with N(A⁷)(—X³-A⁷¹), and the other groupsconsist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-3), formula (2-4-t), formula(2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula(2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkyl group, alower alkyl group substituted with carboxyl group, a lower alkyl groupsubstituted with cyano group, a lower alkyl group substituted withhydroxyl group, a lower alkyl group substituted with a lower alkoxylgroup, a lower alkyl group substituted with an amino group, or a loweralkyl group substituted with aminocarbonyl group, and when the moiety ofthe formula (2) is represented by the formula (2-4-t), formula (2-4-c),formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c),A⁶ is hydrogen atom, or a lower alkyl group (preferred examples alsoinclude compounds wherein A⁶¹ is a lower alkyl group of which end issubstituted with N(A⁷)(—X³-A⁷¹), and the other groups consist of thesame combination as mentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom, or a lower alkyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom, or a lower alkyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-3), formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group,an aralkyl group, a lower alkyl group substituted with carboxyl group, alower alkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, a lower alkyl group substituted with an aminogroup, or a lower alkyl group substituted with aminocarbonyl group, andwhen the moiety of the formula (2) is represented by the formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c), A⁶ is hydrogen atom, or methyl group(preferred examples also include compounds wherein A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and the othergroups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-3), formula (2-4-t), formula(2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula(2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkyl group, alower alkyl group substituted with carboxyl group, a lower alkyl groupsubstituted with cyano group, a lower alkyl group substituted withhydroxyl group, a lower alkyl group substituted with a lower alkoxylgroup, a lower alkyl group substituted with an amino group, or a loweralkyl group substituted with aminocarbonyl group, and when the moiety ofthe formula (2) is represented by the formula (2-4-t), formula (2-4-c),formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c),A⁶ is hydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-3), formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group,an aralkyl group, a lower alkyl group substituted with carboxyl group, alower alkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, a lower alkyl group substituted with an aminogroup, or a lower alkyl group substituted with aminocarbonyl group, andwhen the moiety of the formula (2) is represented by the formula(2-4-t), formula (2-4-c), formula (2-5-t), formula (2-5-c), formula(2-6-t), or formula (2-6-c), A⁶ is hydrogen atom (preferred examplesalso include compounds wherein A⁶¹ is a lower alkyl group of which endis substituted with N(A⁷)(—X³-A⁷¹), and the other groups consist of thesame combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-3), formula (2-4-t), formula(2-4-c), formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula(2-6-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkyl group, alower alkyl group substituted with carboxyl group, a lower alkyl groupsubstituted with cyano group, a lower alkyl group substituted withhydroxyl group, a lower alkyl group substituted with a lower alkoxylgroup, a lower alkyl group substituted with an amino group, or a loweralkyl group substituted with aminocarbonyl group, and when the moiety ofthe formula (2) is represented by the formula (2-4-t), formula (2-4-c),formula (2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c),A⁶ is hydrogen atom (preferred examples also include compounds whereinA⁶¹ is a lower alkyl group of which end is substituted withN(A⁷)(—X³-A⁷¹), and the other groups consist of the same combination asmentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom (preferred examples also include compounds wherein A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe other groups consist of the same combination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-3), formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶¹ ishydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), formula (2-4-c), formula(2-5-t), formula (2-5-c), formula (2-6-t), or formula (2-6-c), A⁶ ishydrogen atom (preferred examples also include compounds wherein A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe other groups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkylgroup, a lower alkyl group substituted with carboxyl group, a loweralkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, a lower alkyl group substituted with an aminogroup, or a lower alkyl group substituted with aminocarbonyl group, andwhen the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group(preferred examples also include compounds wherein A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and the othergroups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or a lower alkyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or a lower alkyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or a lower alkyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkylgroup, a lower alkyl group substituted with carboxyl group, a loweralkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, a lower alkyl group substituted with an aminogroup, or a lower alkyl group substituted with aminocarbonyl group, andwhen the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methyl group(preferred examples also include compounds wherein A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and the othergroups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or methyl group (preferred examples also includecompounds wherein A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and the other groups consist of the samecombination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, a lower alkyl group, an aralkylgroup, a lower alkyl group substituted with carboxyl group, a loweralkyl group substituted with cyano group, a lower alkyl groupsubstituted with hydroxyl group, a lower alkyl group substituted with alower alkoxyl group, a lower alkyl group substituted with an aminogroup, or a lower alkyl group substituted with aminocarbonyl group, andwhen the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom (preferred examplesalso include compounds wherein A⁶¹ is a lower alkyl group of which endis substituted with N(A⁷)(—X³-A⁷¹), and the other groups consist of thesame combination as mentioned above);

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, a lower alkyl group, an aralkyl group, a lower alkylgroup substituted with carboxyl group, a lower alkyl group substitutedwith cyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom (preferred examples also include compounds wherein A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe other groups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom (preferred examples also include compounds wherein A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe other groups consist of the same combination as mentioned above);

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, a lower alkyl group, an aralkyl group, a lower alkyl groupsubstituted with carboxyl group, a lower alkyl group substituted withcyano group, a lower alkyl group substituted with hydroxyl group, alower alkyl group substituted with a lower alkoxyl group, a lower alkylgroup substituted with an amino group, or a lower alkyl groupsubstituted with aminocarbonyl group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom (preferred examples also include compounds wherein A⁶¹ isa lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹), andthe other groups consist of the same combination as mentioned above);

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, a lower alkyl group, or an aralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, and when the moiety of the formula (2) is representedby the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or alower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is an aralkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is an aralkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with carboxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with carboxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with cyanogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with cyano group, and when the moietyof the formula (2) is represented by the formula (2-4-t), or formula(2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with cyano group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with cyano group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with hydroxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with hydroxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with a loweralkoxyl group, and when the moiety of the formula (2) is represented bythe formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with a lower alkoxyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with an aminogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with an amino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹),and when the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a lower alkylgroup;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with a loweralkylcarbonylamino group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with a lower alkylcarbonylaminogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted withaminocarbonyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with aminocarbonyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or a lower alkyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, and when the moiety of the formula (2) is representedby the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, ormethyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is an aralkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is an aralkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with carboxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with carboxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with cyanogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with cyano group, and when the moietyof the formula (2) is represented by the formula (2-4-t), or formula(2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹. is a loweralkyl group substituted with cyano group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with cyano group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with hydroxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with hydroxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with a loweralkoxyl group, and when the moiety of the formula (2) is represented bythe formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with a lower alkoxyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with an aminogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methylgroup;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with an amino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹),and when the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶ is a lower alkyl group substituted with a loweralkylcarbonylamino group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶ isa lower alkyl group substituted with a lower alkylcarbonylamino group,and when the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted withaminocarbonyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom, or methyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with aminocarbonyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom, or methyl group;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is hydrogen atom, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is hydrogen atom, and when the moiety of the formula (2) is representedby the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is hydrogenatom, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is an aralkyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is-an aralkyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is an aralkylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with carboxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with carboxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with carboxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with cyanogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with cyano group, and when the moietyof the formula (2) is represented by the formula (2-4-t), or formula(2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with cyano group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with cyano group, and when the moiety of the formula(2) is represented by the formula (2-4-t), or formula (2-4-c), A⁶ ishydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with hydroxylgroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with hydroxyl group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with hydroxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with a loweralkoxyl group, and when the moiety of the formula (2) is represented bythe formula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with a lower alkoxyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkoxyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with an aminogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with an amino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with an amino group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group of which end is substitutedwith N(A⁷)(—X³-A⁷¹), and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group of which end is substituted with N(A⁷)(—X³-A⁷¹),and when the moiety of the formula (2) is represented by the formula(2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted with a loweralkylcarbonylamino group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with a lower alkylcarbonylaminogroup, and when the moiety of the formula (2) is represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with a lower alkylcarbonylamino group, and when themoiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, chlorine atom, or hydroxyl group,X¹ . . . X² is ethylene group, the moiety of the formula (2) isrepresented by the formula (2-1), formula (2-2), formula (2-4-t), orformula (2-4-c), A⁶¹ is a lower alkyl group substituted withaminocarbonyl group, and when the moiety of the formula (2) isrepresented by the formula (2-4-t), or formula (2-4-c), A⁶ is hydrogenatom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is a lower alkyl group substituted with aminocarbonyl group, and whenthe moiety of the formula (2) is represented by the formula (2-4-t), orformula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is a lower alkylgroup substituted with aminocarbonyl group, and when the moiety of theformula (2) is represented by the formula (2-4-t), or formula (2-4-c),A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, A⁶ is hydrogen atom, and A⁶¹ is2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group, A⁶is hydrogen atom, and A⁶¹ is 2-(2-oxo-1-azetidyl)ethyl group,2-(2-oxo-1-pyrrolidyl)ethyl group, 2-(2-oxo-1-piperidyl)ethyl group,3-(2-oxo-1-azetidyl)propyl group, 3-(2-oxo-1-pyrrolidyl)propyl group, or3-(2-oxo-1-piperidyl)propyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,A⁶ is hydrogen atom, and A⁶¹ is 2-(2-oxo-1-azetidyl)ethyl group,2-(2-oxo-1-pyrrolidyl)ethyl group, 2-(2-oxo-1-piperidyl)ethyl group,3-(2-oxo-1-azetidyl)propyl group, 3-(2-oxo-1-pyrrolidyl)propyl group, or3-(2-oxo-1-piperidyl)propyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is 2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom, or a loweralkyl group;

compounds wherein R¹ is hydrogen atom, or hydroxyl group, X¹ . . . X² isethylene group, the moiety of the formula (2) is represented by theformula (2-1), formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹is 2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom;

compounds wherein R¹ is hydrogen atom, X¹ . . . X² is ethylene group,the moiety of the formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom; and

compounds wherein R¹ is hydroxyl group, X¹ . . . X² is ethylene group,the moiety of the. formula (2) is represented by the formula (2-1),formula (2-2), formula (2-4-t), or formula (2-4-c), A⁶¹ is2-(2-oxo-1-azetidyl)ethyl group, 2-(2-oxo-1-pyrrolidyl)ethyl group,2-(2-oxo-1-piperidyl)ethyl group, 3-(2-oxo-1-azetidyl)propyl group,3-(2-oxo-1-pyrrolidyl)propyl group, or 3-(2-oxo-1-piperidyl)propylgroup, and when the moiety of the formula (2) can be represented by theformula (2-4-t), or formula (2-4-c), A⁶ is hydrogen atom.

Specific examples of the compounds of the present invention representedby the formula (1) further include, for example, the compounds describedin Tables 1 to 10 mentioned below. In the tables, Me represents methyl,and Bn represents benzyl. The compounds of Table 1 have a structurerepresented by the formula (1-A), the compounds of Table 2 have astructure represented by the formula (1-B), the compounds of Table 3have a structure represented by the formula (1-C), the compounds ofTable 4 have a structure represented by the formula (1-D), the compoundsof Table 5 have a structure represented by the formula (1-E), thecompounds of Table 6 have a structure represented by the formula (1-G),the compounds of Table 7 have a structure represented by the formula(1-F), the compounds of Table 8 have a structure represented by theformula (1-H), the compounds of Table 9 have a structure represented bythe formula (1-I), and the compounds of Table 10 have a structurerepresented by the formula (1-J), respectively. However, the scope ofthe present invention is not limited to these compounds.

The compounds mentioned in Table 1 are compounds having a structurerepresented by the following formula (1-A): TABLE 1 (1-A)

Exemplary Compound No. R¹ Z 1-1 H OH 1-2 H NH₂ 1-3 H NHMe 1-4 H NHBn 1-5H NH(CH₂COOH) 1-6 H NH(CH₂CH₂COOH) 1-7 H NH(CH₂CH₂CH₂COOH) 1-8 HNH(CH₂CN) 1-9 H NH(CH₂CH₂CN) 1-10 H NH(CH₂CH₂CH₂CN) 1-11 H NH(CH₂CH₂OH)1-12 H NH(CH₂CH₂CH₂OH) 1-13 H NH(CH₂CH₂CH₂CH₂OH) 1-14 H NH(CH₂CH₂OMe)1-15 H NH(CH₂CH₂CH₂OMe) 1-16 H NH(CH₂CH₂CH₂CH₂OMe) 1-17 H NH(CH₂CH₂NH₂)1-18 H NH(CH₂CH₂CH₂NH₂) 1-19 H NH(CH₂CH₂CH₂CH₂NH₂) 1-20 H NH(CH₂CH₂NHMe)1-21 H NH(CH₂CH₂CH₂NHMe) 1-22 H NH(CH₂CH₂CH₂CH₂NHMe) 1-23 HNH(CH₂CH₂NMe₂) 1-24 H NH(CH₂CH₂CH₂NMe₂) 1-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 1-26H NH(CH₂CONH₂) 1-27 H NH(CH₂CH₂CONH₂) 1-28 H NMeBn 1-29 H NMC(CH₂COOH)1-30 H NMe(CH₂CH₂COOH) 1-31 H NMe(CH₂CH₂CH₂COOH) 1-32 H NMe(CH₂CN) 1-33H NMe(CH₂CH₂CN) 1-34 H NMe(CH₂CH₂CH₂CN) 1-35 H NMe(CH₂CH₂OH) 1-36 HNMe(CH₂CH₂CH₂OH) 1-37 H NMe(CH₂CH₂CH₂CH₂OH) 1-38 H NMe(CH₂CH₂OMe) 1-39 HNMe(CH₂CH₂CH₂OMe) 1-40 H NMe(CH₂CH₂CH₂CH₂OMe) 1-41 H NMe(CH₂CH₂NH₂) 1-42H NMe(CH₂CH₂CH₂NH₂) 1-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 1-44 H NMe(CH₂CH₂NHMe)1-45 H NMe(CH₂CH₂CH₂NHMe) 1-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 1-47 HNMe(CH₂CH₂NMe₂) 1-48 H NMe(CH₂CH₂CH₂NMe₂) 1-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)1-50 H NMe(CH₂CONH₂) 1-51 H NMe(CH₂CH₂CONH₂) 1-52 OH OH 1-53 OH NH₂ 1-54OH NHMe 1-55 OH NHBn 1-56 OH NH(CH₂COOH) 1-57 OH NH(CH₂CH₂COOH) 1-58 OHNH(CH₂CH₂CH₂COOH) 1-59 OH NH(CH₂CN) 1-60 OH NH(CH₂CH₂CN) 1-61 OHNH(CH₂CH₂CH₂CN) 1-62 OH NH(CH₂CH₂OH) 1-63 OH NH(CH₂CH₂CH₂OH) 1-64 OHNH(CH₂CH₂CH₂CH₂OH) 1-65 OH NH(CH₂CH₂OMe) 1-66 OH NH(CH₂CH₂CH₂OMe) 1-67OH NH(CH₂CH₂CH₂CH₂OMe) 1-68 OH NH(CH₂CH₂NH₂) 1-69 OH NH(CH₂CH₂CH₂NH₂)1-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 1-71 OH NH(CH₂CH₂NHMe) 1-72 OHNH(CH₂CH₂CH₂NHMe) 1-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 1-74 OH NH(CH₂CH₂NMe₂)1-75 OH NH(CH₂CH₂CH₂NMe₂) 1-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 1-77 OHNH(CH₂CONH₂) 1-78 OH NH(CH₂CH₂CONH₂) 1-79 OH NMeBn 1-80 OH NMe(CH₂COOH)1-81 OH NMe(CH₂CH₂COOH) 1-82 OH NMe(CH₂CH₂CH₂COOH) 1-83 OH NMe(CH₂CN)1-84 OH NMe(CH₂CH₂CN) 1-85 OH NMe(CH₂CH₂CH₂CN) 1-86 OH NMe(CH₂CH₂OH)1-87 OH NMe(CH₂CH₂CH₂OH) 1-88 OH NMe(CH₂CH₂CH₂CH₂OH) 1-89 OHNMe(CH₂CH₂OMe) 1-90 OH NMe(CH₂CH₂CH₂OMe) 1-91 OH NMe(CH₂CH₂CH₂CH₂OMe)1-92 OH NMe(CH₂CH₂NH₂) 1-93 OH NMe(CH₂CH₂CH₂NH₂) 1-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 1-95 OH NMe(CH₂CH₂NHMe) 1-96 OH NMe(CH₂CH₂CH₂NHMe)1-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 1-98 OH NMe(CH₂CH₂NMe₂) 1-99 OHNMe(CH₂CH₂CH₂NMe₂) 1-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 1-101 OH NMe(CH₂CONH₂)1-102 OH NMe(CH₂CH₂CONH₂) 1-103 H NH(CH₂CH₂NHCOMe) 1-104 HNH(CH₂CH₂NHCOCH₂Me) 1-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 1-106 HNH(CH₂CH₂NHCOCHMe₂) 1-107 H NH(CH₂CH₂NHCOCMe₃) 1-108 HNH(CH₂CH₂CH₂NHCOMe) 1-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 1-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 1-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 1-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 1-113 OH NH(CH₂CH₂NHCOMe) 1-114 OHNH(CH₂CH₂NHCOCH₂Me) 1-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 1-116 OHNH(CH₂CH₂NHCOCHMe₂) 1-117 OH NH(CH₂CH₂NHCOCMeS) 1-118 OHNH(CH₂CH₂CH₂NHCOMe) 1-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 1-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 1-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 1-122 OHNH(CH₂CH₂CH₂NHCOCMeS)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 1-2, 1-3, 1-5, 1-6, 1-7, 1-11, 1-12, 1-13, 1-17, 1-18,1-19, 1-20, 1-21, 1-22, 1-23, 1-24, 1-25, 1-35, 1-36, 1-37, 1-53, 1-54,1-56, 1-57, 1-58, 1-62, 1-63, 1-64, 1-68, 1-69, 1-70, 1-71, 1-72, 1-73,1-74, 1-75, 1-76, 1-86, 1-87, and 1-88. Exemplary Compound Nos. 1-103,1-104, 1-105, 1-108, 1-109, 1-110, 1-113, 1-114, 1-115, 1-118, 1-119,and 1-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 1-2, 1-3, 1-5, 1-6,1-11, 1-12, 1-17, 1-18, 1-20, 1-21, 1-23, 1-24, 1-35, 1-36, 1-53, 1-54,1-56, 1-57, 1-62, 1-63, 1-68, 1-69, 1-71, 1-72, 1-74, 1-75, 1-86, and1-87. Exemplary Compound Nos. 1-103, 1-104, 1-108, 1-109, 1-113, 1-114,1-118, and 1-119 are also more preferred compounds.

The compounds mentioned in Table 2 are compounds having a structurerepresented by the following formula (1-B): TABLE 2 (1-B)

Exemplary Compound No. R¹ Z 2-1 H OH 2-2 H NH₂ 2-3 H NHMe 2-4 H NHBn 2-5H NH(CH₂COOH) 2-6 H NH(CH₂CH₂COOH) 2-7 H NH(CH₂CH₂CH₂COOH) 2-8 HNH(CH₂CN) 2-9 H NH(CH₂CH₂CN) 2-10 H NH(CH₂CH₂CH₂CN) 2-11 H NH(CH₂CH₂OH)2-12 H NH(CH₂CH₂CH₂OH) 2-13 H NH(CH₂CH₂CH₂CH₂OH) 2-14 H NH(CH₂CH₂OMe)2-15 H NH(CH₂CH₂CH₂OMe) 2-16 H NH(CH₂CH₂CH₂CH₂OMe) 2-17 H NH(CH₂CH₂NH₂)2-18 H NH(CH₂CH₂CH₂NH₂) 2-19 H NH(CH₂CH₂CH₂CH₂NH₂) 2-20 H NH(CH₂CH₂NHMe)2-21 H NH(CH₂CH₂CH₂NHMe) 2-22 H NH(CH₂CH₂CH₂CH₂NHMe) 2-23 HNH(CH₂CH₂NMe₂) 2-24 H NH(CH₂CH₂CH₂NMe₂) 2-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 2-26H NH(CH₂CONH₂) 2-27 H NH(CH₂CH₂CONH₂) 2-28 H NMeBn 2-29 H NMe(CH₂COOH)2-30 H NMe(CH₂CH₂COOH) 2-31 H NMe(CH₂CH₂CH₂COOH) 2-32 H NMe(CH₂CN) 2-33H NMe(CH₂CH₂CN) 2-34 H NMe(CH₂CH₂CH₂CN) 2-35 H NMe(CH₂CH₂OH) 2-36 HNMe(CH₂CH₂CH₂OH) 2-37 H NMe(CH₂CH₂CH₂CH₂OH) 2-38 H NMe(CH₂CH₂OMe) 2-39 HNMe(CH₂CH₂CH₂OMe) 2-40 H NMe(CH₂CH₂CH₂CH₂OMe) 2-41 H NMe(CH₂CH₂NH₂) 2-42H NMe(CH₂CH₂CH₂NH₂) 2-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 2-44 H NMe(CH₂CH₂NHMe)2-45 H NMe(CH₂CH₂CH₂NHMe) 2-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 2-47 HNMe(CH₂CH₂NMe₂) 2-48 H NMe(CH₂CH₂CH₂NMe₂) 2-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)2-50 H NMe(CH₂CONH₂) 2-51 H NMe(CH₂CH₂CONH₂) 2-52 OH OH 2-53 OH NH₂ 2-54OH NHMe 2-55 OH NHBn 2-56 OH NH(CH₂COOH) 2-57 OH NH(CH₂CH₂COOH) 2-58 OHNH(CH₂CH₂CH₂COOH) 2-59 OH NH(CH₂CN) 2-60 OH NH(CH₂CH₂CN) 2-61 OHNH(CH₂CH₂CH₂CN) 2-62 OH NH(CH₂CH₂OH) 2-63 OH NH(CH₂CH₂CH₂OH) 2-64 OHNH(CH₂CH₂CH₂CH₂OH) 2-65 OH NH(CH₂CH₂OMe) 2-66 OH NH(CH₂CH₂CH₂OMe) 2-67OH NH(CH₂CH₂CH₂CH₂OMe) 2-68 OH NH(CH₂CH₂NH₂) 2-69 OH NH(CH₂CH₂CH₂NH₂)2-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 2-71 OH NH(CH₂CH₂NHMe) 2-72 OHNH(CH₂CH₂CH₂NHMe) 2-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 2-74 OH NH(CH₂CH₂NMe₂)2-75 OH NH(CH₂CH₂CH₂NMe₂) 2-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 2-77 OHNH(CH₂CONH₂) 2-78 OH NH(CH₂CH₂CONH₂) 2-79 OH NMeBn 2-80 OH NMe(CH₂COOH)2-81 OH NMe(CH₂CH₂COOH) 2-82 OH NMe(CH₂CH₂CH₂COOH) 2-83 OH NMe(CH₂CN)2-84 OH NMe(CH₂CH₂CN) 2-85 OH NMe(CH₂CH₂CH₂CN) 2-86 OH NMe(CH₂CH₂OH)2-87 OH NMe(CH₂CH₂CH₂OH) 2-88 OH NMe(CH₂CH₂CH₂CH₂OH) 2-89 OHNMe(CH₂CH₂OMe) 2-90 OH NMe(CH₂CH₂CH₂OMe) 2-91 OH NMe(CH₂CH₂CH₂CH₂OMe)2-92 OH NMe(CH₂CH₂NH₂) 2-93 OH NMe(CH₂CH₂CH₂NH₂) 2-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 2-95 OH NMe(CH₂CH₂NHMe) 2-96 OH NMe(CH₂CH₂CH₂NHMe)2-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 2-98 OH NMe(CH₂CH₂NMe₂) 2-99 OHNMe(CH₂CH₂CH₂NMe₂) 2-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 2-101 OH NMe(CH₂CONH₂)2-102 OH NMe(CH₂CH₂CONH₂) 2-103 H NH(CH₂CH₂NHCOMe) 2-104 HNH(CH₂CH₂NHCOCH₂Me) 2-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 2-106 HNH(CH₂CH₂NHCOCHMe₂) 2-107 H NH(CH₂CH₂NHCOCMe₃) 2-108 HNH(CH₂CH₂CH₂NHCOMe) 2-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 2-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 2-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 2-112 HNH(CH₂CH₂CH₂NHCOCMeS) 2-113 OH NH(CH₂CH₂NHCOMe) 2-114 OHNH(CH₂CH₂NHCOCH₂Me) 2-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 2-116 OHNH(CH₂CH₂NHCOCHMe₂) 2-117 OH NH(CH₂CH₂NHCOCMe₃) 2-118 OHNH(CH₂CH₂CH₂NHCOMe) 2-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 2-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 2-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 2-122 OHNH(CH₂CH₂CH₂NHCOCMeS)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 2-2, 2-3, 2-5, 2-6, 2-7, 2-11, 2-12, 2-13, 2-17, 2-18,2-19, 2-20, 2-21, 2-22, 2-23, 2-24, 2-25, 2-35, 2-36, 2-37, 2-53, 2-54,2-56, 2-57, 2-58, 2-62, 2-63, 2-64, 2-68, 2-69, 2-70, 2-71, 2-72, 2-73,2-74, 2-75, 2-76, 2-86, 2-87, and 2-88. Exemplary Compound Nos. 2-103,2-104, 2-105, 2-108, 2-109, 2-110, 2-113, 2-114, 2-115, 2-118, 2-119,and 2-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 2-2, 2-3, 2-5, 2-6,2-11, 2-12, 2-17, 2-18, 2-20, 2-21, 2-23, 2-24, 2-35, 2-36, 2-53, 2-54,2-56, 2-57, 2-62, 2-63, 2-68, 2-69, 2-71, 2-72, 2-74, 2-75, 2-86, and2-87. Exemplary Compound Nos. 2-103, 2-104, 2-108, 2-109, 2-113, 2-114,2-118, and 2-119 are also more preferred compounds.

Further,trans-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]dimethylamine(Exemplary Compound No. 2-123), andtrans-1-(4-dimethylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol (Exemplary Compound No. 2-124) are alsopreferred compounds.

The compounds mentioned in Table 3 are compounds having a structurerepresented by the following formula (1-C): TABLE 3 (1-C)

Exemplary Compound No. R¹ Z 3-1 H OH 3-2 H NH₂ 3-3 H NHMe 3-4 H NHBn 3-5H NH(CH₂COOH) 3-6 H NH(CH₂CH₂COOH) 3-7 H NH(CH₂CH₂CH₂COOH) 3-8 HNH(CH₂CN) 3-9 H NH(CH₂CH₂CN) 3-10 H NH(CH₂CH₂CH₂CN) 3-11 H NH(CH₂CH₂OH)3-12 H NH(CH₂CH₂CH₂OH) 3-13 H NH(CH₂CH₂CH₂CH₂OH) 3-14 H NH(CH₂CH₂OMe)3-15 H NH(CH₂CH₂CH₂OMe) 3-16 H NH(CH₂CH₂CH₂CH₂OMe) 3-17 H NH(CH₂CH₂NH₂)3-18 H NH(CH₂CH₂CH₂NH₂) 3-19 H NH(CH₂CH₂CH₂CH₂NH₂) 3-20 H NH(CH₂CH₂NHMe)3-21 H NH(CH₂CH₂CH₂NHMe) 3-22 H NH(CH₂CH₂CH₂CH₂NHMe) 3-23 HNH(CH₂CH₂NMe₂) 3-24 H NH(CH₂CH₂CH₂NMe₂) 3-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 3-26H NH(CH₂CONH₂) 3-27 H NH(CH₂CH₂CONH₂) 3-28 H NMeBn 3-29 H NMe(CH₂COOH)3-30 H NMe(CH₂CH₂COOH) 3-31 H NMe(CH₂CH₂CH₂COOH) 3-32 H NMe(CH₂CN) 3-33H NMe(CH₂CH₂CN) 3-34 H NMe(CH₂CH₂CH₂CN) 3-35 H NMe(CH₂CH₂OH) 3-36 HNMe(CH₂CH₂CH₂OH) 3-37 H NMe(CH₂CH₂CH₂CH₂OH) 3-38 H NMe(CH₂CH₂OMe) 3-39 HNMe(CH₂CH₂CH₂OMe) 3-40 H NMe(CH₂CH₂CH₂CH₂OMe) 3-41 H NMe(CH₂CH₂NH₂) 3-42H NMe(CH₂CH₂CH₂NH₂) 3-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 3-44 H NMe(CH₂CH₂NHMe)3-45 H NMe(CH₂CH₂CH₂NHMe) 3-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 3-47 HNMe(CH₂CH₂NMe₂) 3-48 H NMe(CH₂CH₂CH₂NMe₂) 3-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)3-50 H NMe(CH₂CONH₂) 3-51 H NMe(CH₂CH₂CONH₂) 3-52 OH OH 3-53 OH NH₂ 3-54OH NHMe 3-55 OH NHBn 3-56 OH NH(CH₂COOH) 3-57 OH NH(CH₂CH₂COOH) 3-58 OHNH(CH₂CH₂CH₂COOH) 3-59 OH NH(CH₂CN) 3-60 OH NH(CH₂CH₂CN) 3-61 OHNH(CH₂CH₂CH₂CN) 3-62 OH NH(CH₂CH₂OH) 3-63 OH NH(CH₂CH₂CH₂OH) 3-64 OHNH(CH₂CH₂CH₂CH₂OH) 3-65 OH NH(CH₂CH₂OMe) 3-66 OH NH(CH₂CH₂CH₂OMe) 3-67OH NH(CH₂CH₂CH₂CH₂OMe) 3-68 OH NH(CH₂CH₂NH₂) 3-69 OH NH(CH₂CH₂CH₂NH₂)3-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 3-71 OH NH(CH₂CH₂NHMe) 3-72 OHNH(CH₂CH₂CH₂NHMe) 3-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 3-74 OH NH(CH₂CH₂NMe₂)3-75 OH NH(CH₂CH₂CH₂NMe₂) 3-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 3-77 OHNH(CH₂CONH₂) 3-78 OH NH(CH₂CH₂CONH₂) 3-79 OH NMeBn 3-80 OH NMe(CH₂COOH)3-81 OH NMe(CH₂CH₂COOH) 3-82 OH NMe(CH₂CH₂CH₂COOH) 3-83 OH NMe(CH₂CN)3-84 OH NMe(CH₂CH₂CN) 3-85 OH NMe(CH₂CH₂CH₂CN) 3-86 OH NMe(CH₂CH₂OH)3-87 OH NMe(CH₂CH₂CH₂OH) 3-88 OH NMe(CH₂CH₂CH₂CH₂OH) 3-89 OHNMe(CH₂CH₂OMe) 3-90 OH NMe(CH₂CH₂CH₂OMe) 3-91 OH NMe(CH₂CH₂CH₂CH₂OMe)3-92 OH NMe(CH₂CH₂NH₂) 3-93 OH NMe(CH₂CH₂CH₂NH₂) 3-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 3-95 OH NMe(CH₂CH₂NHMe) 3-96 OH NMe(CH₂CH₂CH₂NHMe)3-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 3-98 OH NMe(CH₂CH₂NMe₂) 3-99 OHNMe(CH₂CH₂CH₂NMe₂) 3-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 3-101 OH NMe(CH₂CONH₂)3-102 OH NMe(CH₂CH₂CONH₂) 3-103 H NH(CH₂CH₂NHCOMe) 3-104 HNH(CH₂CH₂NHCOCH₂Me) 3-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 3-106 HNH(CH₂CH₂NHCOCHMe₂) 3-107 H NH(CH₂CH₂NHCOCMe₃) 3-108 HNH(CH₂CH₂CH₂NHCOMe) 3-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 3-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 3-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 3-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 3-113 OH NH(CH₂CH₂NHCOMe) 3-114 OHNH(CH₂CH₂NHCOCH₂Me) 3-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 3-116 OHNH(CH₂CH₂NHCOCHMe₂) 3-117 OH NH(CH₂CH₂NHCOCMe₃) 3-118 OHNH(CH₂CH₂CH₂NHCOMe) 3-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 3-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 3-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 3-122 OHNH(CH₂CH₂CH₂NHCOCMe₃)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 3-2, 3-3, 3-5, 3-6, 3-7, 3-11, 3-12, 3-13, 3-17, 3-18,3-19, 3-20, 3-21, 3-22, 3-23, 3-24, 3-25, 3-35, 3-36, 3-37, 3-53, 3-54,3-56, 3-57, 3-58, 3-62, 3-63, 3-64, 3-68, 3-69, 3-70, 3-71, 3-72, 3-73,3-74, 3-75, 3-76, 3-86, 3-87, and 3-88. Exemplary Compound Nos. 3-103,3-104, 3-105, 3-108, 3-109, 3-110, 3-113, 3-114, 3-115, 3-118, 3-119,and 3-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 3-2, 3-3, 3-5, 3-6,3-11, 3-12, 3-17, 3-18, 3-20, 3-21, 3-23, 3-24, 3-35, 3-36, 3-53, 3-54,3-56, 3-57, 3-62, 3-63, 3-68, 3-69, 3-71, 3-72, 3-74, 3-75, 3-86, and3-87. Exemplary Compound Nos. 3-103, 3-104, 3-108, 3-109, 3-113, 3-114,3-118, and 3-119 are also more preferred compounds.

Further,cis-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]dimethylamine(Exemplary Compound No. 3-123), andcis-1-(4-dimethylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol(Exemplary Compound No. 3-124) are also preferred compounds.

The compounds mentioned in Table 4 are compounds having a structurerepresented by the following formula (1-D): TABLE 4 (1-D)

Exemplary Compound No. R¹ Z 4-1 H OH 4-2 H NH₂ 4-3 H NHMe 4-4 H NHBn 4-5H NH(CH₂COOH) 4-6 H NH(CH₂CH₂COOH) 4-7 H NH(CH₂CH₂CH₂COOH) 4-8 HNH(CH₂CN) 4-9 H NH(CH₂CH₂CN) 4-10 H NH(CH₂CH₂CH₂CN) 4-11 H NH(CH₂CH₂OH)4-12 H NH(CH₂CH₂CH₂OH) 4-13 H NH(CH₂CH₂CH₂CH₂OH) 4-14 H NH(CH₂CH₂OMe)4-15 H NH(CH₂CH₂CH₂OMe) 4-16 H NH(CH₂CH₂CH₂CH₂OMe) 4-17 H NH(CH₂CH₂NH₂)4-18 H NH(CH₂CH₂CH₂NH₂) 4-19 H NH(CH₂CH₂CH₂CH₂NH₂) 4-20 H NH(CH₂CH₂NHMe)4-21 H NH(CH₂CH₂CH₂NHMe) 4-22 H NH(CH₂CH₂CH₂CH₂NHMe) 4-23 HNH(CH₂CH₂NMe₂) 4-24 H NH(CH₂CH₂CH₂NMe₂) 4-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 4-26H NH(CH₂CONH₂) 4-27 H NH(CH₂CH₂CONH₂) 4-28 H NMeBn 4-29 H NMe(CH₂COOH)4-30 H NMe(CH₂CH₂COOH) 4-31 H NMe(CH₂CH₂CH₂COOH) 4-32 H NMe(CH₂CN) 4-33H NMe(CH₂CH₂CN) 4-34 H NMe(CH₂CH₂CH₂CN) 4-35 H NMe(CH₂CH₂OH) 4-36 HNMe(CH₂CH₂CH₂OH) 4-37 H NMe(CH₂CH₂CH₂CH₂OH) 4-38 H NMe(CH₂CH₂OMe) 4-39 HNMe(CH₂CH₂CH₂OMe) 4-40 H NMe(CH₂CH₂CH₂CH₂OMe) 4-41 H NMe(CH₂CH₂NH₂) 4-42H NMe(CH₂CH₂CH₂NH₂) 4-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 4-44 H NMe(CH₂CH₂NHMe)4-45 H NMe(CH₂CH₂CH₂NHMe) 4-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 4-47 HNMe(CH₂CH₂NMe₂) 4-48 H NMe(CH₂CH₂CH₂NMe₂) 4-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)4-50 H NMe(CH₂CONH₂) 4-51 H NMe(CH₂CH₂CONH₂) 4-52 OH OH 4-53 OH NH₂ 4-54OH NHMe 4-55 OH NHBn 4-56 OH NH(CH₂COOH) 4-57 OH NH(CH₂CH₂COOH) 4-58 OHNH(CH₂CH₂CH₂COOH) 4-59 OH NH(CH₂CN) 4-60 OH NH(CH₂CH₂CN) 4-61 OHNH(CH₂CH₂CH₂CN) 4-62 OH NH(CH₂CH₂OH) 4-63 OH NH(CH₂CH₂CH₂OH) 4-64 OHNH(CH₂CH₂CH₂CH₂OH) 4-65 OH NH(CH₂CH₂OMe) 4-66 OH NH(CH₂CH₂CH₂OMe) 4-67OH NH(CH₂CH₂CH₂CH₂OMe) 4-68 OH NH(CH₂CH₂NH₂) 4-69 OH NH(CH₂CH₂CH₂NH₂)4-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 4-71 OH NH(CH₂CH₂NHMe) 4-72 OHNH(CH₂CH₂CH₂NHMe) 4-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 4-74 OH NH(CH₂CH₂NMe₂)4-75 OH NH(CH₂CH₂CH₂NMe₂) 4-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 4-77 OHNH(CH₂CONH₂) 4-78 OH NH(CH₂CH₂CONH₂) 4-79 OH NMeBn 4-80 OH NMe(CH₂COOH)4-81 OH NMe(CH₂CH₂COOH) 4-82 OH NMe(CH₂CH₂CH₂COOH) 4-83 OH NMe(CH₂CN)4-84 OH NMe(CH₂CH₂CN) 4-85 OH NMe(CH₂CH₂CH₂CN) 4-86 OH NMe(CH₂CH₂OH)4-87 OH NMe(CH₂CH₂CH₂OH) 4-88 OH NMe(CH₂CH₂CH₂CH₂OH) 4-89 OHNMe(CH₂CH₂OMe) 4-90 OH NMe(CH₂CH₂CH₂OMe) 4-91 OH NMe(CH₂CH₂CH₂CH₂OMe)4-92 OH NMe(CH₂CH₂NH₂) 4-93 OH NMe(CH₂CH₂CH₂NH₂) 4-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 4-95 OH NMe(CH₂CH₂NHMe) 4-96 OH NMe(CH₂CH₂CH₂NHMe)4-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 4-98 OH NMe(CH₂CH₂NMe₂) 4-99 OHNMe(CH₂CH₂CH₂NMe₂) 4-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 4-101 OH NMe(CH₂CONH₂)4-102 OH NMe(CH₂CH₂CONH₂) 4-103 H NH(CH₂CH₂NHCOMe) 4-104 HNH(CH₂CH₂NHCOCH₂Me) 4-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 4-106 HNH(CH₂CH₂NHCOCHMe₂) 4-107 H NH(CH₂CH₂NHCOCMe₃) 4-108 HNH(CH₂CH₂CH₂NHCOMe) 4-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 4-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 4-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 4-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 4-113 OH NH(CH₂CH₂NHCOMe) 4-114 OHNH(CH₂CH₂NHCOCH₂Me) 4-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 4-116 OHNH(CH₂CH₂NHCOCHMe₂) 4-117 OH NH(CH₂CH₂NHCOCMe₃) 4-118 OHNH(CH₂CH₂CH₂NHCOMe) 4-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 4-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 4-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 4-122 OHNH(CH₂CH₂CH₂NHCOCMeS)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 4-2, 4-3, 4-5, 4-6, 4-7, 4-11, 4-12, 4-13, 4-17, 4-18,4-19, 4-20, 4-21, 4-22, 4-23, 4-24, 4-25, 4-35, 4-36, 4-37, 4-53, 4-54,4-56, 4-57, 4-58, 4-62, 4-63, 4-64, 4-68, 4-69, 4-70, 4-71, 4-72, 4-73,4-74, 4-75, 4-76, 4-86, 4-87, and 4-88. Exemplary Compound Nos. 4-103,4-104, 4-105, 4-108, 4-109, 4-110, 4-113, 4-114, 4-115, 4-118, 4-119,and 4-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 4-2, 4-3, 4-5, 4-6,4-11, 4-12, 4-17, 4-18, 4-20, 4-21, 4-23, 4-24, 4-35, 4-36, 4-53, 4-54,4-56, 4-57, 4-62, 4-63, 4-68, 4-69, 4-71, 4-72, 4-74, 4-75, 4-86, and4-87. Exemplary Compound Nos. 4-103, 4-104, 4-108, 4-109, 4-113, 4-114,4-118, and 4-119 are also more preferred compounds.

The compounds mentioned in Table 5 are compounds having a structurerepresented by the following formula (1-E): TABLE 5 (1-E)

Exemplary Compound No. R¹ Z 5-1 H OH 5-2 H NH₂ 5-3 H NHMe 5-4 H NHBn 5-5H NH(CH₂COOH) 5-6 H NH(CH₂CH₂COOH) 5-7 H NH(CH₂CH₂CH₂COOH) 5-8 HNH(CH₂CN) 5-9 H NH(CH₂CH₂CN) 5-10 H NH(CH₂CH₂CH₂CN) 5-11 H NH(CH₂CH₂OH)5-12 H NH(CH₂CH₂CH₂OH) 5-13 H NH(CH₂CH₂CH₂CH₂OH) 5-14 H NH(CH₂CH₂OMe)5-15 H NH(CH₂CH₂CH₂OMe) 5-16 H NH(CH₂CH₂CH₂CH₂OMe) 5-17 H NH(CH₂CH₂NH₂)5-18 H NH(CH₂CH₂CH₂NH₂) 5-19 H NH(CH₂CH₂CH₂CH₂NH₂) 5-20 H NH(CH₂CH₂NHMe)5-21 H NH(CH₂CH₂CH₂NHMe) 5-22 H NH(CH₂CH₂CH₂CH₂NHMe) 5-23 HNH(CH₂CH₂NMe₂) 5-24 H NH(CH₂CH₂CH₂NMe₂) 5-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 5-26H NH(CH₂CONH₂) 5-27 H NH(CH₂CH₂CONH₂) 5-28 H NMeBn 5-29 H NMe(CH₂COOH)5-30 H NMe(CH₂CH₂COOH) 5-31 H NMe(CH₂CH₂CH₂COOH) 5-32 H NMe(CH₂CN) 5-33H NMe(CH₂CH₂CN) 5-34 H NMe(CH₂CH₂CH₂CN) 5-35 H NMe(CH₂CH₂OH) 5-36 HNMe(CH₂CH₂CH₂OH) 5-37 H NMe(CH₂CH₂CH₂CH₂OH) 5-38 H NMe(CH₂CH₂OMe) 5-39 HNMe(CH₂CH₂CH₂OMe) 5-40 H NMe(CH₂CH₂CH₂CH₂OMe) 5-41 H NMe(CH₂CH₂NH₂) 5-42H NMe(CH₂CH₂CH₂NH₂) 5-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 5-44 H NMe(CH₂CH₂NHMe)5-45 H NMe(CH₂CH₂CH₂NHMe) 5-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 5-47 HNMe(CH₂CH₂NMe₂) 5-48 H NMe(CH₂CH₂CH₂NMe₂) 5-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)5-50 H NMe(CH₂CONH₂) 5-51 H NMe(CH₂CH₂CONH₂) 5-52 OH OH 5-53 OH NH₂ 5-54OH NHMe 5-55 OH NHBn 5-56 OH NH(CH₂COOH) 5-57 OH NH(CH₂CH₂COOH) 5-58 OHNH(CH₂CH₂CH₂COOH) 5-59 OH NH(CH₂CN) 5-60 OH NH(CH₂CH₂CN) 5-61 OHNH(CH₂CH₂CH₂CN) 5-62 OH NH(CH₂CH₂OH) 5-63 OH NH(CH₂CH₂CH₂OH) 5-64 OHNH(CH₂CH₂CH₂CH₂OH) 5-65 OH NH(CH₂CH₂OMe) 5-66 OH NH(CH₂CH₂CH₂OMe) 5-67OH NH(CH₂CH₂CH₂CH₂OMe) 5-68 OH NH(CH₂CH₂NH₂) 5-69 OH NH(CH₂CH₂CH₂NH₂)5-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 5-71 OH NH(CH₂CH₂NHMe) 5-72 OHNH(CH₂CH₂CH₂NHMe) 5-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 5-74 OH NH(CH₂CH₂NMe₂)5-75 OH NH(CH₂CH₂CH₂NMe₂) 5-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 5-77 OHNH(CH₂CONH₂) 5-78 OH NH(CH₂CH₂CONH₂) 5-79 OH NMeBn 5-80 OH NMe(CH₂COOH)5-81 OH NMe(CH₂CH₂COOH) 5-82 OH NMe(CH₂CH₂CH₂COOH) 5-83 OH NMe(CH₂CN)5-84 OH NMe(CH₂CH₂CN) 5-85 OH NMe(CH₂CH₂CH₂CN) 5-86 OH NMe(CH₂CH₂OH)5-87 OH NMe(CH₂CH₂CH₂OH) 5-88 OH NMe(CH₂CH₂CH₂CH₂OH) 5-89 OHNMe(CH₂CH₂OMe) 5-90 OH NMe(CH₂CH₂CH₂OMe) 5-91 OH NMe(CH₂CH₂CH₂CH₂OMe)5-92 OH NMe(CH₂CH₂NH₂) 5-93 OH NMe(CH₂CH₂CH₂NH₂) 5-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 5-95 OH NMe(CH₂CH₂NHMe) 5-96 OH NMe(CH₂CH₂CH₂NHMe)5-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 5-98 OH NMe(CH₂CH₂NMe₂) 5-99 OHNMe(CH₂CH₂CH₂NMe₂) 5-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 5-101 OH NMe(CH₂CONH₂)5-102 OH NMe(CH₂CH₂CONH₂) 5-103 H NH(CH₂CH₂NHCOMe) 5-104 HNH(CH₂CH₂NHCOCH₂Me) 5-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 5-106 HNH(CH₂CH₂NHCOCHMe₂) 5-107 H NH(CH₂CH₂NHCOCMeS) 5-108 HNH(CH₂CH₂CH₂NHCOMe) 5-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 5-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 5-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 5-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 5-113 OH NH(CH₂CH₂NHCOMe) 5-114 OHNH(CH₂CH₂NHCOCH₂Me) 5-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 5-116 OHNH(CH₂CH₂NHCOCHMe₂) 5-117 OH NH(CH₂CH₂NHCOCMe₃) 5-118 OHNH(CH₂CH₂CH₂NHCOMe) 5-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 5-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 5-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 5-122 OHNH(CH₂CH₂CH₂NHCOCMeS)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 5-2, 5-3, 5-5, 5-6, 5-7, 5-11, 5-12, 5-13, 5-17, 5-18,5-19, 5-20, 5-21, 5-22, 5-23, 5-24, 5-25, 5-35, 5-36, 5-37, 5-53, 5-54,5-56, 5-57, 5-58, 5-62, 5-63, 5-64, 5-68, 5-69, 5-70, 5-71, 5-72, 5-73,5-74, 5-75, 5-76, 5-86, 5-87, and 5-88. Exemplary Compound Nos. 5-103,5-104, 5-105, 5-108, 5-109, 5-110, 5-113, 5-114, 5-115, 5-118, 5-119,and 5-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 5-2, 5-3, 5-5, 5-6,5-11, 5-12, 5-17, 5-18, 5-20, 5-21, 5-23, 5-24, 5-35, 5-36, 5-53, 5-54,5-56, 5-57, 5-62, 5-63, 5-68, 5-69, 5-71, 5-72, 5-74, 5-75, 5-86, and5-87. Exemplary Compound Nos. 5-103, 5-104, 5-108, 5-109, 5-113, 5-114,5-118, and 5-119 are also more preferred compounds.

The compounds mentioned in Table 6 are compounds having a structurerepresented by the following formula (1-F): TABLE 6 (1-F)

Exemplary Compound No. R¹ Z 6-1 H OH 6-2 H NH₂ 6-3 H NHMe 6-4 H NHBn 6-5H NH(CH₂COOH) 6-6 H NH(CH₂CH₂COOH) 6-7 H NH(CH₂CH₂CH₂COOH) 6-8 HNH(CH₂CN) 6-9 H NH(CH₂CH₂CN) 6-10 H NH(CH₂CH₂CH₂CN) 6-11 H NH(CH₂CH₂OH)6-12 H NH(CH₂CH₂CH₂OH) 6-13 H NH(CH₂CH₂CH₂CH₂OH) 6-14 H NH(CH₂CH₂OMe)6-15 H NH(CH₂CH₂CH₂OMe) 6-16 H NH(CH₂CH₂CH₂CH₂OMe) 6-17 H NH(CH₂CH₂NH₂)6-18 H NH(CH₂CH₂CH₂NH₂) 6-19 H NH(CH₂CH₂CH₂CH₂NH₂) 6-20 H NH(CH₂CH₂NHMe)6-21 H NH(CH₂CH₂CH₂NHMe) 6-22 H NH(CH₂CH₂CH₂CH₂NHMe) 6-23 HNH(CH₂CH₂NMe₂) 6-24 H NH(CH₂CH₂CH₂NMe₂) 6-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 6-26H NH(CH₂CONH₂) 6-27 H NH(CH₂CH₂CONH₂) 6-28 H NMeBn 6-29 H NMe(CH₂COOH)6-30 H NMe(CH₂CH₂COOH) 6-31 H NMe(CH₂CH₂CH₂COOH) 6-32 H NMe(CH₂CN) 6-33H NMe(CH₂CH₂CN) 6-34 H NMe(CH₂CH₂CH₂CN) 6-35 H NMe(CH₂CH₂OH) 6-36 HNMe(CH₂CH₂CH₂OH) 6-37 H NMe(CH₂CH₂CH₂CH₂OH) 6-38 H NMe(CH₂CH₂OMe) 6-39 HNMe(CH₂CH₂CH₂OMe) 6-40 H NMe(CH₂CH₂CH₂CH₂OMe) 6-41 H NMe(CH₂CH₂NH₂) 6-42H NMe(CH₂CH₂CH₂NH₂) 6-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 6-44 H NMe(CH₂CH₂NHMe)6-45 H NMe(CH₂CH₂CH₂NHMe) 6-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 6-47 HNMe(CH₂CH₂NMe₂) 6-48 H NMe(CH₂CH₂CH₂NMe₂) 6-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)6-50 H NMe(CH₂CONH₂) 6-51 H NMe(CH₂CH₂CONH₂) 6-52 OH OH 6-53 OH NH₂ 6-54OH NHMe 6-55 OH NHBn 6-56 OH NH(CH₂COOH) 6-57 OH NH(CH₂CH₂COOH) 6-58 OHNH(CH₂CH₂CH₂COOH) 6-59 OH NH(CH₂CN) 6-60 OH NH(CH₂CH₂CN) 6-61 OHNH(CH₂CH₂CH₂CN) 6-62 OH NH(CH₂CH₂OH) 6-63 OH NH(CH₂CH₂CH₂OH) 6-64 OHNH(CH₂CH₂CH₂CH₂OH) 6-65 OH NH(CH₂CH₂OMe) 6-66 OH NH(CH₂CH₂CH₂OMe) 6-67OH NH(CH₂CH₂CH₂CH₂OMe) 6-68 OH NH(CH₂CH₂NH₂) 6-69 OH NH(CH₂CH₂CH₂NH₂)6-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 6-71 OH NH(CH₂CH₂NHMe) 6-72 OHNH(CH₂CH₂CH₂NHMe) 6-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 6-74 OH NH(CH₂CH₂NMe₂)6-75 OH NH(CH₂CH₂CH₂NMe₂) 6-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 6-77 OHNH(CH₂CONH₂) 6-78 OH NH(CH₂CH₂CONH₂) 6-79 OH NMeBn 6-80 OH NMe(CH₂COOH)6-81 OH NMe(CH₂CH₂COOH) 6-82 OH NMe(CH₂CH₂CH₂COOH) 6-83 OH NMe(CH₂CN)6-84 OH NMe(CH₂CH₂CN) 6-85 OH NMe(CH₂CH₂CH₂CN) 6-86 OH NMe(CH₂CH₂OH)6-87 OH NMe(CH₂CH₂CH₂OH) 6-88 OH NMe(CH₂CH₂CH₂CH₂OH) 6-89 OHNMe(CH₂CH₂OMe) 6-90 OH NMe(CH₂CH₂CH₂OMe) 6-91 OH NMe(CH₂CH₂CH₂CH₂OMe)6-92 OH NMe(CH₂CH₂NH₂) 6-93 OH NMe(CH₂CH₂CH₂NH₂) 6-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 6-95 OH NMe(CH₂CH₂NHMe) 6-96 OH NMe(CH₂CH₂CH₂NHMe)6-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 6-98 OH NMe(CH₂CH₂NMe₂) 6-99 OHNMe(CH₂CH₂CH₂NMe₂) 6-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 6-101 OH NMe(CH₂CONH₂)6-102 OH NMe(CH₂CH₂CONH₂) 6-103 H NH(CH₂CH₂NHCOMe) 6-104 HNH(CH₂CH₂NHCOCH₂Me) 6-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 6-106 HNH(CH₂CH₂NHCOCHMe₂) 6-107 H NH(CH₂CH₂NHCOCMe₃) 6-108 HNH(CH₂CH₂CH₂NHCOMe) 6-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 6-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 6-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 6-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 6-113 OH NH(CH₂CH₂NHCOMe) 6-114 OHNH(CH₂CH₂NHCOCH₂Me) 6-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 6-116 OHNH(CH₂CH₂NHCOCHMe₂) 6-117 OH NH(CH₂CH₂NHCOCMe₃) 6-118 OHNH(CH₂CH₂CH₂NHCOMe) 6-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 6-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 6-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 6-122 OHNH(CH₂CH₂CH₂NHCOCMe₃)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 6-2, 6-3, 6-5, 6-6, 6-7, 6-11, 6-12, 6-13, 6-17, 6-18,6-19, 6-20, 6-21, 6-22, 6-23, 6-24, 6-25, 6-35, 6-36, 6-37, 6-53, 6-54,6-56, 6-57, 6-58, 6-62, 6-63, 6-64, 6-68, 6-69, 6-70, 6-71, 6-72, 6-73,6-74, 6-75, 6-76, 6-86, 6-87, and 6-88. Exemplary Compound Nos. 6-103,6-104, 6-105, 6-108, 6-109, 6-110, 6-113, 6-114, 6-115, 6-118, 6-119,and 6-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 6-2, 6-3, 6-5, 6-6,6-11, 6-12, 6-17, 6-18, 6-20, 6-21, 6-23, 6-24, 6-35, 6-36, 6-53, 6-54,6-56, 6-57, 6-62, 6-63, 6-68, 6-69, 6-71, 6-72, 6-74, 6-75, 6-86, and6-87. Exemplary Compound Nos. 6-103, 6-104, 6-108, 6-109, 6-113, 6-114,6-118, and 6-119 are also more preferred compounds.

The compounds mentioned in Table 7 are compounds having a structurerepresented by the following formula (1-G): TABLE 7 (1-G)

Exemplary Compound No. R¹ Z 7-1 H OH 7-2 H NH₂ 7-3 H NHMe 7-4 H NHBn 7-5H NH(CH₂COOH) 7-6 H NH(CH₂CH₂COOH) 7-7 H NH(CH₂CH₂CH₂COOH) 7-8 HNH(CH₂CN) 7-9 H NH(CH₂CH₂CN) 7-10 H NH(CH₂CH₂CH₂CN) 7-11 H NH(CH₂CH₂OH)7-12 H NH(CH₂CH₂CH₂OH) 7-13 H NH(CH₂CH₂CH₂CH₂OH) 7-14 H NH(CH₂CH₂OMe)7-15 H NH(CH₂CH₂CH₂OMe) 7-16 H NH(CH₂CH₂CH₂CH₂OMe) 7-17 H NH(CH₂CH₂NH₂)7-18 H NH(CH₂CH₂CH₂NH₂) 7-19 H NH(CH₂CH₂CH₂CH₂NH₂) 7-20 H NH(CH₂CH₂NHMe)7-21 H NH(CH₂CH₂CH₂NHMe) 7-22 H NH(CH₂CH₂CH₂CH₂NHMe) 7-23 HNH(CH₂CH₂NMe₂) 7-24 H NH(CH₂CH₂CH₂NMe₂) 7-25 H NH(CH₂CH₂CH₂CH₂NMe₂) 7-26H NH(CH₂CONH₂) 7-27 H NH(CH₂CH₂CONH₂) 7-28 H NMeBn 7-29 H NMe(CH₂COOH)7-30 H NMe(CH₂CH₂COOH) 7-31 H NMe(CH₂CH₂CH₂COOH) 7-32 H NMe(CH₂CN) 7-33H NMe(CH₂CH₂CN) 7-34 H NMe(CH₂CH₂CH₂CN) 7-35 H NMe(CH₂CH₂OH) 7-36 HNMe(CH₂CH₂CH₂OH) 7-37 H NMe(CH₂CH₂CH₂CH₂OH) 7-38 H NMe(CH₂CH₂OMe) 7-39 HNMe(CH₂CH₂CH₂OMe) 7-40 H NMe(CH₂CH₂CH₂CH₂OMe) 7-41 H NMe(CH₂CH₂NH₂) 7-42H NMe(CH₂CH₂CH₂NH₂) 7-43 H NMe(CH₂CH₂CH₂CH₂NH₂) 7-44 H NMe(CH₂CH₂NHMe)7-45 H NMe(CH₂CH₂CH₂NHMe) 7-46 H NMe(CH₂CH₂CH₂CH₂NHMe) 7-47 HNMe(CH₂CH₂NMe₂) 7-48 H NMe(CH₂CH₂CH₂NMe₂) 7-49 H NMe(CH₂CH₂CH₂CH₂NMe₂)7-50 H NMe(CH₂CONH₂) 7-51 H NMe(CH₂CH₂CONH₂) 7-52 OH OH 7-53 OH NH₂ 7-54OH NHMe 7-55 OH NHBn 7-56 OH NH(CH₂COOH) 7-57 OH NH(CH₂CH₂COOH) 7-58 OHNH(CH₂CH₂CH₂COOH) 7-59 OH NH(CH₂CN) 7-60 OH NH(CH₂CH₂CN) 7-61 OHNH(CH₂CH₂CH₂CN) 7-62 OH NH(CH₂CH₂OH) 7-63 OH NH(CH₂CH₂CH₂OH) 7-64 OHNH(CH₂CH₂CH₂CH₂OH) 7-65 OH NH(CH₂CH₂OMe) 7-66 OH NH(CH₂CH₂CH₂OMe) 7-67OH NH(CH₂CH₂CH₂CH₂OMe) 7-68 OH NH(CH₂CH₂NH₂) 7-69 OH NH(CH₂CH₂CH₂NH₂)7-70 OH NH(CH₂CH₂CH₂CH₂NH₂) 7-71 OH NH(CH₂CH₂NHMe) 7-72 OHNH(CH₂CH₂CH₂NHMe) 7-73 OH NH(CH₂CH₂CH₂CH₂NHMe) 7-74 OH NH(CH₂CH₂NMe₂)7-75 OH NH(CH₂CH₂CH₂NMe₂) 7-76 OH NH(CH₂CH₂CH₂CH₂NMe₂) 7-77 OHNH(CH₂CONH₂) 7-78 OH NH(CH₂CH₂CONH₂) 7-79 OH NMeBn 7-80 OH NMe(CH₂COOH)7-81 OH NMe(CH₂CH₂COOH) 7-82 OH NMe(CH₂CH₂CH₂COOH) 7-83 OH NMe(CH₂CN)7-84 OH NMe(CH₂CH₂CN) 7-85 OH NMe(CH₂CH₂CH₂CN) 7-86 OH NMe(CH₂CH₂OH)7-87 OH NMe(CH₂CH₂CH₂OH) 7-88 OH NMe(CH₂CH₂CH₂CH₂OH) 7-89 OHNMe(CH₂CH₂OMe) 7-90 OH NMe(CH₂CH₂CH₂OMe) 7-91 OH NMe(CH₂CH₂CH₂CH₂OMe)7-92 OH NMe(CH₂CH₂NH₂) 7-93 OH NMe(CH₂CH₂CH₂NH₂) 7-94 OHNMe(CH₂CH₂CH₂CH₂NH₂) 7-95 OH NMe(CH₂CH₂NHMe) 7-96 OH NMe(CH₂CH₂CH₂NHMe)7-97 OH NMe(CH₂CH₂CH₂CH₂NHMe) 7-98 OH NMe(CH₂CH₂NMe₂) 7-99 OHNMe(CH₂CH₂CH₂NMe₂) 7-100 OH NMe(CH₂CH₂CH₂CH₂NMe₂) 7-101 OH NMe(CH₂CONH₂)7-102 OH NMe(CH₂CH₂CONH₂) 7-103 H NH(CH₂CH₂NHCOMe) 7-104 HNH(CH₂CH₂NHCOCH₂Me) 7-105 H NH(CH₂CH₂NHCOCH₂CH₂Me) 7-106 HNH(CH₂CH₂NHCOCHMe₂) 7-107 H NH(CH₂CH₂NHCOCMe₃) 7-108 HNH(CH₂CH₂CH₂NHCOMe) 7-109 H NH(CH₂CH₂CH₂NHCOCH₂Me) 7-110 HNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 7-111 H NH(CH₂CH₂CH₂NHCOCHMe₂) 7-112 HNH(CH₂CH₂CH₂NHCOCMe₃) 7-113 OH NH(CH₂CH₂NHCOMe) 7-114 OHNH(GH₂CH₂NHCOCH₂Me) 7-115 OH NH(CH₂CH₂NHCOCH₂CH₂Me) 7-116 OHNH(CH₂CH₂NHCOCHMe₂) 7-117 OH NH(CH₂CH₂NHCOCMe₃) 7-118 OHNH(CH₂CH₂CH₂NHCOMe) 7-119 OH NH(CH₂CH₂CH₂NHCOCH₂Me) 7-120 OHNH(CH₂CH₂CH₂NHCOCH₂CH₂Me) 7-121 OH NH(CH₂CH₂CH₂NHCOCHMe₂) 7-122 OHNH(CH₂CH₂CH₂NHCOCMe₃)

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 7-2, 7-3, 7-5, 7-6, 7-7, 7-11, 7-12, 7-13, 7-17, 7-18,7-19, 7-20, 7-21, 7-22, 7-23, 7-24, 7-25, 7-35, 7-36, 7-37, 7-53, 7-54,7-56, 7-57, 7-58, 7-62, 7-63, 7-64, 7-68, 7-69, 7-70, 7-71, 7-72, 7-73,7-74, 7-75, 7-76, 7-86, 7-87, and 7-88. Exemplary Compound Nos. 7-103,7-104, 7-105, 7-108, 7-109, 7-110, 7-113, 7-114, 7-115, 7-118, 7-119,and 7-120 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 7-2, 7-3, 7-5, 7-6,7-11, 7-12, 7-17, 7-18, 7-20, 7-21, 7-23, 7-24, 7-35, 7-36, 7-53, 7-54,7-56, 7-57, 7-62, 7-63, 7-68, 7-69, 7-71, 7-72, 7-74, 7-75, 7-86, and7-87. Exemplary Compound Nos. 7-103, 7-104, 7-108, 7-109, 7-113, 7-114,7-118, and 7-119 are also more preferred compounds.

The compounds mentioned in Table 8 are compounds having a structurerepresented by the following formula (1-H): TABLE 8 (1-H)

Exemplary Compound No. R¹ A⁶¹ 8-1 H H 8-2 H Me 8-3 H CH₂COOH 8-4 HCH₂CH₂COOH 8-5 H CH₂CH₂CH₂COOH 8-6 H CH₂CN 8-7 H CH₂CH₂CN 8-8 HCH₂CH₂CH₂CN 8-9 H CH₂CH₂OH 8-10 H CH₂CH₂CH₂OH 8-11 H CH₂CH₂CH₂CH₂OH 8-12H CH₂CH₂OMe 8-13 H CH₂CH₂CH₂OMe 8-14 H CH₂CH₂CH₂CH₂OMe 8-15 H CH₂CH₂NH₂8-16 H CH₂CH₂CH₂NH₂ 8-17 H CH₂CH₂CH₂CH₂NH₂ 8-18 H CH₂CH₂NHMe 8-19 HCH₂CH₂CH₂NHMe 8-20 H CH₂CH₂CH₂CH₂NHMe 8-21 H CH₂CH₂NMe₂ 8-22 HCH₂CH₂CH₂NMe₂ 8-23 H CH₂CH₂CH₂CH₂NMe₂ 8-24 H CH₂CONH₂ 8-25 H CH₂CH₂CONH₂8-26 OH H 8-27 OH Me 8-28 OH CH₂COOH 8-29 OH CH₂CH₂COOH 8-30 OHCH₂CH₂CH₂COOH 8-31 OH CH₂CN 8-32 OH CH₂CH₂CN 8-33 OH CH₂CH₂CH₂CN 8-34 OHCH₂CH₂OH 8-35 OH CH₂GH₂CH₂OH 8-36 OH CH₂CH₂CH₂CH₂OH 8-37 OH CH₂CH₂OMe8-38 OH CH₂CH₂CH₂OMe 8-39 OH CH₂CH₂CH₂CH₂OMe 8-40 OH CH₂CH₂NH₂ 8-41 OHCH₂CH₂CH₂NH₂ 8-42 OH CH₂CH₂CH₂CH₂NH₂ 8-43 OH CH₂CH₂NHMe 8-44 OHCH₂CH₂CH₂NHMe 8-45 OH CH₂CH₂CH₂CH₂NHMe 8-46 OH CH₂CH₂NMe₂ 8-47 OHCH₂CH₂CH₂NMe₂ 8-48 OH CH₂CH₂CH₂CH₂NMe₂ 8-49 OH CH₂CONH₂ 8-50 OHCH₂CH₂CONH₂ 8-51 H CH₂CH₂NHCOMe 8-52 H CH₂CH₂NHCOCH₂Me 8-53 HCH₂CH₂NHCOCH₂CH₂Me 8-54 H CH₂CH₂NHCOCHMe₂ 8-55 H CH₂CH₂NHCOCMe₃ 8-56 HCH₂CH₂CH₂NHCOMe 8-57 H CH₂CH₂CH₂NHCOCH₂Me 8-58 H CH₂CH₂CH₂NHCOCH₂CH₂Me8-59 H CH₂CH₂CH₂NHCOCHMe₂ 8-60 H CH₂CH₂CH₂NHCOCMe₃ 8-61 OH CH₂CH₂NHCOMe8-62 OH CH₂GH₂NHCOCH₂Me 8-63 OH CH₂CH₂NHCOCH₂CH₂Me 8-64 OHCH₂CH₂NHCOCHMe₂ 8-65 OH CH₂CH₂NHCOCMe₃ 8-66 OH CH₂GH₂CH₂NHCOMe 8-67 OHCH₂CH₂CH₂NHCOCH₂Me 8-68 OH CH₂CH₂CH₂NHCOCH₂CH₂Me 8-69 OHCH₂CH₂CH₂NHCOCHMe₂ 8-70 OH CH₂CH₂CH₂NHCOCMe₃

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 8-1, 8-2, 8-3, 8-4, 8-5, 8-9, 8-10, 8-11, 8-15, 8-16,8-17, 8-18, 8-19, 8-20, 8-21, 8-22, 8-23, 8-26, 8-27, 8-28, 8-29, 8-30,8-34, 8-35, 8-36, 8-40, 8-41, 8-42, 8-43, 8-44, 8-45, 8-46, 8-47, and8-48. Exemplary Compound Nos. 8-51, 8-52, 8-53, 8-56, 8-57, 8-58, 8-61,8-62, 8-63, 8-66, 8-67, and 8-68 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 8-1, 8-3, 8-4, 8-9,8-10, 8-15, 8-16, 8-18, 8-19, 8-21, 8-22, 8-26, 8-28, 8-29, 8-34, 8-35,8-40, 8-41, 8-43, 8-44, 8-46, and 8-47. Exemplary Compound Nos. 8-51,8-52, 8-56, 8-57, 8-61, 8-62, 8-66, and 8-67 are also more preferredcompounds.

Further,N-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 8-71),N-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 8-72),1-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}azetidin-2-one(Exemplary Compound No. 8-73),1-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}azetidin-2-one(Exemplary Compound No. 8-74),1-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 8-75),1-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 8-76),1-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 8-77), and1-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 8-78) are also preferred compounds. Further,Exemplary Compound Nos. 8-71, 8-72, 8-73, and 8-74 are also morepreferred compounds.

The compounds mentioned in Table 9 are compounds having a structurerepresented by the following formula (1-I): TABLE 9 (1-I)

Exemplary Compound No. R¹ A⁶¹ 9-1 H H 9-2 H Me 9-3 H CH₂COOH 9-4 HCH₂CH₂COOH 9-5 H CH₂CH₂CH₂COOH 9-6 H CH₂CN 9-7 H CH₂CH₂CN 9-8 HCH₂CH₂CH₂CN 9-9 H CH₂CH₂OH 9-10 H CH₂CH₂CH₂OH 9-11 H CH₂CH₂CH₂CH₂OH 9-12H CH₂CH₂OMe 9-13 H CH₂CH₂CH₂OMe 9-14 H CH₂CH₂CH₂CH₂OMe 9-15 H CH₂CH₂NH₂9-16 H CH₂CH₂CH₂NH₂ 9-17 H CH₂CH₂CH₂CH₂NH₂ 9-18 H CH₂CH₂NHMe 9-19 HCH₂CH₂CH₂NHMe 9-20 H CH₂CH₂CH₂CH₂NHMe 9-21 H CH₂CH₂NMe₂ 9-22 HCH₂CH₂CH₂NMe₂ 9-23 H CH₂CH₂CH₂CH₂NMe₂ 9-24 H CH₂CONH₂ 9-25 H CH₂CH₂CONH₂9-26 OH H 9-27 OH Me 9-28 OH CH₂COOH 9-29 OH CH₂CH₂COOH 9-30 OHCH₂CH₂CH₂COOH 9-31 OH CH₂CN 9-32 OH CH₂CH₂CN 9-33 OH CH₂CH₂CH₂CN 9-34 OHCH₂CH₂OH 9-35 OH CH₂CH₂CH₂OH 9-36 OH CH₂CH₂CH₂CH₂OH 9-37 OH CH₂CH₂OMe9-38 OH CH₂CH₂CH₂OMe 9-39 OH CH₂CH₂CH₂CH₂OMe 9-40 OH CH₂CH₂NH₂ 9-41 OHCH₂CH₂CH₂NH₂ 9-42 OH CH₂CH₂CH₂CH₂NH₂ 9-43 OH CH₂CH₂NHMe 9-44 OHCH₂CH₂CH₂NHMe 9-45 OH CH₂CH₂CH₂CH₂NHMe 9-46 OH CH₂CH₂NMe₂ 9-47 OHGH₂CH₂CH₂NMe₂ 9-48 OH CH₂CH₂CH₂CH₂NMe₂ 9-49 OH CH₂CONH₂ 9-50 OHCH₂CH₂CONH₂ 9-51 H CH₂CH₂NHCOMe 9-52 H CH₂CH₂NHCOCH₂Me 9-53 HCH₂CH₂NHCOCH₂CH₂Me 9-54 H CH₂CH₂NHCOCHMe₂ 9-55 H CH₂CH₂NHCOCMe₃ 9-56 HCH₂CH₂CH₂NHCOMe 9-57 H CH₂CH₂CH₂NHCOCH₂Me 9-58 H CH₂CH₂CH₂NHCOCH₂CH₂Me9-59 H CH₂CH₂CH₂NHCOCHMe₂ 9-60 H CH₂CH₂CH₂NHCOCMe₃ 9-61 OH CH₂CH₂NHCOMe9-62 OH CH₂CH₂NHCOCH₂Me 9-63 OH CH₂CH₂NHCOCH₂CH₂Me 9-64 OHCH₂CH₂NHCOCHMe₂ 9-65 OH CH₂CH₂NHCOCMe₃ 9-66 OH CH₂CH₂CH₂NHCOMe 9-67 OHCH₂CH₂CH₂NHCOCH₂Me 9-68 OH CH₂CH₂CH₂NHCOCH₂CH₂Me 9-69 OHCH₂CH₂CH₂NHCOCHMe₂ 9-70 OH CH₂CH₂CH₂NHCOCMe₃

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 9-1, 9-2, 9-3, 9-4, 9-5, 9-9, 9-10, 9-11, 9-15, 9-16,9-17, 9-18, 9-19, 9-20, 9-21, 9-22, 9-23, 9-26, 9-27, 9-28, 9-29, 9-30,9-34, 9-35, 9-36, 9-40, 9-41, 9-42, 9-43, 9-44, 9-45, 9-46, 9-47, and9-48. Exemplary Compound Nos. 9-51, 9-52, 9-53, 9-56, 9-57, 9-58, 9-61,9-62, 9-63, 9-66, 9-67, and 9-68 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 9-1, 9-3, 9-4, 9-9,9-10, 9-15, 9-16, 9-18, 9-19, 9-21, 9-22, 9-26, 9-28, 9-29, 9-34, 9-35,9-40, 9-41, 9-43, 9-44, 9-46, and 9-47. Exemplary Compound Nos. 9-51,9-52, 9-56, 9-57, 9-61, 9-62, 9-66, and 9-67 are also more preferredcompounds.

Further,N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 9-71),N-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 9-72),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}azetidin-2-one(Exemplary Compound No. 9-73),1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}azetidin-2-one(Exemplary Compound No. 9-74),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 9-75),1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 9-76),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 9-77),1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 9-78),1-(3-fluoropiperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalene (ExemplaryCompound No. 9-79), and1-(3-fluoropiperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol(Exemplary Compound No. 9-80) are also preferred compounds. Further,Exemplary Compound Nos. 9-71, 9-72, 9-73, 9-74, 9-79, and 9-80 are alsomore preferred compounds.

The compounds mentioned in Table 10 are compounds having a structurerepresented by the following formula (1-J): TABLE 10 (1-J)

Exemplary Compound No. R¹ A61 10-1 H H 10-2 H Me 10-3 H CH₂COOH 10-4 HCH₂CH₂COOH 10-5 H CH₂CH₂CH₂COOH 10-6 H CH₂CN 10-7 H CH₂CH₂CN 10-8 HCH₂CH₂CH₂CN 10-9 H CH₂CH₂OH 10-10 H CH₂CH₂CH₂OH 10-11 H CH₂CH₂CH₂CH₂OH10-12 H CH₂CH₂OMe 10-13 H CH₂CH₂CH₂OMe 10-14 H CH₂CH₂CH₂CH₂OMe 10-15 HCH₂CH₂NH₂ 10-16 H CH₂CH₂CH₂NH₂ 10-17 H CH₂CH₂CH₂CH₂NH₂ 10-18 HCH₂CH₂NHMe 10-19 H CH₂CH₂CH₂NHMe 10-20 H CH₂CH₂CH₂CH₂NHMe 10-21 HCH₂CH₂NMe₂ 10-22 H CH₂CH₂CH₂NMe₂ 10-23 H CH₂CH₂CH₂CH₂NMe₂ 10-24 HCH₂CONH₂ 10-25 H CH₂CH₂CONH₂ 10-26 OH H 10-27 OH Me 10-28 OH CH₂COOH10-29 OH CH₂CH₂COOH 10-30 OH CH₂CH₂CH₂COOH 10-31 OH CH₂CN 10-32 OHCH₂CH₂CN 10-33 OH CH₂CH₂CH₂CN 10-34 OH CH₂CH₂OH 10-35 OH CH₂CH₂CH₂OH10-36 OH CH₂CH₂CH₂CH₂OH 10-37 OH CH₂CH₂OMe 10-38 OH CH₂CH₂CH₂OMe 10-39OH CH₂CH₂CH₂CH₂OMe 10-40 OH CH₂CH₂NH₂ 10-41 OH CH₂CH₂CH₂NH₂ 10-42 OHCH₂CH₂CH₂CH₂NH₂ 10-43 OH CH₂CH₂NHMe 10-44 OH CH₂CH₂CH₂NHMe 10-45 OHCH₂CH₂CH₂CH₂NHMe 10-46 OH CH₂CH₂NMe₂ 10-47 OH CH₂CH₂CH₂NMe₂ 10-48 OHCH₂CH₂CH₂CH₂NMe₂ 10-49 OH CH₂CONH₂ 10-50 OH CH₂CH₂CONH₂ 10-51 HCH₂CH₂NHCOMe 10-52 H CH₂CH₂NHCOCH₂Me 10-53 H CH₂CH₂NHCOCH₂CH₂Me 10-54 HCH₂CH₂NHCOCHMe₂ 10-55 H CH₂CH₂NHCOCMe₃ 10-56 H CH₂CH₂CH₂NHCOMe 10-57 HCH₂CH₂CH₂NHCOCH₂Me 10-58 H CH₂CH₂CH₂NHCOCH₂CH₂Me 10-59 HCH₂CH₂CH₂NHCOCHMe₂ 10-60 H CH₂CH₂CH₂NHCOCMe₃ 10-61 OH CH₂CH₂NHCOMe 10-62OH CH₂CH₂NHCOCH₂Me 10-63 OH CH₂CH₂NHCOCH₂CH₂Me 10-64 OH CH₂CH₂NHCOCHMe₂10-65 OH CH₂CH₂NHCOCMe₃ 10-66 OH CH₂CH₂CH₂NHCOMe₃ 10-67 OHCH₂CH₂CH₂NHCOCH₂Me 10-68 OH CH₂CH₂CH₂NHCOCH₂CH₂Me 10-69 OHCH₂CH₂CH₂NHCOCHMe₂ 10-70 OH CH₂CH₂CH₂NHCOCMe₃

Among the compounds mentioned above, preferred compounds are ExemplaryCompound Nos. 10-1, 10-2, 10-3, 10-4, 10-5, 10-9, 10-10, 10-11, 10-15,10-16, 10-17, 10-18, 10-19, 10-20, 10-21, 10-22, 10-23, 10-26, 10-27,10-28, 10-29, 10-30, 10-34, 10-35, 10-36, 10-40, 10-41, 10-42, 10-43,10-44, 10-45, 10-46, 10-47, and 10-48. Exemplary Compound Nos. 10-51,10-52, 10-53, 10-56, 10-57, 10-58, 10-61, 10-62, 10-63, 10-66, 10-67,and 10-68 are also preferred compounds.

More preferred compounds are Exemplary Compound Nos. 10-1, 10-3, 10-4,10-9, 10-10, 10-15, 10-16, 10-18, 10-19, 10-21, 10-22, 10-26, 10-28,10-29, 10-34, 10-35, 10-40, 10-41, 10-43, 10-44, 10-46, and 10-47.Exemplary Compound Nos. 10-51, 10-52, 10-56, 10-57, 10-61, 10-62, 10-66,and 10-67 are also more preferred compounds.

Further,N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 10-71),N-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}-N-methylacetamide(Exemplary Compound No. 10-72),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-ylmethyl]ethyl}azetidin-2-one(Exemplary Compound No. 10-73),1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}azetidin-2-one(Exemplary Compound No. 10-74),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 10-75),1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}pyrrolidin-2-one(Exemplary Compound No. 10-76),1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 10-77), and1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-ylmethyl)piperidin-1-yl]ethyl}piperidin-2-one(Exemplary Compound No. 10-78) are also preferred compounds. Further,Exemplary Compound Nos. 10-71, 10-72, 10-73, and 10-74 are also morepreferred compounds.

The compounds of the present invention represented by the formula (1)may have one or more asymmetric carbons, and stereoisomers based on suchasymmetric carbons such as optical antipodes and diastereoisomer mayexist. The stereoisomers in pure forms, any mixtures, racemates and thelike of the stereoisomers all fall within the scope of the presentinvention. Further, when the compounds of the present invention have anolefinic double bond or a cyclic structure, two or more kinds ofstereoisomers may exist, and such stereoisomers in pure forms, anymixtures, and the like of such stereoisomers all fall within the scopeof the present invention. Furthermore, the compounds of the presentinvention represented by the formula (1) may exist as tautomers.Existence of such tautomers is apparent to those skilled in the art, andsuch tautomers all fall within the scope of the present invention.

The compounds of the present invention may also exist as salts. Forms ofthe salts are not particularly limited. Acid addition salts aregenerally formed, or base addition salts may be formed depending on thetypes of substituents. The types of physiologically acceptable salts arewell known to those skilled in the art, and examples include, forexample, those described by Berge et al. in J. Pharm. Sci., 66, 1-19(1977). Examples of the acid addition salts include, for example,mineral acid salts such as hydrochlorides, hydrobromides, hydroiodides,nitrates, sulfates, and hydrogensulfates, phosphates,hydrogenphosphates, organic acid salts such as acetates,trifluoroacetates, gluconates, lactates, salicylates, citrates,tartrates, ascorbates, succinates, maleates, fumarates, formates,benzoates, methanesulfonates, ethanesulfonates, benzenesulfonates andp-toluenesulfonates. Where one or more substituents contain an acidicmoiety, examples of suitable pharmacologically acceptable base additionsalts include, for example, metal salts such as sodium salts, potassiumsalts, magnesium salts, lithium salts, calcium salts, aluminum salts andzinc salts, and salts of organic amines such as ethanolamine.

Methods for preparation of the compounds represented by the formula (1)are not particularly limited. For example, they can be preparedaccording to the methods described below.

(Preparation Method 1)

The compounds represented by the formula (1) can be prepared from acompound represented by the following formula (A):

wherein R¹ represents hydrogen atom, chlorine atom, or hydroxyl group;

X¹ . . . X² represents —CH(R²)—CH(R³)—, —CH(R²)—CH(R³)—CH(R⁴)—,—C(R²)═C(R³)—, or —C(R²)═C(R³)—CH(R⁴)—;

R², R³, and R⁴ independently represent hydrogen atom, or an alkyl group;

A¹, A¹¹, A², and A²¹ independently represent hydrogen atom, or an alkylgroup;

Y represents —CH(A³)-, —CH(A³)-C(A⁴)(A⁴¹)-,—CH(A³)-C(A⁴)(A⁴¹)-C(A⁵)(A⁵¹)-, or a single bond;

A³, A⁴, A⁴¹, A⁵, and A⁵¹ independently represent hydrogen atom, or analkyl group;

Z^(a) represents —O(PG¹), —OH, —N(A⁶)(PG²), —NH(A⁶), —N(A⁶)(A⁶²), or—N(A⁶)(A⁶³);

PG¹ represents a protective group of hydroxyl group, PG² represents anamino protective group;

A⁶² represents an alkyl group, an aralkyl group, an alkyl groupsubstituted with carboxyl group, an alkyl group substituted withcarboxyl group protected with a protective group for carboxyl group PG³,an alkyl group substituted with cyano group, an alkyl group substitutedwith hydroxyl group, an alkyl group substituted with hydroxyl groupprotected with PG¹, an alkyl group substituted with an alkoxyl group, analkyl group substituted with amino group, an alkyl group substitutedwith amino group protected with PG², an alkyl group of which end issubstituted with N(A⁷)(—X³-A⁷¹), or an alkyl group substituted withaminocarbonyl group;

A⁶³ represents an alkyl group of which end is substituted with NH(A⁷),where A⁷ in this case represents hydrogen atom, or an alkyl group; and

groups in one or more combinations selected from the group consisting ofcombinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ and A², A² and A³,A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ may bind to each other toform a 5- or 6-membered ring, by removing a protective group of thecompound (Step 1-1) if the protective group exists in the compound.

The PG¹ group used herein is not particularly limited so long as itprotects hydroxyl group, does not react in reactions in this preparationprocess other than the deprotection step, and further can be easilyremoved. Preferred examples of the protective group of hydroxyl groupinclude a trialkylsilyl group such as tert-butyldimethylsilyl group(TBDMS group), an acyl group such as acetyl group, benzyl group (Bngroup), and tetrahydropyranyl (THP) group, and particularly preferredexamples include Bn group and THP group.

The PG² group is not particularly limited so long as it protects aminogroup, does not react in reactions in this preparation process otherthan the deprotection step, and further can be easily removed. Preferredexamples include t-butoxycarbonyl group (Boc group), benzyloxycarbonylgroup (Cbz group), benzyl group (Bn group), phthaloyl group, andtriphenylmethyl group, and particularly preferred examples include Bocgroup, Cbz group, and Bn group.

The PG³ group is not particularly limited so long as it protectscarboxyl group, does not react in reactions in this preparation processother than the deprotection step, and further can be easily removed.Examples include alkyl groups, and specifically, tert-butyl group ispreferred, for example.

In the aforementioned deprotection steps, when PG¹, PG², or PG³ existsin a compound of the formula (A), it can be removed by a known reactiondepending on a kind of the protective group. These methods are apparentto those skilled in the art by referring to prior art described in, forexample, Greene, T. W. and Wuts, P. G. M. “Protective Groups in OrganicSynthesis”, John Wiley and Sons Inc. (3rd edition); and Kocienski, P.J., “Protecting Groups”, Georg Thieme Verlag (1994).

More specific explanation will be set forth below. For example, a methodof preparing the compounds of the formula (1) by removing Bn group froma compound of the formula (A) wherein PG¹ represents Bn group can beperformed by using known reduction conditions of hydrogenation. Examplesof the method include a method performed in an alcohol, ethyl acetate,an ether solvent such as 1,4-dioxane, or a mixed solvent thereof, andexamples of catalyst include, for example, palladium/carbon. Examples ofthe reaction include a method of performing the reaction at 0 to 80° C.,preferably 10 to 40° C.

For example, examples of a method of preparing the compounds of theformula (1), by removing THP group from a compound of the formula (A)wherein PG¹ represents THP group, include a method utilizing acidolysis.Examples of the acid include mineral acids, and specific examples arehydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and thelike, and hydrochloric acid is preferred. The acid is preferably used inan amount of 1 to 100 fold moles. Examples of the solvent include water,alcohols, ether type solvents such as 1,4-dioxane, and mixed solventsthereof. The reaction is preferably performed in the temperature rangeof from room temperature to reflux temperature of the solvent.

For example, a method of preparing the compounds of the formula (1) byremoving Boc group from a compound of the formula (A) wherein PG²represents Boc group can be performed by using known acidic conditions.As for the solvent used for the reaction, the reaction can be performed,for example, without solvent, or in water, an alcohol, acetonitrile, anether solvent such as 1,4-dioxane, or a mixed solvent thereof. As theacid, a mineral acid and organic acid can be used. Specific examplesinclude hydrochloric acid, sulfuric acid, nitric acid, acetic acid,methanesulfonic acid, phosphoric acid, and the like, and hydrochloricacid is preferred. The acid is preferably used in an amount of 1 to 100fold moles based on the compound of the formula (A). The reaction ispreferably performed in the temperature range of from room temperatureto the reflux temperature of the solvent. Alternatively, the removal ofBoc group can be performed by using trifluoroacetic acid. Examples ofthis method include a method of using trifluoroacetic acid alone, and amethod of using trifluoroacetic acid as a mixed solvent system withwater or dichloromethane. The reaction is performed, for example, in thetemperature range of from 0 to 100° C., preferably from room temperatureto 50° C. As for the amount of trifluoroacetic acid, 1 to 100 fold molesare preferably used based on the compound of the formula (A).

Further, the method of preparing the compounds of the formula (1) byremoving Cbz group (or Bn group) from a compound of the formula (A)wherein PG² represents Cbz group or Bn group can be performed by usingknown reduction conditions of hydrogenation. Examples of the methodinclude a method performed in an alcohol, ethyl acetate, an ether typesolvent such as 1,4-dioxane, or a mixed solvent thereof, and examples ofcatalyst include, for example, palladium/carbon. The reaction isperformed, for example, at 0 to 100° C., preferably 10 to 80° C.

Further, the method of preparing the compounds of the formula (1) byremoving tert-butyl group from a compound of the formula (A) wherein PG³represents tert-butyl group can be performed by known acidolysis.Examples of the acid include mineral acids. Specific examples includehydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, and thelike, and hydrochloric acid is preferred. As for the amount of the acidused, it is preferable to use 1 to 100 fold moles. Examples of thesolvent used for the reaction include, for example, water, alcohols,ether solvents such as 1,4-dioxane and mixed solvents thereof, and1,4-dioxane is preferred. The reaction is preferably performed in thetemperature range of from room temperature to the reflux temperature ofthe solvent.

When Z^(a) represents the same group as that represented by Z in thegeneral formula (1), such compounds of the formula (A) constitute a partof the compounds of the formula (1), and thus Step 1-1 mentioned aboveis unnecessary.

Furthermore, the compounds represented by the aforementioned formula (A)can be prepared by the following methods. i) When a compound representedby the formula (A-a):

wherein Y, A¹, A¹¹, A², A²¹, Z^(a), and X¹ . . . X² have the samemeanings as those defined above, which corresponds to a compound of theformula (A) wherein R¹ is hydrogen atom, said compound can be used as itis,

-   ii) when a compound represented by the formula (A-b):-    wherein Y, A¹, A¹¹, A², A²¹, Z^(a), and X¹ . . . X² have the same    meanings as those defined above, which corresponds to a compound of    the formula (A) wherein R¹ is chlorine atom, is prepared, the    compound of the aforementioned formula (A-a) can be oxidized to    prepare a compound represented by the formula (B):-    wherein Y, A¹, A¹¹, A², A²¹, Z^(a), and X¹ . . . X² have the same    meanings as those defined above, and this compound can be    chlorinated to obtain a compound of the formula (A-b), and thereby    obtain a compound of the formula (A), or-   iii) when a compound represented by the formula (A-c):-    wherein Y, A¹, A¹¹, A², A²¹, Z^(a), and X¹ . . . X² have the same    meanings as those defined above, which corresponds to a compound of    the formula (A) wherein R¹ is hydroxyl group, is prepared, a    compound of the aforementioned formula (A-b) can be hydroxylated to    obtain a compound of the formula (A-c), and thereby obtain a    compound of the formula (A).

The compounds of the aforementioned formula (B) can be prepared byoxidizing a compound of the aforementioned formula (A-a) (Step 1-2).Examples of oxidizing agent include aqueous hydrogen peroxide, sodiumperiodate, sodium perborate, 3-chloroperbenzoic acid, rutheniumtrichloride, and dimethyldioxirane. The oxidizing agent is preferablyused in an amount of 0.1 fold mole or more, most preferably 1 to 20 foldmoles, based on the compound of the formula (A-a). Examples of thesolvent include acetic acid, trifluoroacetic acid, dichloromethane,1,2-dichloroethane, chloroform, acetonitrile, acetone,trichlorofluoromethane, benzene, 1,4-dioxane, tert-butanol, water, andmixed solvents of these, and preferred examples include acetic acid. Thereaction is preferably performed at room temperature or a highertemperature. This step is preferably preformed with a compound whereinZ^(a) is —O(PG¹), —N(A⁶)(PG²), or —N(A⁶)(A⁶²).

Further, the compounds of the aforementioned formula (A-b) can beprepared by allowing a chlorination reagent to react on a compound ofthe aforementioned formula (B) to chlorinating the compound (Step 1-3).Examples of the chlorination reagent include phosphorus trichloride,phosphorus pentachloride, and phosphorous oxychloride, and phosphorousoxychloride is preferred. The chlorination reagent is preferably used inan amount of 0.1 fold mole or more, most preferably 1 to 10 fold moles,based on the compound of the formula (B). As for the solvent, examplesof methods include those performed without solvent or in an inertsolvent, and the method is preferably performed, for example, withoutsolvent or by using dichloromethane, 1,2-dichloroethane, chloroform, ortoluene as a solvent. The reaction is preferably performed at roomtemperature or a higher temperature. This step is preferably preformedwith a compound wherein Z^(a) is —O(PG¹), —N(A⁶)(PG²), or —N(A⁶)(A⁶²).

The compounds represented by the aforementioned formula (A-c) can beprepared by hydroxylating a compound of the aforementioned formula (A-b)(Step 1-4). A hydrolysis reaction performed under an acidic condition ispreferred, and the reaction is more preferably carried out in a mineralacid. Examples of the mineral acid to be used include hydrochloric acid,sulfuric acid, nitric acid and the like, and a particularly preferredexample is hydrochloric acid. The acid is preferably used in an amountof 0.1 fold mole or more, most preferably 1 to 100 fold moles, based onthe compound of the formula (A-b). As for the reaction solvent, thereaction is performed, for example, without solvent or in an inertsolvent, and the reaction is preferably performed, for example, withoutsolvent, or in an ether type solvent such as tetrahydrofuran, and1,4-dioxane. The reaction is carried out, for example, at roomtemperature or a higher temperature. This step is preferably preformedwith a compound wherein Z^(a) is —O(PG¹), —N(A⁶)(PG²), or —N(A⁶)(A⁶²).

Further, as for the compounds of the formula (A-a), the compounds of theformula (A-a) wherein Z^(a) is —N(A⁶)(A⁶²) can be prepared bydeprotecting a compound of the formula (A-a) wherein Z^(a) is—N(A⁶)(PG²) to prepare a compound of the formula (A-a) wherein Z^(a) is—NH(A⁶) (Step 1-5), and reacting this compound with a compoundrepresented as A⁶²-W wherein A⁶² has the same meaning as defined above,and W represents a leaving group (Step 1-6).

For the deprotection step performed for the preparation of a compound ofthe formula (A-a) wherein Z^(a) is —NH(A⁶) from a compound of theformula (A-a) wherein Z^(a) is —N(A⁶)(PG²), an ordinary deprotectionreaction can be utilized as explained above.

W in A⁶²-W used for the preparation of a compound of the formula (A-a)wherein Z^(a) is —N(A⁶)(A⁶²) from a compound of the formula (A-a)wherein Z^(a) is —NH(A⁶) is not particularly limited so long as W is aleaving group. Examples include, for example, a halogen atom, analkylsulfonyloxy group, and an arylsulfonyloxy group, preferred examplesinclude chlorine atom, bromine atom, iodine atom, methanesulfonyloxygroup, and p-toluenesulfonyloxy group, particularly preferred examplesare chlorine atom, bromine atom, and iodine atom, and a still moreparticularly preferred examples are chlorine atom, and bromine atom.

Conditions of the reaction for preparing the compounds of the formula(A-a) wherein Z^(a) is —N(A⁶)(A⁶²) from a compound of the formula (A-a)wherein Z^(a) is —NH(A⁶) are as follows. That is, the reaction isusually performed in the presence of a base, and a mineral base ispreferred. Examples include potassium carbonate, sodium carbonate,cesium carbonate, sodium hydrogencarbonate, potassium hydroxide, andsodium hydroxide, and potassium carbonate is particularly preferred.

The compound represented as A⁶²-W is preferably used in an amount of 1fold mole or more, most preferably 2 to 10 fold moles, based on thecompound of the aforementioned formula (A-a) wherein Z^(a) is —NH(A⁶).

Examples of the reaction solvent include inert solvents, for example,alcoholic solvents such as methanol and ethanol, dimethylformamide,dimethylacetamide, tetrahydrofuran, 1,4-dioxane, acetone, 2-butanone,dimethyl sulfoxide, acetonitrile, and the like, which can be used aloneor as a mixed solvent thereof, and water, dimethylformamide and acetoneare preferred.

The reaction temperature is, for example, −10° C. or higher, preferably10 to 40° C. The reaction time is, for example, usually 0.5 hour ormore, preferably 2 to 10 hours.

Further, as for the compounds of the formula (A-a), in the same mannersas Steps 1-5 and 1-6 mentioned above, a compound of the formula (A-a)wherein Z^(a) is —N(A⁶)(PG²) can be deprotected to prepare a compound ofthe formula (A-a) wherein Z^(a) is —NH(A⁶), and this compound can befurther reacted with a compound represented as A⁶³-W wherein A⁶³ and Whave the same meanings as defined above to prepare a compound of theformula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³).

As for the compounds represented by the formula (B), in the same mannersas Steps 1-5 and 1-6 mentioned above, a compound of the formula (B)wherein Z^(a) is —N(A⁶)(PG²) can be deprotected to prepare a compound ofthe formula (B) wherein Z^(a) is —NH(A⁶), and this compound can befurther reacted with a compound represented as A⁶²-W wherein A⁶² has thesame meaning as defined above, and W represents a leaving group, orA⁶³-W wherein A⁶³ and W have the same meanings as defined above toprepare a compound of the formula (B) wherein Z^(a) is —N(A⁶)(A⁶²), or—N(A⁶)(A⁶³).

Also as for the compounds represented by the formula (A-b), in the samemanners as Steps 1-5 and 1-6 mentioned above, a compound of the formula(A-b) wherein Z^(a) is —N(A⁶)(PG²) can be deprotected to prepare acompound of the formula (A-b) wherein Z^(a) is —NH(A⁶), and thiscompound can be further reacted with a compound represented as A⁶²-Wwherein A⁶² has the same meaning as defined above, and W represents aleaving group, or A⁶³-W wherein A⁶³ and W have the same meanings asdefined above to prepare a compound of the formula (A-b) wherein Z^(a)is —N(A⁶)(A⁶²), or —N(A⁶)(A⁶³).

Furthermore, as for the compounds represented by the formula (A-c), inthe same manners as Steps 1-5 and 1-6 mentioned above, a compound of theformula (A-c) wherein Z^(a) is —N(A⁶)(PG²) can be deprotected to preparea compound of the formula (A-c) wherein Z^(a) is —NH(A⁶), and thiscompound can be reacted with a compound represented as A⁶²-W wherein A⁶²has the same meaning as defined above, and W represents a leaving group,or A⁶³-W wherein A⁶³ and W have the same meanings as defined above toprepare a compound of the formula (A-c) wherein Z^(a) is —N(A⁶)(A⁶²), or—N(A⁶)(A⁶³).

Further, the compounds of the formula (A-a) wherein Z^(a) is—N(A⁶)(A⁶²), and A⁶² is an alkyl group of which end is substituted withN(A⁷)(—X³-A⁷¹), where —X³— has the same meaning as defined above, A⁷represents hydrogen atom, or an alkyl group, and A⁷¹ represents an alkylgroup, an aralkyl group, or an aryl group, can be prepared by reactingthe compound of the formula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³) obtainedabove with an acylation reagent suitably corresponding to an objectivecompound to be prepared (Step 1-6-1). Examples of the acylation reagentinclude carboxylic acid chlorides, carboxylic acid anhydrides,carboxylic acid active esters, carboxylic acids, and the like. Examplesof acetylation reagent include, for example, acetyl chloride, aceticanhydride, acetic acid active esters, acetic acid, and the like.Examples of the carboxylic acid active esters include carboxylic acidsuccinimides, imidazole carboxylates, carboxylic acid 4-nitrophenylesters, carboxylic acid pentafluorophenyl esters, and the like. Theacylation reagent is usually used preferably in an amount of 1 or morefold moles, most preferably 1.1 to 10 fold moles, based on the compoundof the aforementioned formula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³). When acarboxylic acid is directly used as the acylation reagent, it is usuallypreferable to perform the reaction in the presence of a dehydrationcondensing agent. Examples of the dehydration condensing agent usedherein include N,N-dicyclohexylcarbodiimide,N,N-diisopropylcarbodiimide,1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC),2-chloro-1-methylpyridinium iodide,2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate(TBTU), benzotriazol-1-yloxytris(dimethylamino)phosphoniumhexafluorophosphate (BOP),2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate(HBTU), O-(N-succinimidyl)-1,1,3,3-tetramethyluronium tetrafluoroborate(TSTU), benzotriazol-1-yloxytrispyrrolidinophosphoniumhexafluorophosphate (PyBOP), bromotrispyrrolidinophosphoniumhexafluorophosphate (PyBrOP), tetramethylfluoroformamidiniumhexafluorophosphate (TFFH), 2-chloro-1-methylpyridinium iodide,2,2-dipyridyl disulfide/triphenylphosphine, diethylazodicarboxylate/triphenylphosphine, and the like. These dehydrationcondensing agent is usually preferably used in an amount of 1 or morefold moles, most preferably 1.1 to 10 fold moles, based on the compoundof the aforementioned formula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³).

The acylation reaction is also preferably performed, for example, in thepresence of an additive such as 1-hydroxybenzotriazole (HOBt),1-hydroxy-7-azabenzotriazole (HOAt), N-hydroxysuccinimide (HOSu),4-nitrophenol (HONp) and pentafluorophenol (HOPfp). As for the amount ofthe additive, preferably 0.01 to 10 fold moles or more, most preferably0.1 to 5 fold moles, are usually used based on the compound of theaforementioned formula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³).

The acylation reaction is also preferably performed, for example, in thepresence of an organic tertiary amine such as triethylamine,N,N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine, and1,8-diazabicyclo[5.4.0]undec-7-ene, or an inorganic base such aspotassium carbonate, sodium carbonate, cesium carbonate, sodiumhydrogencarbonate, potassium hydroxide, and sodium hydroxide. As for theamount of the base, preferably 0.01 to 10 fold moles or more, mostpreferably 0.1 to 5 fold moles, are usually used based on the compoundof the aforementioned formula (A-a) wherein Z^(a) is —N(A⁶)(A⁶³).

As the reaction solvent, an inert solvent, for example, water, analcoholic solvent such as tert-butanol, N,N-dimethylformamide,N,N-dimethylacetamide, 1-methylpyrolidone, tetrahydrofuran, 1,4-dioxane,1,2-dimethoxyethane, dichloromethane, chloroform, benzene, toluene,dimethyl sulfoxide, sulfolane, acetonitrile, or the like can be used aseach kind, or a mixed solvent thereof.

The reaction temperature is, for example, −10° C. or higher, preferably10 to 40° C. The reaction time is, for example, usually 0.5 hour ormore, preferably 2 to 10 hours.

Further, the compounds of the formula (A-a) wherein A⁶² is an alkylgroup of which end is substituted with N(A⁷)(—X³-A⁷¹), and A⁷ and A⁷¹together become an alkylene group, or an alkylene group substituted withan alkyl group to form a ring can be prepared in the same manner as Step1-6 by reacting the “compound of the formula (A-a) wherein A⁷ ishydrogen atom” obtained above as a starting material with a compoundrepresented as (PG³)O—X³-A⁷² where PG³ and —X³— have the same meaningsas defined above, and A⁷² represents an alkyl group of which end issubstituted with a leaving group (the alkyl group may be substitutedwith another alkyl group), then removing PG³ in a known manner, andcyclizing the resultant using a dehydration condensing agent similar tothose used in the aforementioned acylation reaction (Step 1-6-2). Theleaving group is the same as that described above.

The compounds of the aforementioned formula (A-a) can be classified intocompounds represented by the formula (A-a-1):

wherein Y, A¹, A¹¹, A², A²¹, and Z^(a) have the same meanings as thosedefined above, and X¹—X² represents —CH(R²)—CH(R³)—, or—CH(R²)—CH(R³)—CH(R⁴)—, and compounds represented by the formula(A-a-2):

wherein Y, A¹, A¹¹, A², A²¹, and Z^(a) have the same meanings as thosedefined above, and X¹═X² represents —C(R²)═C(R³)—, or—C(R²)═C(R³)—CH(R⁴)—. As explained below, the compounds of the formula(A-a-2) are prepared from a compound of the formula (A-a-1), and thecompounds of the formula (A-a-1) can be prepared from a compound of thefollowing formula (C).

The compounds of the formula (A-a-1) can be prepared by cyclizing acompound represented by the following formula (C):

wherein Y, A¹, A¹¹, A², A²¹, Z^(a), and X¹—X² have the same meanings asthose defined above (Step 1-7).

Examples of the cyclization method include a method of performing thecyclization in the presence of a phosphorus reagent and an azo compound,and a method of reacting the compound with an alkylsulfonyl chloride, anarylsulfonyl chloride, an alkylsulfonic acid anhydride or anarylsulfonic acid anhydride in the presence of a base, and a preferredmethod is a method of performing the cyclization in the presence of aphosphorus reagent and an azo compound in an inert solvent (see, forexample, Tsunoda et al., Chemistry Letters, 539 (1994); or Mitsunobu,O., Synthesis, 1 (1981)). Examples of the inert solvent include, forexample, tetrahydrofuran, toluene, and dichloromethane, and a preferredexample is tetrahydrofuran. Examples of the phosphorus reagent include,for example, triphenylphosphine, and tri(n-butyl)phosphine. Example ofthe azo compound include, for example, diethyl azodicarboxylate,di(iso-propyl) azodicarboxylate, and 1,1′-azobis(N,N-dimethylformamide).Each of the phosphorus reagent and the azo compound may be the same ordifferent, and is used in an amount of 1 fold mole or more, preferably 2to 4 fold moles, based on the compound of the formula (C). The reactiontemperature is, for example, −10° C. or higher, preferably about 0 to60° C. This step is preferably preformed with a compound wherein Z^(a)is —O(PG¹), —N(A⁶)(PG²), or —N(A⁶)(A⁶²).

The compounds of the formula (A-a-2) can be prepared by dehydrogenationof a compound of the formula (A-a-1) in an inert solvent (Step 1-8). Asthe catalyst, for example, palladium catalysts such as 5%palladium/carbon, 10% palladium/carbon, or palladium black, and sulfurare preferred. Examples of the inert solvent include xylene, mesitylene,toluene, and the like, and xylene is preferred. The reaction temperatureis 60° C. or higher, preferably 120 to 150° C.

The compounds of the aforementioned formula (C) can be prepared byhydration of a compound represented by the following formula (D):

wherein Y, A¹, A¹¹, A², A²¹, and Z^(a) have the same meanings as thosedefined above, and X represents —C(R²)═CH(R³), or —CH(R²)—C(R³)═CH(R⁴)(Step 1-9).

For example, a compound of the formula (D) can be hydroborated with aboron reagent, then oxidized and hydrolyzed to obtain the compound. Asfor the hydroboration, examples of the boron reagent includedicyclohexylborane, disyamyl borane, thexyl borane, catechol borane,9-borabicyclo[3.3.1]nonane (9-BBN) dimmer, 9-BBN monomer, and the like,and 9-BBN dimmer, and 9-BBN monomer are preferred. The boron reagent ispreferably used in an amount of usually 1 fold mole or more, preferably2 to 5 fold moles. Examples of the solvent include ether type solventssuch as tetrahydrofuran and 1,4-dioxane, and the like, andtetrahydrofuran is preferred. The reaction temperature is 0° C. to theboiling temperature of the solvent used, preferably 10 to 60° C. Thereaction time is 2 hours or more, preferably 10 to 20 hours. As for thesubsequent oxidization and hydrolysis, examples of the oxidizing agentinclude 30% aqueous hydrogen peroxide, sodium peroxoborate,N-methylmorpholine N-oxide, triethylamine N-oxide, and the like, and 30%aqueous hydrogen peroxide, and sodium peroxoborate are preferred. Theoxidizing agent is used in an amount of, for example, 1 fold mole ormore, preferably 2 to 20 fold moles. The reaction time is, for example,0.25 to 10 hours, preferably 0.5 to 4 hours. Then, the hydrolysis isperformed in the presence of an alkali, and examples of the alkaliinclude aqueous sodium hydroxide, aqueous potassium hydroxide, and thelike. The alkali is used in an amount of, for example, usually 2 to 100fold moles, preferably 3 to 20 fold moles, and the reaction time is, forexample, 2 hours or more, preferably 2 to 4 hours. This step ispreferably preformed with a compound wherein Z^(a) is —O(PG¹),—N(A⁶)(PG²), or —N(A⁶)(A⁶²).

The compounds represented by the formula (D) can be prepared by reactinga compound represented by the following formula (E):

wherein Y, A¹, A¹¹, A², A²¹, and Z^(a) have the same meanings as thosedefined above, with a tin compound represented by the following formula(F):X—SnBu₃  (F)wherein X has the same meaning as defined above, and Bu representsn-butyl (Step 1-10). Examples of the tin compound represented by theformula (F) include those commercially available and those known fromliteratures (see, for example, Seyferth et al., Chem. Ind., 402 (1959);J. Amer. Chem. Soc., 361 (1962); and J. Amer. Chem. Soc., 515 (1957)).The amount of this tin compound is, for example, 1 fold mole or more,preferably 1 to 3 fold moles, based on the compound of the formula (E).This step is preferably preformed with a compound wherein Z^(a) is—O(PG¹), —N(A⁶)(PG²), or —N(A⁶) (A⁶²).

As for the preparation of the compounds of the formula (D) by thecoupling reaction of a compound of the formula (E), and a compound ofthe formula (F), preferable examples include, for example, the followingtwo kinds of reaction conditions.

The first reaction condition corresponds to a method of performing thereaction in toluene or an ether type solvent in the presence oftetrakis(triphenylphosphine)palladium(0) as a catalyst, and2,6-di(tert-butyl)-4-cresol (BHT) as a polymerization inhibitor. Basedon the compound of the formula (E),tetrakis(triphenylphosphine)palladium(0) is used in an amount of, forexample, 0.001 fold mole or more, preferably 0.01 to 0.2 fold mole, andBHT is used in an amount of, for example, 0.001 fold mole or more,preferably 0.005 to 0.01 fold mole. As the solvent, toluene or1,4-dioxane is preferred, and the reaction temperature is, for example,10° C. or higher, preferably 80 to 120° C. This step is preferablypreformed with a compound wherein Z^(a) is —O(PG¹), —N(A⁶)(PG²), or—N(A⁶)(A⁶²).

The second reaction condition corresponds to a method of performing thereaction in an ether type solvent in the presence of a palladiumcompound such as tetrakis(triphenylphosphine)palladium(0), palladium(II)acetate, or tris(dibenzylideneacetone)dipalladium(0), or a phosphoruscompound such as triphenylphosphine or tri(tert-butyl)phosphine, andcesium fluoride as an additive. As the palladium compound,tris(dibenzylideneacetone)dipalladium(0) is preferred, andtri(tert-butyl)phosphine is preferred as the phosphorus compound. Thesolvent is preferably 1,4-dioxane. Based on the compound of the formula(E), the palladium compound is used in an amount of, for example, 0.001fold mole or more, preferably 0.01 to 0.2 fold mole, and the phosphoruscompound is preferably used in an amount of about 4 fold moles. Cesiumfluoride is preferably used in an amount of about 1 to 3 fold molesbased on the tin compound of the formula (F). The reaction temperatureis, for example, 10° C. or higher, preferably 60 to 100° C. This step ispreferably preformed with a compound wherein Z^(a) is —O(PG¹),—N(A⁶)(PG²), or —N(A⁶)(A⁶²). As for these reactions, Gregory, C, Fu etal., Angew. Chem. Int. Ed., 2411 (1999) can be referred to.

The compounds of the formula (E) can be prepared from5-amino-4-bromoisoquinoline (Reference Example 1), and a carbonylcompound represented by the following formula (G):

wherein the bond represented by the broken line represents a singlebond, or a double bond;

when the bond represented by the broken line is a single bond, Y^(a)represents —C(A³)═O, —C(A⁴)(A⁴¹)-C(A³)═O, or—C(A⁵)(A⁵¹)-C(A⁴)(A⁴¹)-C(A³)═O,

A¹¹, A²¹, A⁴¹, and A⁵¹ have the same meanings as those defined above;

A¹, A², Z^(a), A³, A⁴, and A⁵ have the same meanings as those definedabove, provided that when any of combinations of A⁶ and A³, A⁶ and A⁴,A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ is not present, said combination is excluded;

when the bond represented by the broken line is a double bond, Y^(a) isoxygen atom, All is hydrogen atom, A²¹, A⁴¹, and A⁵¹ have the samemeanings as those defined above; and

A¹, A², Z^(a), A³, A⁴, and A⁵ have the same meanings as those definedabove, provided that when any of combinations of A⁶ and A³, A⁶ and A⁴,A⁶ and A¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ is not present, said combination is excluded, which carbonylcompound is commercially available, or can be prepared (Step 1-11).

This step includes a step of forming a Schiff base from known5-amino-4-bromoisoquinoline and a compound of the formula (G), and areduction step. This step is preferably preformed with a compoundwherein Z^(a) is —O(PG¹), —N(A⁶)(PG²), or —N(A⁶)(A⁶²).

As for the Schiff base formation step, two kinds of reaction conditionscan be mentioned as preferred examples.

The first condition corresponds to a method of forming a Schiff base ina solvent such as benzene, toluene, dichloromethane, 1,4-dioxane,tetrahydrofuran, and an alcohol in the presence of an acid. Examples ofthe acid include hydrochloric acid, methanesulfonic acid,p-toluenesulfonic acid, and camphorsulfonic acid, and p-toluenesulfonicacid (monohydrate) is preferred. Based on 5-amino-4-bromoisoquinoline,the compound of the formula (G) is used in an amount of, for example, 1fold mole or more, preferably 1 to 2 fold moles, and p-toluenesulfonicacid is used in an amount of, for example, 0.0001 fold mole or more,preferably 0.01 to 0.2 fold mole. The reaction temperature is, forexample, 0° C. or higher, preferably 20 to 120° C. The reaction time is,for example, 0.1 hour or more, preferably 0.3 to 12 hours.

The second condition corresponds to a method of forming a Schiff basewithout solvent, or in an inert solvent such as tetrahydrofuran,1,4-dioxane, toluene, and dichloromethane in the presence oftitanium(IV) isopropoxide or titanium tetrachloride. It is preferable tocarry out the reaction without solvent, or in tetrahydrofuran, ordichloromethane in the presence of titanium(IV) isopropoxide. Based on5-amino-4-bromoisoquinoline, the compound of the formula (G) is used inan amount of, for example, 1 fold mole or more, preferably 1 to 2 foldmoles, and titanium(IV) isopropoxide is used in an amount of, forexample, 1 fold mole or more, preferably 2 to 3 fold moles. The reactiontemperature is, for example, −20° C. to the reflux temperature of thesolvent, preferably 10 to 60° C. The reaction time is, for example, 10to 72 hours, preferably 20 to 60 hours.

The reduction step can be performed by allowing a reducing agent to acton the aforementioned Schiff base in a solvent without isolating theSchiff base. Examples of the solvent include, in addition to thesolvents used for the Schiff base formation reaction, alcohols such asmethanol, ethanol, and isopropanol, and preferred examples are methanol,and ethanol. Examples of the reducing agent include metal hydridereducing agents such as sodium borohydride, potassium borohydride,lithium borohydride, zinc borohydride, sodium cyanoborohydride, andsodium triacetoxyborohydride, borane/tetrahydrofuran complex,borane/pyridine complex, borane/triethylamine complex, borane/dimethylsulfide complex, and lithium triethylborohydride, and a preferredexample is sodium borohydride. Based on 5-amino-4-bromoisoquinoline,sodium borohydride is used in an amount of, for example, 0.5 fold moleor more, preferably 1 to 20 fold moles. The reaction temperature is, forexample, 0° C. or higher, preferably 10 to 80° C. The reaction time is,for example, 0.1 hour or more, preferably 0.5 to 12 hours.

As an alternative method, the compounds of the formula (D) can beprepared by using a compound represented by the following formula (H):

wherein X has the same meaning as defined above, as a starting materialinstead of 5-amino-4-bromoisoquinoline, and subjecting it to the sameconditions as those used in Step 1-11 (Step 1-12). The compounds of theformula (H) can be prepared by using 5-amino-4-bromoisoquinoline as astarting material instead of the compound of the formula (E), andsubjecting it to the same conditions as those used in Step 1-10 (Step1-13).(Preparation Method 2)

The compounds represented by the following formula (1-a):

wherein A¹¹, and X¹ . . . X² have the same meanings as those definedabove; and

Y, A¹, A², and Z have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, which correspond to the compoundsof the formula (1) wherein both of A²¹ and R¹ are hydrogen atoms, can beprepared from a compound represented by the following formula (J):

wherein A¹¹, and X¹ . . . X² have the same meanings as those definedabove; and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded (Step 2-1).

Examples of the method for producing the compounds of the formula (1-a)wherein Z is hydroxyl group include a method of allowing a reducingagent to react on the starting compound in a solvent. Examples of thereducing agent include metal hydride reducing agents such as sodiumborohydride, zinc borohydride, borane/tetrahydrofuran complex,borane/pyridine complex, borane/triethylamine complex, borane/dimethylsulfide complex, and lithium triethylboride, and sodium borohydride ispreferred. Based on the compound of the formula (J), sodium borohydrideis used in an amount of, for example, 0.5 fold mole or more, preferably1 to 20 fold moles. Examples of the solvent include alcohols such asmethanol, ethanol, and isopropanol, ethers such as tetrahydrofuran,1,2-dimethoxyethane, and 1,4-dioxane, dichloromethane, andN,N-dimethylformamide, and methanol and ethanol are preferred. Thereaction temperature is, for example, 0° C. or higher, preferably 10° C.to the reflux temperature of the solvent. The reaction time is, forexample, 0.1 hour or more, preferably 0.5 to 12 hours.

Further, the compounds of the formula (1-a) wherein Z is —N(A⁶)(A⁶¹) canbe prepared by subjecting the starting compound to the same conditionsas those of Step 2-1 in the presence of a compound represented by theformula NH(A⁶)(A⁶¹) wherein A⁶ and A⁶¹ have the same meanings as thosedefined above (Step 2-2). The aforementioned compound of the formulaNH(A⁶)(A⁶¹) is used in an amount of, for example, 1 fold mole or more,preferably 1 to 10 fold moles, based on the compound of the formula (J).

The compounds of the formula (J) can be prepared form a compoundrepresented by the following formula (K):

wherein n represents 2 or 3,

A¹¹, and X¹ . . . X² have the same meanings as those defined above; and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded (Step 2-3). This step is performedby a method of carrying out the reaction in a solvent in the presence ofan acid catalyst. Examples of the solvent include alcohols such asmethanol, ethanol, tert-butanol, and ethylene glycol, ethers such astetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane, nitromethane,dimethyl sulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide,1-methylpyrolidone, sulfolane, acetic acid, and water, and methanol,ethanol, tert-butanol, tetrahydrofuran, and 1,4-dioxane are preferred.Examples of the acid include mineral acids such as hydrochloric acid,sulfuric acid, and nitric acid, methanesulfonic acid, p-toluenesulfonicacid, trifluoromethanesulfonic acid, trifluoroacetic acid, perchloricacid, and the like, and hydrochloric acid, and perchloric acid arepreferred. The reaction temperature is, for example, 0° C. or higher,preferably 10 to 120° C. The reaction time is, for example, 0.1 hour ormore, preferably 0.5 to 12 hours.

The compounds of the formula (K) can be classified into the followingtwo types of compounds, namely, compounds represented by the followingformula (K-a):

wherein n, A¹¹, and X¹—X² have the same meanings as those defined above;and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, and compounds represented by thefollowing formula (K-b):

wherein n, A¹¹, and X¹═X² have the same meanings as those defined above;and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded. As explained below, the compoundsof the formula (K-b) can be prepared from a compound of the formula(K-a), and the compounds of the formula (K-a) can be prepared from acompound of the following formula (L).

The compounds of the formula (K-a) can be prepared by using a compoundrepresented by the following formula (L):

wherein n, A¹¹, and X¹—X² have the same meanings as those defined above;and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, instead of the compound of theformula (C), and cyclizing it in the same manner as that of Step 1-7(Step 2-4).

The compounds of the formula (K-b) can be prepared by using a compoundof the formula (K-a) instead of the compound of the formula (A-a-1), andsubjecting it to dehydrogenation in the same manner as that of Step 1-8(Step 2-5).

The compounds of the aforementioned formula (L) can be prepared by usinga compound represented by the following formula (M):

wherein n, A¹¹, and X have the same meanings as those defined above; and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, instead of the compound of theformula (D), and subjecting it to hydration in the same manner as thatof Step 1-9 (Step 2-6).

The compounds of the formula (M) can be prepared by using a compoundrepresented by the following formula (N):

wherein n, and All have the same meanings as those defined above; and

Y, A¹, and A² have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, and a compound of theaforementioned formula (F) instead of the compound of the formula (E),and subjecting them to a substitution reaction in the same manner asthat of Step 1-10 (Step 2-7).

The compounds of the formula (N) can be prepared by using5-amino-4-bromoisoquinoline mentioned above and a compound representedby the following formula (P):

wherein n, and A¹¹ have the same meanings as those defined above; and

Y^(a), A¹, and A² have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded, instead of the compound ofthe formula (G), and subjecting them to reductive amination in the samemanner as that of Step 1-11 (Step 2-8). The compounds of theaforementioned formula (M) can also be prepared by subjecting a compoundof the aforementioned formula (H), and a compound of the formula (P) toreductive amination in the same manner as that of Step 1-11.

(Preparation Method 3)

The compounds represented by the following formula (1-b):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, which correspond to the compoundsof the formula (1) wherein R¹ is hydrogen atom, and X¹ . . . X² is—CH(R²)—CH₂—, can be prepared by subjecting a compound represented bythe following formula (A-d):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded, to the deprotectionreaction of Step 1-1 (Step 3-1).

When Z and Z^(a) in the formula (1-b) represent the same group, thecompounds of the formula (A-d) constitute a part of the compounds of theformula (1-b), and Step 3-1 mentioned above is unnecessary.

Further, in the case of the compounds of the aforementioned formula(A-d) wherein Z^(a) in the formula (A-d) is —N(A⁶)(A⁶²), it is alsopossible to prepare a compound of the formula (1-b) by using any of Step1-5, Step 1-6, Step 1-6-1, and Step 1-6-2 in combination.

The compounds of the formula (A-d) can be prepared by cyclizing acompound represented by the following formula (D-a):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded (Step 3-2). Examples of themethod for the cyclization include a method of allowing a base to reacton the compound in an inert solvent. Examples of the inert solventinclude ether type solvents such as tetrahydrofuran,1,2-dimethoxyethane, and 1,4-dioxane, benzene, toluene, dimethylsulfoxide, N,N-dimethylformamide, 1-methylpyrolidone, and sulfolane, andtetrahydrofuran, and 1,4-dioxane are preferred. Examples of the baseinclude alkali metals such as sodium and potassium, alkali metalhydrides such as sodium hydride, and potassium hydride, alkali metalalkoxides such as sodium methoxide, potassium methoxide, sodiumethoxide, sodium isopropoxide, sodium tert-butoxide, and potassiumtert-butoxide, organic metal bases such as methyl lithium, n-butyllithium, phenyl lithium, tert-butyl lithium, lithium diisopropylamide,sodium bis(trimethylsilyl)amide, potassium bis(trimethylsilyl)amide, andlithium 2,2,6,6-tetramethylpiperizide, and the like, potassium,potassium hydride, potassium tert-butoxide, and potassiumbis(trimethylsilyl)amide are preferred, and potassium tert-butoxide isparticularly preferred.

The amount of the base used is, for example, 0.01 fold mole or more,preferably 0.1 to 5 fold moles, based on the compound of the formula(D-a). The reaction temperature is, for example, 0° C. or higher,preferably 10 to 120° C. The reaction time is, for example, 0.001 houror more, preferably 0.01 to 5 hours.

The compounds of the formula (D-a) can be prepared by, for example,subjecting a compound of the aforementioned formula (E), and a tincompound represented by the following formula (F-a):

wherein R² and Bu have the same meanings as those defined above, to thesame conditions as those of Step 1-10 mentioned above (Step 3-3).

Alternatively, the compounds of the formula (D-a) can be prepared by,for example, subjecting a compound represented by the following formula(H-a):

wherein R² has the same meaning as defined above, and a compound of theaforementioned formula (G) to the same conditions as those of Step 1-11mentioned above (Step 3-4).

The compounds of the formula (H-a) can be prepared by, for example,subjecting 5-amino-4-bromoisoquinoline mentioned above and a compound ofthe aforementioned formula (F-a) to the same conditions as those of Step1-10 (Step 3-5).

The compounds of the aforementioned formula (A-d) can be prepared alsoby the following method. The compounds of the formula (A-d) can beprepared by reacting a compound represented by the following formula(Q):

wherein R² has the same meaning as defined above, and a compoundrepresented by the following formula (S):

wherein A¹¹, A²¹ and W have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded (Step 3-6). This step ispreferably preformed with a compound wherein Z^(a) is —O(PG¹),—N(A⁶)(PG²), or —N(A⁶)(A⁶²). For example, it is preferred that thereaction is performed in an inert solvent in the presence of a base.Examples of the inert solvent include water, alcohol type solvents suchas methanol, and ethanol, ether type solvents such as tetrahydrofuran,1,2-dimethoxyethane, and 1,4-dioxane, benzene, toluene, dimethylsulfoxide, N,N-dimethylformamide, 1-methylpyrolidone, sulfolane, and thelike, and tetrahydrofuran, N,N-dimethylformamide, and 1,4-dioxane, forexample, are preferred. Examples of the base include alkali metals suchas sodium and potassium, alkali metal hydrides such as sodium hydride,and potassium hydride, alkali metal hydroxides such as potassiumhydroxide, and sodium hydroxide, and the like, and sodium hydride, andpotassium hydride are preferred. The amount of the base used is, forexample, 1 fold mole or more, preferably 1.5 to 10 fold moles, based onthe compound of the formula (Q). The reaction temperature is, forexample, 0° C. or higher, preferably 10 to 80° C. The reaction time is,for example, 1 hour or more, preferably 10 to 40 hours.

Further, the compounds of the formula (Q) can also be prepared by usinga compound of the formula (H-a) instead of the compound of the formula(D-a) and subjecting it to the same conditions as those of Step 3-2mentioned above (Step 3-7).

(Preparation Method 4)

The compounds represented by the following formula (1-c):

wherein A¹¹, and A²¹ have the same meanings as those defined above; and

Y, A¹, A², and Z have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, which correspond to the compoundsof the formula (1) wherein R¹ is hydrogen atom, and X¹ . . . X² is—CH₂—CH₂—, can be prepared by subjecting a compound represented by thefollowing formula (A-e):

wherein A¹¹, and A²¹ have the same meanings as those defined above; and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A^(3, A) ² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵and A¹ is not present, said combination is excluded, to the deprotectionreaction of Step 1-1 (Step 4-1).

When Z and Z^(a) in the formula (1-c) represent the same group, thecompounds of the formula (A-e) constitute a part of the compounds of theformula (1-c), and Step 4-1 mentioned above is unnecessary.

Further, in the case of the compounds of the aforementioned formula(A-e) wherein Z^(a) in the formula (A-e) is —N(A⁶)(A⁶²), it is alsopossible to prepare a compound of the formula (1-c) by using any of Step1-5, Step 1-6, Step 1-6-1, and Step 1-6-2 in combination.

The compounds of the formula (A-e) can be prepared by using a compoundrepresented by the following formula (T):

wherein A¹¹, and A²¹ have the same meanings as those defined above; and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded instead of the compound ofthe formula (C), and cyclizing it according to Step 1-7 (Step 4-2). Thisstep is preferably preformed with a compound wherein Z^(a) is —O(PG¹),—N(A⁶)(PG²), or —N(A⁶)(A⁶²).

The compounds of the formula (T) can be prepared by subjecting acompound represented by following formula (U):

to reductive amination together with a carbonyl compound of theaforementioned formula (G) under the same conditions as those of Step1-11 (Step 4-3).

The compounds of the formula (U) can be prepared by reducing a compoundrepresented by following formula (V):

(for the nitro group moiety) (Step 4-4). Examples of the method for thereduction include a method of performing hydrogenation in an alcoholsolvent in the presence of a metal catalyst. As the solvent, methanol,and ethanol are preferred. Examples of the metal catalyst includepalladium black, 5% palladium/carbon, 10% palladium/carbon, palladiumhydroxide, Raney nickel, and platinum oxide, and platinum oxide is apreferred example. The hydrogen pressure is preferably ordinary pressureto 4 atm. The reaction temperature is, for example, −20° C. or higher,preferably 10 to 50° C. The reaction time is, for example, 2 hours ormore, preferably 4 to 15 hours.

The compounds of the formula (V) can be prepared by subjecting acompound represented by following formula (W):

to reduction (for the aldehyde moiety) (Step 4-5). Examples of themethod for the reduction include a method of allowing a reducing agentto react on the compound in a solvent. Examples of the solvent include,alcohols such as methanol, ethanol, and isopropanol, ethers such astetrahydrofuran, 1,2-dimethoxyethane, and 1,4-dioxane, dichloromethane,and N,N-dimethylformamide, and methanol, and ethanol are preferred.Examples of the reducing agent include metal hydride reducing agentssuch as sodium borohydride, zinc borohydride, borane/tetrahydrofurancomplex, borane/pyridine complex, borane/triethylamine complex,borane/dimethyl sulfide complex, and lithium triethylboride, and apreferred example is sodium borohydride. Based on the compound of theformula (W), sodium borohydride is used in an amount of, for example,0.5 fold mole or more, preferably 1 to 20 fold moles. The reactiontemperature is, for example, 0° C. or higher, preferably 10° C. to thereflux temperature of the solvent. The reaction time is, for example,0.1 hour or more, preferably 0.5 to 12 hours.

The compounds of the formula (W) can be prepared by cleaving a diolrepresented by following formula (X):

through oxidization (Step 4-6). Oxidization with sodium periodate ispreferably used. Examples of the solvent include mixtures of a solventsuch as tetrahydrofuran, dimethyl sulfoxide, tert-butanol, acetone, or1,4-dioxane, and water, and a mixed solvent of tetrahydrofuran and wateris preferred. Based on the compound of the formula (X), sodium periodateis used in an amount of, for example, 1 fold mole or more, preferably1.3 to 5 fold moles. The reaction temperature is, for example, −20° C.or higher, preferably −10 to 20° C. The reaction time is, for example,0.01 hour or more, preferably 0.5 to 1 hour.

The compounds of the formula (X) can be prepared by converting an allylcompound represented by following formula (Y):

into a diol (Step 4-7). This is performed by a method of performing areaction with osmium tetroxide or microencapsulated osmium tetroxide(Wako Pure Chemical Industries) in a solvent in the presence ofN-methylmorpholine N-oxide (NMO) (for example, Kobayashi. S. et al., J.Org. Chem., 6094 (1998)). Examples of the solvent include mixed solventsof a solvent such as acetone or 2-butanone, and water, and a mixedsolvent of acetone and water is preferred. Based on the compound of theformula (Y), NMO is used in an amount of, for example, 1 fold mole ormore, preferably 1.3 to 3 fold moles. Osmium tetroxide ormicroencapsulated osmium tetroxide is used in an amount of, for example,0.01 to 0.2 fold mole, preferably 0.03 to 0.1 fold mole. The reactiontemperature is, for example, 0° C. or higher, preferably 20 to 80° C.The reaction time is, for example, 1 hour or more, preferably 5 to 20hours.

The compounds of the formula (Y) can be prepared by allylating known4-bromo-5-nitroisoquinoline (Reference Example 1) using allyltributyltinas a compound of the formula (F) under the same conditions as those ofStep 1-10 (Step 4-8).

(Preparation Method 5)

The compounds represented by the following formula (1-b-1):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, which correspond to the compoundsof the formula (1) wherein R¹ is hydroxyl group, and X¹ . . . X² is—CH(R²)—CH₂—, can be prepared by subjecting a compound represented bythe following formula (A-c-1):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded, to a deprotection reaction(Step 5-1). This step can be performed by referring to Step 1-1mentioned above. When Z and Z^(a) in the formula (1-b-1) represent thesame group, the compounds of the formula (A-c-1) constitute a part ofthe compounds of the formula (1-b-1), and Step 5-1 mentioned above isunnecessary.

Further, in the case of the compounds of the aforementioned formula(A-c-1) wherein Z^(a) in the formula (A-c-1) is —N(A⁶)(A⁶²), it is alsopossible to prepare a compound of the formula (1-b-1) by using any ofStep 1-5, Step 1-6, Step 1-6-1, and Step 1-6-2 in combination.

The compounds of the formula (A-c-1) mentioned above can be prepared byhydroxylating a compound represented by the following formula (A-b-1):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded (Step 5-2). This step canbe performed by referring to Step 1-4 mentioned above.

The compounds represented by the following formula (1-b-2):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z have the same meanings as those defined above, providedthat when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ andA², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ is notpresent, said combination is excluded, which correspond to the compoundsof the formula (1) wherein R¹ is chlorine atom, and X¹ . . . X² is—CH(R²)—CH₂—, can be prepared by subjecting a compound represented bythe aforementioned formula (A-b-1) to a deprotection reaction (Step5-3). This step can be performed by referring to Step 1-1 mentionedabove. When Z and Z^(a) in the formula (1-b-2) represent the same group,the compounds of the formula (A-b-1) constitute a part of the compoundsof the formula (1-b-2), and Step 5-3 mentioned above is unnecessary.Further, in the case of the compounds of the aforementioned formula(A-b-1) wherein Z^(a) in the formula (A-b-1) is —N(A⁶)(A⁶²), it is alsopossible to prepare a compound of the formula (1-b-2) by using any ofStep 1-5, Step 1-6, Step 1-6-1, and Step 1-6-2 in combination.

The compounds of the formula (A-b-1) can be prepared by cyclizing acompound represented by the following formula (D-a-1):

wherein R², A¹¹, and A²¹ have the same meanings as those defined above;and

Y, A¹, A², and Z^(a) have the same meanings as those defined above,provided that when any of combinations of A⁶ and A³, A⁶ and A⁴, A⁶ andA¹, A⁶ and A², A² and A³, A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹is not present, said combination is excluded (Step 5-4). This step canbe performed by referring to Step 3-2 mentioned above.

The compounds of the formula (D-a-1) can be prepared from, for example,a compound represented by the following formula (H-a-1):

wherein R² has the same meaning as defined above, and a compound of theaforementioned formula (G) (Step 5-5). This step can be performed byreferring to Step 1-11 (or Step 3-4) mentioned above.

The compounds of the formula (H-a-1) can be prepared by reducing (forthe nitro group moiety) a compound represented by following formula(H-a-2):

wherein R² has the same meaning as defined above (Step 5-6). Thisreduction is preferably performed in an inert solvent. Examples of theinert solvent include alcohols, ethers, and esters, and preferredexamples are esters. A particularly preferred example is ethyl acetate.Examples of the reduction reagent include tin (divalent) reagents.Preferred examples of the tin (divalent) reagents include stannouschloride, and hydrate thereof. The reaction temperature is, for example,−20° C. or higher, preferably 10 to 50° C. The reaction time is, forexample, 2 hours or more, preferably 4 to 15 hours.

The compounds of the formula (H-a-2) can be prepared by chlorinating acompound represented by the following formula (H-a-3):

wherein R² has the same meaning as defined above (Step 5-7). This stepcan be performed by referring to Step 1-3 mentioned above.

The compounds of the formula (H-a-3) can be prepared by oxidizing acompound represented by the following formula (H-a-4):

wherein R² has the same meaning as defined above (Step 5-8). This stepcan be performed by referring to Step 1-2 mentioned above.

The compounds of the formula (H-a-4) can be prepared by, for example,subjecting known 4-bromo-5-nitroisoquinoline (Reference Example 1) tothe same conditions as those of Step 1-10 (Step 5-9).

The compounds of the present invention represented by the aforementionedformula (1) and salts thereof have cell movement inhibitory actions onthe basis of inhibition against phosphorylation of the myosin regulatorylight chain in the cells, and are useful as active ingredients ofmedicaments. Among the cell movement inhibitory actions of the compoundsof the present invention, the cell contraction inhibitory action can beconfirmed by measuring vasoconstriction inhibitory activity, intraocularpressure reducing activity, or the like. The action to regulate changeof cell morphology can be confirmed by, for example, measuring neuriteoutgrowth of nerve cells, or the like. The inhibitory action on cellmigration (the action will be abbreviated as “cell migration inhibitoryaction”) can be confirmed by measuring neutrophil migration inhibitoryactivity, respiratory tract inflammation suppressing activity, or thelike. The cell release inhibitory action can be confirmed by measuringthe chemical mediator releasing amount from neutrophils. The cellaggregation inhibitory action can be confirmed by measuring plateletaggregation inhibitory activity, or the like. Further, the apoptosisinhibitory action can be confirmed by, for example, giving stimulationto induce apoptosis to cells and then measuring cell viability oroccurring frequencies of morphological changes of cells characteristicto apoptosis such as nuclear condensation, nuclear fragmentation, andblebbing of cells.

However, since the cell movement inhibitory actions on the basis of theinhibition of phosphorylation of the myosin regulatory light chain inthe cells are known to be associated with various biological actions asdescribed in the section of related art in the specification, the cellmovement inhibitory actions must be construed in their broadest senseincluding the aforementioned cell contraction inhibitory action, actionto regulate change of cell morphology, cell migration inhibitory action,cell release inhibitory action, cell aggregation inhibitory action, andapoptosis inhibitory action.

For example, the compounds of the present invention represented by theaforementioned formula (1) and salts thereof have an inhibitory activityagainst phosphorylation of the myosin regulatory light chain (see, TestExample 1 of the specification), vasoconstriction inhibitory activity(see, Test Example 2 in the specification), respiratory tractconstriction suppressing activity (see, Test Example 3 in thespecification), intraocular pressure reducing activity (see, TestExample 4 in the specification), neurite outgrowth activity(see, TestExample 5 in the specification), neutrophil migration inhibitoryactivity (see, Test Example 6 in the specification), respiratory tractinflammation suppressing activity (see, Test Example 7 in thespecification), and pulmonary inflammation suppressing activity (see,Test Example 8 in the specification). Further, as demonstrated by thetest examples, the compounds represented by the aforementioned formula(1) and salts thereof have notably higher vasoconstriction inhibitoryactivity, respiratory tract constriction inhibitory activity,intraocular pressure reducing activity, neurite outgrowth activity,neutrophil migration inhibitory activity, and respiratory tractinflammation suppression activity as compared with the conventionalisoquinoline compounds. Therefore, the compounds represented by theaforementioned formula (1) and salts thereof are useful as activeingredients of medicaments for prophylactic and/or therapeutic treatmentof diseases relating to contraction of various cells, diseases relatingto morphological change of various cells, diseases relating to migrationof various cells, diseases relating to release of various cells,diseases relating to aggregation of various cells, and/or diseasesrelating to apoptosis of various cells, and the like.

Although it is not intended to be bound by any specific theory, actionmechanism of the compounds of the present invention represented by theaforementioned general formula (1) and salts thereof can be presumed asfollows. It is known that increase of the amount of phosphorylatedmyosin regulatory light chain activates the actomyosin system, which isa movement apparatus of cytoskeleton, and activates cell movements.Therefore, it is considered that the phosphorylation reaction of myosinregulatory light chain is important for cell movements (Kamm, K., etal., Annu. Rev. Physiol., 51, pp. 299-313, 1989; Niggli, V., FEBS Lett.,445, pp. 69-72, 1999; Itoh, K., et al., Biochim. Biophys. Acta., 1136,pp. 52-56, 1992; Kitani, S., et al., Biochem. Biophys. Res. Commun.,183, pp. 48-54, 1992). Measurement of the amount of phosphorylatedmyosin regulatory light chain in the cells revealed that the compoundsrepresented by the aforementioned formula (1) and salts thereof decreasethe amount of phosphorylated myosin regulatory light chain in the cells(refer to Test Example 1 in the specification).

It is known that the amount of phosphorylated myosin regulatory lightchain in the cells is determined by activated states of two reactionroutes including Reaction route 1 and Reaction route 2 described below(Fukata, Y., et al., Trends Pharmacol. Sci., 22, pp. 32-39, 2001).

<Reaction Route 1>

Increase of intracellular calcium concentration→Activation of myosinlight chain kinase→Increase of amount of phosphorylated myosinregulatory light chain

<Reaction Route 2>

Activation of low molecular weight G protein Rho→Activation of Rhokinase→Phosphorylation (inactivation) of myosin phosphatase→Increase ofamount of phosphorylated myosin regulatory light chain

It is considered that a compound that inhibits Reaction route 1 and/orReaction route 2 mentioned above has an activity for decreasing theamount of phosphorylated myosin regulatory light chain. In order toestimate whether either or both of Reaction route 1 and Reaction route 2mentioned above are the target site for the compounds of the presentinvention represented by the aforementioned formula (1) and saltsthereof, effects of the compounds of the present invention representedby the aforementioned formula (1) and salts thereof on increase ofintracellular calcium concentration and activity of myosin light chainkinase were examined. As a result, it was found that the compounds ofthe present invention and salts thereof gave no influence on theincrease of intracellular calcium concentration (see, Test Example 9),and did not inhibit the myosin light chain kinase activity (see, TestExample 10). Therefore, it is presumed that the compounds of the formula(1) according to the present invention do not inhibit Reaction route 1mentioned above, but inhibit Reaction route 2 mentioned above todecrease the amount of phosphorylated myosin regulatory light chain.Thus, the compounds of the present invention can be used as inhibitorsof the Rho/Rho kinase pathway. The inhibition of Reaction route 2mentioned above by the compounds of the present invention represented bythe aforementioned formula (1) and salts thereof may be confirmed bymeasuring the inhibitory activity for the Rho kinase activity, oralternatively, by measuring the inhibitory activity for thephosphorylation reaction of myosin phosphatase.

The activity of Rho kinase can be measured by the method disclosed inWO01/56988. More specifically, ATP (γ³²P-ATP) is added to a substrate(Ribosomal S6 kinase substrate) together with a commercially availableRho kinase (Upstate) to start the enzymatic reaction and phosphorylatethe substrate. The substrate is adsorbed on filter paper, and ATP iswashed off with the phosphate buffer. Then, the amount of thephosphorylated substrate is measured by using a liquid scintillationcounter. The inhibitory activity of the compounds of the presentinvention represented by the aforementioned formula (1) for the Rhokinase activity can be determined by adding the compounds beforestarting the enzymatic reaction, and measuring suppression of thephosphorylation amount of the substrate. The phosphorylation reaction ofmyosin phosphatase can be measured by, for example, using an antibodyspecifically recognizing the phosphorylated myosin phosphatase (Feng, J.et al., J. Biol. Chem., 274, pp. 37385-37390, 1999). More specifically,proteins including myosin phosphatase are extracted from a tissue,subjected to electrophoresis on acrylamide gel, and transferred to anitrocellulose membrane. The proteins are reacted with antibodiesspecifically recognizing phosphorylated myosin phosphatase to detect theamount of phosphorylated myosin phosphatase. The inhibitory activity onthe phosphorylation reaction of myosin phosphatase can be determined byadding the compounds before starting the extraction from the tissue, andmeasuring suppression of the phosphorylation amount of the myosinphosphatase.

It is considered that the compounds of the present invention representedby the aforementioned formula (1) and salts thereof inhibit the Rho/Rhokinase pathway, which is Reaction route 2 mentioned above, and exhibitmore potent cell contraction inhibitory activity and cell migrationinhibitory activity compared with the conventional isoquinolinecompounds. It is known that the Rho/Rho kinase route plays an importantrole for cell contraction and cell migration. Other than the above, ithas been reported that the Rho/Rho kinase pathway controls a variety ofcellular functions such as aggregation, release, production, division,apoptosis, and gene expression in various cell lines (Fukata, Y., etal., Trends in Pharmacological Sciences, 22, pp. 32-39, 2001; Murata T.,et al., J. Hepatotol., 35, pp. 474-481, 2001; Ohnaka, K., et al.,Biochem. Biophys. Res. Commun., 287, pp. 337-342, 2001; Yuhong, S., etal., Exp. Cell Res., 278, pp. 45-52, 2002; Arakawa, Y. et al., BIOClinica, 17(13), pp. 26-28, 2002). Therefore, the compounds of thepresent invention which inhibit the Rho/Rho kinase pathway exhibit,based on that effect, more potent cell contraction inhibitory activity(Test Examples 2, 3, and 4), cell morphology change regulating activity(Test Example 5), cell migration inhibitory activity (Test Examples 6,7, and 8), cell release inhibitory activity, cell aggregation inhibitoryactivity, apoptosis inhibitory activity, and activity of regulating geneexpression compared with the conventional isoquinoline compounds, andare useful as active ingredients of medicaments for prophylactic and/ortherapeutic treatment of diseases relating to contraction of variouscells, diseases relating to morphological change of various cells,diseases relating to migration of various cells, diseases relating torelease from various cells, diseases relating to aggregation of variouscells, diseases relating to apoptosis of various cells, and/or diseasesrelating to abnormal gene expression in various cells (Jikken Igaku(Experimental Medicine) Vol. 17, 7, 1999).

Examples of the diseases relating to contraction of various cellsinclude, for example, as those relating to vascular smooth muscles,hypertension, arteriosclerosis, cerebral circulatory disturbance, brainfunction disorder with the aforementioned disease (mental disorder,memory disorder, dementia, delirium, poriomania, dyskinesia and thelike), dizziness, cardiac diseases, pokkuri-byou (sudden death),disturbances of peripheral circulation, disturbances of retinalcirculation, renal failure and the like, as those relating to airwaysmooth muscles, asthma, acute respiratory distress syndrome (ARDS),pulmonary emphysema, peripheral respiratory tract disease, chronicbronchitis, chronic obstructive pulmonary disease (COPD), and the like(Ueki, J. et al., Gendai Iryo (Contemporary Medical Care), Vol.34, No.9,pp. 87-92, 2002), as those relating to digestive tract smooth muscles,vomiting, chronic gastritis, reflux esophagitis, irritable bowelsyndrome and the like, as those relating to smooth muscle cells existingin eyes, glaucoma, and the like, as those relating to vitreum of eyes,vitreoretinal diseases, and the like (Hirayama, K., et al., PreliminaryPublished Abstracts of the 42nd Congress of the Vitreoretina Society ofJapan), as those relating to smooth muscles of bladder and urethra,dysuria, pollakiuria, incontinence and the like, as those relating tosmooth muscles of uterus, gestational toxicosis, threatened prematuredelivery, abortion and the like, and as those relating to smooth musclesof penis, erectile dysfunction is known. However, the diseases are notlimited to the aforementioned examples.

More precisely, examples of hypertension include essential hypertension,renal hypertension, renovascular hypertension, hypertension duringpregnancy, endocrine hypertension, cardiovascular hypertension,neurogenic hypertension, iatrogenic hypertension, pulmonary hypertensionand the like, and examples of arteriosclerosis include those in whichpathological change is observed in major arteries in whole body such ascoronary artery, aorta abdominalis, renal artery, carotid artery,ophthalmic artery, and cerebral artery. Examples of cerebral circulatorydisturbance include cerebral thrombosis, cerebral infarction, cerebralhemorrhage, transient brain ischemic attack, hypertensiveencephalopathy, cerebral arteriosclerosis, subdural hemorrhage, epiduralhemorrhage, subarachnoid hemorrhage, brain hypoxia, cerebral edema,encephalitis, brain tumor, head injury, mental disorder, metabolicintoxication, drug intoxication, transient aphyxia, deep anesthesia inoperation and the like. The cardiac diseases include congestive heartfailure, acute myocardial infarction, previous myocardial infarction,subendocardial infarction, right ventricular infarction, atypicalmyocardial infarction, ischemic cardiomyopathy, variant angina pectoris,stable angina, effort angina, coronary vasospasm, postinfarction angina,unstable angina pectoris, arrhythmia, and acute cardiac death.

The peripheral circulatory disturbances include aortic diseases such asBuerger's disease, arteriosclerotic obliteration, and Raynaud'ssyndrome, venous diseases such as venous thrombosis andthrombophlebitis, hyperviscosity syndrome, frostbite and chilblain,psychoesthesia and hypnagogic disturbance due to feeling of cold,bedsore, cleft, and alopecia. Examples of the retinal circulatorydisturbances include retinal vascular obstruction, arterioscleroticretinopathy, vasospastic retinopathy, hypertonic fundus, hypertensiveretinopathy, renal retinopathy, hypertensive neuroretinopathy, diabeticretinopathy and the like. Glaucoma includes primary glaucoma, secondaryglaucoma, developmental glaucoma, childhood secondary glaucoma and thelike, as well as more narrowly classified types of the foregoings,including primary open-angle glaucoma, primary angle-closure glaucoma,mixed-type glaucoma, ocular hypertension, and the like (Japanese Journalof Ophthalmology, vol. 107, No. 3, 2003). Further, examples of thevitreoretinal diseases include retinal detachment, retinoschisis,vitreoretinal interface syndrome, retinal pigment epitheliosis, macularhole, phacomatosis, vitreous hemorrhage, retinal circulatorydisturbances, and the like (the vitreoretinal diseases mentioned hereininclude more narrowly classified diseases belonging to each of thecategories according to the pathological typology described in ShinZusetsu Rinsho Ganka Koza (Illustrative Lecture of ClinicalOphthalmology, New Edition), Ed. By Tano, Y., Araie, M., et al, Vol. 5,Vitreoretinal Diseases, MEDICAL VIEW, 2003). The urinary disturbancesinclude dysuria, bladder neck contracture, bladder neck occlusion,urethral syndrome, detrusor sphincter dyssynergia, unstable bladder,chronic prostatitis, chronic cystitis, prostate pain, Hinman's syndrome,Fowler's syndrome, psychogenic dysuria, drug-induced dysuria, dysuriawith aging and the like. The erectile dysfunction include organicerectile dysfunction accompanying diseases of diabetes mellitus,arteriosclerosis, hypertension, multiple-sclerotic cardiac diseases,hyperlipidemia, depression and the like, functional erectiledysfunction, erectile dysfunction with aging, and erectile dysfunctionafter spinal cord injury or radical prostatectomy.

Examples of the diseases relating to morphological change of variouscells include, for example, various nerve dysfunctions as those relatingto nerve cells. As the nerve dysfunctions, for example, neural damagescaused by trauma (spinal cord injury and the like), neurodegenerativediseases such as Alzheimer's disease, Parkinson's disease, diabeticretinopathy, and glaucoma, and the like can be exemplified. Glaucomarefers to the same as that mentioned above.

Examples of the diseases relating to migration of various cells include,for example, as those relating to cancer cells, infiltration andmetastasis of cancer. Examples of those relating to vascular endothelialcells include angiogenesis, neovascular maculopathy, macular edema, andthe like (the macular diseases mentioned herein include more narrowlyclassified diseases belonging to each of the categories according to thepathological typology described in Shin Zusetsu Rinsho Ganka Koza(Illustrative Lecture of Clinical Ophthalmology, New Edition), Ed. ByTano, Y., Araie, M., et al, Vol. 5, Vitreoretinal Diseases, MEDICALVIEW, 2003). Examples of those relating to leukocytes include bacterialinfection, allergic hypersensitive diseases (e.g., bronchial asthma,atopic dermatitis, pollinosis, anaphylactic shock and the like),collagen diseases (e.g., rheumatoid arthritis, systemic lupuserythematodes, multiple sclerosis, Sjogren's disease and the like),angiitis, inflammatory bowel diseases (e.g., ulcerative colitis, Crohn'sdisease and the like), ischemic reperfusion injury of visceral organs,traumatic spinal cord injury, pneumonia, hepatitis, nephritis,pancreatitis, otitis media, sinusitis, arthritis (for example,osteoarthritis, gout and the like can be exemplified), fibrosis, AIDS,adult T-cell leukemia, rejection after organ transplantation (graftversus host reaction), vascular restenosis, and endotoxin shock. Exampleof the cancer include myelocytic leukemia, lymphatic leukemia, gastriccancer, carcinoma of the colon and rectum, lung cancer, pancreaticcarcinoma, hepatocellular carcinoma, carcinoma of the esophagus, ovariancancer, breast cancer, skin cancer, head and neck cancer, cancer of thetesticles, neuroblastoma, urinary tract epithelial cancer, multiplemyeloma, carcinoma uteri, melanoma, brain tumor and the like. Examplesof hepatitis include hepatitis by virus infection (e.g., hepatitis B,hepatitis C and the like), and alcoholic hepatitis. Examples of thepneumonia include chronic obstructive pulmonary disease (COPD) andinterstitial pneumonia, which may shift to fibrosis. Examples ofnephritis include chronic nephritic syndrome, asymptomatic proteinuria,acute nephritic syndrome, nephrotic syndrome, IgA nephropathy,pyelonephritis, glomerulonephritis and the like. Fibrosis includechronic pathological changes characterized by excess deposition ofconnective tissue proteins in lung, skin, heart, liver, pancreas, kidneyand the like. The major pathological conditions are pulmonary fibrosis,hepatic fibrosis, and skin fibrosis. However, fibrosis is not limited tothese examples. In hepatic fibrosis, viral hepatitis progresses byinfection of, in particular, hepatitis B virus or hepatitis C virus,thus hepatic cells cause necrosis, and thereby fibrosis progresses,which means macronodular hepatic cirrhosis. Further, hepatic fibrosisalso includes micronodular hepatic cirrhosis caused by progress ofalcoholic hepatitis.

Examples of diseases relating to release of various cells include, asthose relating to leukocytes, for example, allergic diseases.

Examples of the allergic diseases include asthma, atopic dermatitis,allergic conjunctivitis, allergic arthritis, allergic rhinitis, allergicpharyngitis and the like.

Examples of the diseases relating to aggregation of various cellsinclude, as those relating to platelets, for example, thrombosis.

Thrombosis include the aforementioned circulatory disturbances of majorarteries, major veins and peripheral arteries and veins in whole body,as well as shock caused by hemorrhage, drug intoxication, or endotoxin,disseminated intravascular coagulation (DIC) following it, and multipleorgan failure (MOF).

Examples of the diseases relating to apoptosis of various cells include,as those relating to nerves, for example, neurodegenerative diseasessuch as Alzheimer's disease, Parkinson's disease, diabetic peripheralneuropathy, retinopathy, amyotrophic lateral sclerosis due to cerebralischemia, pigmented retinitis, and cerebellar degeneration, andglaucoma. Examples of glaucoma are mentioned above. AIDS, and fulminanthepatites are examples of disease relating to viruses, chronic heartfailure due to myocardial ischemia is an example of diseases relating tosmooth muscles, myelodysplasia, aplastic anemia, sideroblastic anemia,and graft-versus-host disease (GVHD) after organ transplantation areexamples of diseases relating to blood, arthrosteitis, and osteoporosisis an example of diseases relating to bones.

Examples of the diseases relating to abnormal gene expression of variouscells include, for example, bone diseases as those relating to bonecells, AIDS as one relating to virus, and cancers as those relating tocancer cells.

Examples of the bone diseases include osteoporosis, hypercalcemia, bonePaget's disease, renal osteodystrophy, rheumatoid arthritis,osteoarthritis, osteogenesis imperfecta tarda, bone damage, periodontalbone disorder, and the like. Examples of AIDS include acquiredimmunodeficiency syndrome caused by human immunodeficiency virus (HIV)infection. Examples of the cancers include gastric cancer, carcinoma ofthe colon and rectum, hepatocellular carcinoma, pancreatic carcinoma,lung cancer, leukemia, malignant lymphoma, carcinoma uteri, ovariancancer, breast cancer, skin cancer and the like.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofhypertension can be confirmed by, for example, administering thecompound to various hypertension model animals or the like. Examples ofhypertension animal models include spontaneous hypertensive rat (SHR),renal hypertensive rat, DOCA-salt hypertensive rat and the like (Uehata,M. et al., Nature, 389, 990-994, 1997). A compound is orally,intravenously or intraperitoneally administered to a hypertension modelanimal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andthe diastolic blood pressure is measured. The usefulness as a medicamentfor hypertension can be confirmed based on an action of reducing thediastolic blood pressure.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of pulmonaryhypertension can be confirmed by using, for example, a rat model ofpulmonary hypertension created by administering monocrotaline to a ratfor 2 to 3 weeks (Ito, K. M. et al., Am. J. Physiol., 279, H1786-H1795,2000). A compound is orally, intravenously or intraperitoneallyadministered to a model animal of pulmonary hypertension at a dose of0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, and the intrapulmonarypressure is measured. The usefulness as a medicament for pulmonaryhypertension can be confirmed based on an action of decreasing theintrapulmonary pressure.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofarteriosclerosis can be confirmed by using, for example, a rat model ofL-NAME-induced arteriosclerosis (Cir. Res. 89(5):415-21, 2001), a ratmodel of balloon-induced neointimal formation (Sawada N. et al.,Circulation 101 (17):2030-3, 2000) or the like. A compound is orally,intravenously or intraperitoneally administered to a model animal ofarteriosclerosis at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100mg/kg, and thickening of arteries is observed. The usefulness as amedicament for arteriosclerosis can be confirmed based on an action ofsuppressing neointimal formation in arteries.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of cerebralcirculatory dysfunction can be confirmed by using, for example, a gerbilmodel of hippocampal neuronal death (Kirino et al., Brain Res., 239,57-69, 1982) or the like. A compound is orally, intravenously orintraperitoneally administered to the model animal at a dose of 0.1 to1,000 mg/kg, preferably 0.1 to 100 mg/kg, and the amount ofenergy-related substances and survival period of gerbil, or inhibitionof late-onset of neuronal death is measured. The usefulness as amedicament for cerebral circulatory dysfunction can be confirmed basedon actions for maintaining, improving and activating cerebral metabolicability, brain and nerve protective action, and action for suppressingformation of cerebral infarction.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of cardiacdiseases can be confirmed by using, for example, a rat model ofmyocardial infarction based on the ligation of artery (Xia Q. G. et al.,Cardiovasc. Res., 49(1):110-7, 2001) or the like. Effectiveness as amedicament for cardiac diseases can be confirmed by orally,intravenously or intraperitoneally administering a compound to the modelanimal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andobserving a cardiac tissue fixed by formalin perfusion after ischemicreperfusion.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofdisturbances of peripheral circulation can be confirmed by using, forexample, a rat model of bedsore (Pierce S. M. et al., Am. J. Physiol.Heart Circ. Physiol., 281(1):H67-74, 2001) or the like. Effectiveness asa medicament for bedsore (peripheral circulatory disturbance) can beconfirmed by orally, intravenously or intraperitoneally administering acompound to the model animal at a dose of 0.1 to 1,000 mg/kg, preferably0.1 to 100 mg/kg, compressing the hind leg skin at a pressure of 50mmHg, and then observing a tissue of necrotic area of the lesion ormeasuring epithelial blood flow of the same.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofdisturbances of retinal circulation can be confirmed by using, forexample, rabbit model of rose bengal-mediated argon laser retinal veinphotothrombosis (Jpn. J. Ophthalmol., 45(4):359-62, 2001), or the like.Effectiveness as a medicament for retinal circulatory disturbance can beconfirmed by orally, intravenously or intraperitoneally administering acompound to the model animal at a dose of 0.1 to 1,000 mg/kg, preferably0.1 to 100 mg/kg, comparing the degree of retinal circulatorydisturbance with that of a control based on count of laser spots.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of renalfailure can be confirmed by using, for example, a rat model ofone-kidney, one-clip renal hypertension (Kiso to Rinsho, 30, 511-524,1996). Effectiveness as a medicament for renal failure can be confirmedby orally, intravenously or intraperitoneally administering a compoundto the model animal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to100 mg/kg, and measuring the diuretic effect.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of asthma, forexample, bronchial asthma, can be confirmed by using, for example,suppression of constriction of an isolated trachea, a model animal ofbronchial asthma, inhibition of chemotaxis of human peripheralleucocytes (Kunihiko Iizuka, Allergy, 47:943, 1998; Kunihiko Iizuka, andAkihiro Yoshii, Jpn.J.Respirol Soc, 37:196, 1999.), or the like. Theusefulness as a medicament for bronchial asthma can be confirmed byorally, intravenously or intraperitoneally administering a compound tothe model animal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100mg/kg, and measuring elevation of airway resistance caused byacetylcholine inhalation, or performing histological analysis.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of irritablebowel syndrome can be confirmed by administering the compounds to astress burden model animal, or the like. Examples of the stress burdenmodel animal include, for example, a rat model of arresting stress(Miyata, K. et al., J. Pharmacol. Exp. Ther., 259, pp. 815-819, 1991), aCRH-administered rat model (Miyata, K. et al., Am. J. Physiol., 274,G827-831, 1998), and the like. A compound is orally, intravenously orintraperitoneally administered to a stress burden model animal at a doseof 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, and counting thenumber of fecal pellets. The usefulness as a medicament for curativemedicine of irritable bowel syndrome can be confirmed based on effectfor reducing the number of fecal pellets.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of glaucomacan be confirmed by, for example, measuring intraocular pressure of arabbit, cat or monkey after administration of the medicaments byinstillation (Surv. Ophthalmol. 41:S9-S18, 1996). The usefulness as amedicament for glaucoma can be confirmed by instilling or orally,intravenously or intraperitoneally administering a compound to a locallyanesthetized rat or monkey model animal at a dose of 0.1 to 1,000 mg/kg,preferably 0.1 to 100 mg/kg, and measuring the intraocular pressure overtime using an tonometer.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofvitreoretinal diseases can be confirmed by a known method, for example,the methods described in Oshima, Y. et al., Gene Ther., 9(18), pp.1214-20, 2002; and Ito, S., et al., Graefes Arch. Clin. Exp.Ophthalmol., 237(8), pp. 691-6., 1999. The usefulness as a medicamentfor vitreoretinal diseases can be confirmed by orally, intravenously,intraperitoneally, or intraocularly administering (direct administrationto vitreum or retina) a compound to a rabbit in which retinal detachmentis induced by cell transfer to the vitreoretinal interface, vitrectomy,or the like at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100mg/kg, and evaluating amelioration of the pathological conditions on thebasis of histological analysis.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of dysuria canbe confirmed by using, for example, a model of rhythmic bladdercontraction (Kaneko S. et al., Folia Pharmacol. Japon, Vol. 93(2),55-60, 1989; Nomura N. et al., Folia Pharmacol. Japon, Vol. 94(3), 173-,1989.) or the like. The usefulness as a medicament for urinarydisturbance can be confirmed by orally, intravenously orintraperitoneally administering a compound to an anesthetized rat or dogat a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andmeasuring the number of rhythmic contraction of filled bladder(micturition).

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of erectiledysfunction can be confirmed by a known method, for example, the methoddescribed in J. Uro., 151, 797-800, 1994. A compound is dissolved in ahydrophilic ointment, 30 mg of the ointment was applied to a rat penis,and the rat is held in an acrylic cylinder for 10 minutes so that therat was not able to lick the penis. The rat is moved to an acrylic cageof 30 cm×30 cm, and videotaped for 60 minutes from the side and thebottom of the cage. Then, the number of erection of the penis per 30minutes can be counted to confirm the usefulness as a medicament forerectile dysfunction.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for suppressing cancer metastasis and invasion can beconfirmed by, for example, the method described in Cancer Res.,55:3551-3557 (1995). The usefulness as a medicament for cancermetastasis and invasion can be confirmed by orally, intravenously orintraperitoneally administering a compound at a dose of 0.1 to 1,000mg/kg, preferably 0.1 to 100 mg/kg, to a nude mouse transplanted withhuman cancer cell suspension transplantable to immunodeficient mice atthe same site (spontaneous metastasis model), and measuring themetastasized lesion.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of collagendisease can be confirmed by using, for example, collagen-inducedarthritis model of a rat or mouse (Griffith, M. M. et al., ArthritisRheumatism, 24:781, 1981; Wooley, P. H. et al., J. Exp. Med., 154:688,1981). The usefulness as a medicament for collagen disease can beconfirmed by orally, intravenously or intraperitoneally administering acompound to the model mouse or rat at a dose of 0.1 to 1,000 mg/kg,preferably 0.1 to 100 mg/kg, and measuring footpad volume or progressionof bone destruction.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofinflammatory bowel disease can be confirmed by using a rat model ofidiopathic ulcerative colitis induced by subserosal injection of aceticacid, a model of sodium dextransulfate-induced colitis, a model oftrinitrobenzenesulfonic acid-induced colitis (Kojima et al., Folia.Pharmacol. Jpn., 118, 123-130, 2001), or the like. The usefulness as amedicament for inflammatory bowel disease can be confirmed by, forexample, orally, intravenously or intraperitoneally administering acompound at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg,to a rat in which colitis is induced by intraintestinal injection ofacetic acid, dissecting the rat after several days to two weeks, thenobserving and measuring the ulcer area of the intestinal epithelium, andamount of leucotriene B4 in a colon homogenate.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of spinal cordinjury can be confirmed by using, for example, a rat model of spinalcord ablation (Sayer F. T. et al., Exp. Neurol., 175(1):282-96, 2002) orthe like. Effectiveness as a medicament for spinal cord injury can beconfirmed by orally, intravenously or intraperitoneally administering acompound to the model animal at a dose of 0.1 to 1,000 mg/kg, preferably0.1 to 100 mg/kg, and, after several weeks, examining a tissue of thespinal cord with a microscope to measure a degree of nerve regeneration.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of pneumoniacan be confirmed by using, for example, a mouse model of OVA-inducedchronic pneumonia (Henderson W. R. et al., Am. J. Respir. Crit. CareMed., 165(1):108-16, 2002), a mouse model of LPS-induced acute pneumonia(Gonzales de Moraes, V L., et al., Br. J. Pharmacol., 123, pp. 631-6,1998), or the like. Effectiveness as a medicament for pneumonia can beconfirmed by orally, intravenously or intraperitoneally administering acompound to the model animal at a dose of 0.1 to 1,000 mg/kg, preferably0.1 to 100 mg/kg, and counting number of eosinophils or monocytes in thepulmonary cavity.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of hepatitiscan be confirmed by using a mouse model of endotoxin-induced liverinjury according to, for example, the method described in J. Immunol.,159, 3961-3967, 1997. The usefulness as a medicament for hepatitis canbe confirmed by orally, intravenously or intraperitoneally administeringa compound to the mouse model of endotoxin-induced liver injury at adose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, and measuringthe plasmic transaminase level or amount of hydroxyproline in a hepatictissue, which are indicators of liver function, or performinghistological analysis.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment ofpancreatitis can be confirmed by using, for example, a mouse model ofcerulein-inducted acute pancreatitis (Niedirau, C. et al.,Gastroenterology 88 (5 Pt 1):1192-204, 1985) or the like. Effectivenessas a medicament for pancreatitis can be confirmed by orally,intravenously or intraperitoneally administering a compound to the modelanimal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andmeasuring the serum amylase activity, or weight of pancreas.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of nephritiscan be confirmed by using, for example, a nephritis rat model preparedby administering anti-GBM antibodies obtained by immunizing a rabbitwith a GBM fraction derived from a rat to a rat (WO01/56988), or thelike. A compound is orally, intravenously or intraperitoneallyadministered to the nephritis rat model at a dose of 0.1 to 1,000 mg/kg,preferably 0.1 to 100 mg/kg, and the urinary proteins are measured. Theusefulness as a medicament for nephritis can be confirmed based on anaction of reducing the urinary protein level.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients forsuppressing allograft rejection at the time of organ transplantation canbe confirmed by using, for example, a rat model of skin transplantation,rat model of heart transplantation (Ochiai T. et al., Transplant. Proc.,19, 1284-1286, 1987), or the like. Effectiveness as a medicament forsuppressing rejection at the time of organ transplantation can beconfirmed by orally, intravenously or intraperitoneally administering acompound to a model animal at a dose of 0.1 to 1,000 mg/kg, preferably0.1 to 100 mg/kg, and estimating the graft survival ratio.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of rheumatoidarthritis can be confirmed by using collagen-induced arthritis model ofa rat or mouse (Griffith, M. M. et al., Arthritis Rheumatism, 24:781,1981; Wooley, P. H. et al., J. Exp. Med., 154:688, 1981). The usefulnessas a medicament for rheumatoid arthritis can be confirmed by orally,intravenously or intraperitoneally administering a compound to a modelmouse or model rat at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to100 mg/kg, and measuring footpad volume or progression of bonedestruction.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of chronicobstructive pulmonary disease (COPD) can be confirmed by using, forexample, suppression of constriction of an isolated trachea, a modelanimal of bronchial asthma, a guinea pig model of tobacco smokeexposition (Fuchigami J. et al., 73rd Meeting of JapanesePharmacological Society, Collection of Abstracts, 2000), inhibition ofchemotaxis of human peripheral leucocytes or the like. The usefulness asa medicament for COPD can be confirmed by orally, intravenously orintraperitoneally administering a compound to a guinea pig exposed totobacco smoke at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100mg/kg, and counting the number of migrating leucocytes in abronchoalveolar lavage fluid, or performing histological analysis.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of hepaticfibrosis can be confirmed by using a carbon tetrachloride-inducedhepatic fibrosis model according to, for example, the method describedin J. Hepatol., 35(4), 474-81, 2001. The usefulness as a medicament forhepatic fibrosis can be confirmed by orally, intravenously orintraperitoneally administering a compound to the hepatic fibrosis modelat a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andmeasuring the plasmic transaminase level, or amount of hydroxyproline ina hepatic tissue, which are indicators of liver function, or performinghistological analysis.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of pulmonaryfibrosis can be confirmed by using an animal model of Bleomycin-inducedpulmonary fibrosis according to the method described in, for example,Am. J. Respir. Crit. Care Med., 163(1), pp. 210-217, 2001. Theusefulness as a medicament for pulmonary fibrosis can be confirmed byorally, intravenously or intraperitoneally administering a compound tothe pulmonary fibrosis mouse model at a dose of 0.1 to 1,000 mg/kg,preferably 0.1 to 100 mg/kg, and measuring respiratory function, oramount of hydroxyproline in a pulmonary tissue.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of allergy canbe confirmed by using an atopic dermatitis mouse model or the likeaccording to the method described in, for example, Allergy, 50 (12)1152-1162, 2001. The usefulness as a medicament for allergy can beconfirmed by orally, intravenously or intraperitoneally administering acompound to an NC/Nga mouse pretreated with a surfactant or an organicsolvent at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg,when eruption is induced in the mouse by using housedust mite antigens,and measuring the plasmic IgE level, number of eosinophils and the like.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of thrombosiscan be confirmed by using, for example, a rabbit model ofexperimentally-induced venous thrombus (Maekawa, T. et al., Trombos.Diathes. Haemorrh., 60, pp. 363-370, 1974), or the like. Effectivenessas a medicament for thrombosis can be confirmed by orally, intravenouslyor intraperitoneally administering a compound to the model animal at adose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, and estimatingthe incidence of thrombus.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) as active ingredients of medicaments forprophylactic and/or therapeutic treatment of Alzheimer's disease can beconfirmed by using, for example, an in vitro culture system of nervecells derived from rat embryos (Yankner, B. A. et al., Science, 250, pp.279-282, 1990), or the like. Effectiveness as a medicament forAlzheimer's disease can be confirmed by adding 0.1 to 1 mM, preferably0.1 to 100 μM, of a compound, and measuring suppression ratio for celldeath induced by beta-amyloid proteins.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of bonedisease can be confirmed by using, for example, a mouse model ofosteoporosis prepared by ovariectomy (OVX mouse, Golub, L. M. et al.,Ann. N.Y. Acad. Sci., 878, pp. 290-310, 1999). A compound is orally,intravenously or intraperitoneally administered to the OVX mouse at adose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, and deciduousdental roots are measured, or weight of skeletal bones is measured. Theusefulness as a medicament for periodontal bone disorder or osteoporosiscan be confirmed based on an action for suppressing periodontalbreakdowns, or an action for suppressing skeletal bone weight loss.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of AIDS can beconfirmed by using, for example, a rhesus monkey model of SIV-infection(Crub S. et al., Acta Neuropathol., 101(2), pp. 85-91, 2001) or thelike. Effectiveness as a medicament for AIDS can be confirmed by orally,intravenously or intraperitoneally administering a compound to the modelanimal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andquantifying the SIV mRNA level in blood.

Usefulness of the compounds of the present invention represented by theaforementioned formula (1) and salts thereof as active ingredients ofmedicaments for prophylactic and/or therapeutic treatment of cancer canbe confirmed by using, for example, a mouse model of ultraviolet rayirradiation-induced skin cancer, a nude mouse model of tumor xenograft(Orengo I. F. et al., Arch Dermatol., 138(6), pp. 823-4, 2002; Ki D. W.et al., Anticancer Res., 22(2A), pp. 777-88, 2002) or the like.Effectiveness as a medicament for cancer can be confirmed by orally,intravenously or intraperitoneally administering a compound to a modelanimal at a dose of 0.1 to 1,000 mg/kg, preferably 0.1 to 100 mg/kg, andobserving progression or reduction of the grafted cancer tissues on thebody surface.

Further, when test compounds of the compounds of the present inventionor salts thereof were introduced into wells of a 96-well plate at aconcentration three times higher than the IC₅₀ values obtained in TestExample 1, and the cell suspension prepared in Test Example 1 was addedat a density of 10⁶/well, incubated for 30 minutes at room temperatureand stained with trypan blue to determine the survival rates of thecells, a viability as high as 90% or more was observed in all the wells.Furthermore, when the compounds of the present invention or saltsthereof were orally administered to mice every day at a dose of 30 mg/kgfor 5 days, death was not observed. Therefore, the compounds of thepresent invention had no particular problem also in safety.

As the active ingredients of the medicaments of the present invention,the compounds represented by the aforementioned formula (1), orphysiologically acceptable salts thereof may be used. The aforementionedsubstance, per se, may be administrated as the medicament of the presentinvention. However, a pharmaceutical composition containing one or morekinds of the aforementioned substances as the active ingredients and oneor more kinds of pharmaceutical additives can be generally prepared andadministrated orally or parenterally (e.g., intravenous administration,intramuscular administration, subcutaneous administration, transrectaladministration, transdermal administration, inhalation, instillation,intraurethral administration, intrarectal administration, and the like)to human or an animal other than human. The aforementionedpharmaceutical composition can be prepared in a dosage form suitable foran intended administration route. More specifically, examples of thepharmaceutical composition suitable for oral administration include oraldrug products (tablets, capsules, powders, granules, syrups, pills,troches, and the like), and examples of the pharmaceutical compositionsuitable for parenteral administration include injections (liquid dosageforms, suspensions, and the like), drip infusions, inhalants,suppositories, transdermally absorbed agents (e.g., tapes), ointments,ophthalmic solutions, ophthalmic ointments, ophthalmic membrane adherentagents, and the like.

These pharmaceutical compositions can be prepared in a conventionalmanner by using pharmaceutical additives ordinarily used in this field(e.g., excipients, disintegrants, binders, lubricants, colorants,buffering agents, coating agents, flavors, fragrances, emulsifyingagents, isotonic agents, solubilizing agents, preservatives, viscosityimprovers, pH adjusters and the like). Examples include tablets preparedby adding crystalline cellulose, magnesium stearate, or the like to thecompounds of the present of invention or salts thereof.

A content of the active ingredient in the aforementioned pharmaceuticalcomposition can be suitably chosen depending on a dosage form. Thecontent may be, for example, about 0.1 to 100% by weight, preferablyabout 1 to 50% by weight, based on the total weight of the composition.A dose of the medicament of the present invention can be suitablydetermined for each administration in consideration of the age, weight,sexuality of a patient, the type of a disease, the severity ofpathological condition and the like. Examples of the doses include, forexample, about 1 to 500 mg, preferably about 1 to 100 mg, and mostpreferably about 1 to 30 mg. These doses can be administered once in aday or several times a day as divided portions.

EXAMPLES

The present invention will be further specifically explained withreference to the following examples. However, the present invention isnot limited to these examples.

For thin layer chromatography (TLC), Precoated Silica Gel 60 F254(produced by Merck) was used. After development with chloroform:methanol(100:1 to 4:1), or ethyl acetate:n-hexane (100:1 to 1:10), spots wereobserved by UV irradiation (254 nm) or coloration with ninhydrine orphosphomolybdic acid. For drying organic solvent, anhydrous magnesiumsulfate or anhydrous sodium sulfate was used. For flash columnchromatography, Silica gel 60N (spherical shape, neutral, 40 to 100 μm,produced by Kanto Chemicals) was used. For preparative thin layerchromatography (PTLC), Precoated Silica Gel 60 F254 (20×20 cm,thickness: 2 mm, produced by Merck) was used. For the measurement ofnuclear magnetic resonance (NMR) spectra, the measurement was performedby using Gemini-300 (FT-NMR, produced by Varian), or AL-300 (FT-NMR,produced by JOEL). As a solvent, deuterated chloroform was used, unlessotherwise indicated. Chemical shifts were measured by usingtetramethylsilane (TMS) as an internal standard, and indicated with δ(ppm), and binding constant was indicated with J (Hz). Mass spectrum(MS) was measured by liquid chromatography-mass spectrometry (LC-MS).Platform-LC type mass spectrometry apparatus (produced by Micromass) wasused as the mass spectrometer, and the measurement was performed by theelectrospray ionization (ESI) method. As the liquid chromatographyapparatus, an apparatus produced by GILSON was used. As the separationcolumn, Mightysil RP-18 GP 50-4.6 (produced by Kanto Chemicals) wasused. Elution was generally performed at a flow rate of 2 ml/minuteusing a linear gradient of 5 to 100% (v/v) Solution B [acetonitrilecontaining 0.1% (v/v) acetic acid] in Solution A [water containing 0.1%(v/v) acetic acid] from 0 minute to 5 minutes as the solvent.

Reference Example 1 4-Bromo-5-aminoisoquinoline

(Step A) Synthesis of 4-bromo-5-nitroisoquinoline

With vigorous stirring, concentrated sulfuric acid (36 ml) was addedwith 4-bromoisoquinoline (10.0 g, Tokyo Kasei Kogyo) to such an extentthat the temperature should not exceed 10° C. and stirred for a while toattain complete dissolution. Potassium nitrate (4.9 g, Kanto Chemicals)was dissolved in concentrated sulfuric acid (20 ml), added dropwise tothe aforementioned solution at a temperature below −5° C. and furtherstirred for 2 hours while maintaining that temperature. Disappearance of4-bromoisoquinoline was confirmed by thin layer chromatography(n-hexane:ethyl acetate═1:1), and then the reaction mixture was slowlypoured into cold aqueous ammonia (200 ml, Wako Pure Chemical Industries)with vigorous stirring. The reaction mixture was stirred for 15 minutesand then extracted three times with ethyl acetate (150 ml for eachtime), and the combined organic layer was washed successively with water(250 ml) and saturated brine (250 ml) and dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure, and theresidue was recrystallized with ethyl acetate to obtain the titlecompound (5.9 g) as thick yellow needle-like crystals.

(Step B) Synthesis of 5-amino-4-bromoisoquinoline

The synthesized 4-bromo-5-nitroisoquinoline (1.0 g) and stannouschloride dihydrate (4.5 g, Wako Pure Chemical Industries) were suspendedin ethanol (30 ml), added with concentrated hydrochloric acid (2.3 ml)and stirred at 80° C. for 30 minutes and at room temperature for further12 hours. The reaction mixture was adjusted to pH 12 with addition of 2N aqueous sodium hydroxide. The target compound was extracted threetimes with ethyl acetate (100 ml for each time), and the combinedorganic layer was washed with water (200 ml) and saturated brine (200ml) and dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure, and then the residue was purified by silica gelcolumn chromatography (n-hexane:ethyl acetate=3:1) to obtain the titlecompound (493 mg) as yellow powdery crystals.

¹H-NMR(CDCl₃) δ (ppm): 5.23 (2H, br.s), 6.92 (1H, dd, J=1.6, 7.3 Hz),7.38 (2H, m), 8.50 (1H, s), 8.98 (1H, s)

Example 1 Exemplary Compound No. 8-1

(Step A) 5-Amino-4-vinylisoquinoline (Intermediate 1)

A suspension of 5-amino-4-bromoisoquinoline obtained in ReferenceExample 1 (10 g), tri(n-butyl)vinyltin (21.0 ml, Tokyo Kasei Kogyo),tetrakis(triphenylphosphine)palladium(0) (1.04 g, Aldrich), and2,6-di-tert-butyl-p-cresol (11.3 mg, Tokyo Kasei Kogyo) in toluene (90ml) was stirred at 110° C. for 15 hours. The reaction mixture was cooledto room temperature, then added with 10% aqueous potassium fluoride (90ml), and stirred for 4 hours. The reaction mixture was added with ethylacetate (100 ml), and the precipitates were removed by filtration. Then,the organic layer was separated, and dried over anhydrous magnesiumsulfate. The solvent was evaporated under reduced pressure, and then theresidue was purified by silica gel column chromatography (n-hexane:ethylacetate=3:1) to obtain the title compound (7.00 g).

(Step B)3-(4-Vinyl-5-isoquinolyl)amino-1-(tert-butoxycarbonyl)pyrrolidine(Intermediate 2)

A solution of Intermediate 1 (251 mg), and tert-butyl3-oxo-1-pyrrolidinecarboxylate (563 mg, AstaTech) in dichloromethane (85ml) was added with titanium tetraisopropoxide (905 μl, Aldrich) at roomtemperature, and stirred at room temperature for 19 hours. The reactionmixture was added with methanol (6 ml), and sodium borohydride (249 mg,Kanto Chemicals), and stirred at room temperature for 3.5 hours. Thereaction mixture was added with saturated aqueous sodiumhydrogencarbonate (20 ml), and ethyl acetate (20 ml), and then theprecipitates were removed by filtration. Then, the organic layer wasseparated, and the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography (n-hexane:ethylacetate=4:1) to obtain the title compound (321 mg).(Step C) (Intermediate 3)

A suspension of Intermediate 2 (321 mg), and potassium tert-butoxide(212 mg, Tokyo Kasei Kogyo) in THF (6 ml) was stirred at 50° C. for 4hours. The suspension was cooled to room temperature, then insolublesolids were removed by filtration, and the solvent was evaporated underreduced pressure. The residue was purified by silica gel columnchromatography (n-hexane:ethyl acetate=2:1) to obtain the title compound(117 mg).

(Step D)

Intermediate 3 (117 mg) was added with a 10% hydrochloric acid/methanolsolution (1 ml, Tokyo Kasei Kogyo), and stirred at room temperature for2 hours. The solvent was evaporated under reduced pressure from thereaction mixture to obtain the compound of Exemplary Compound No. 8-1 asa hydrochloride (41.8 mg).

¹H-NMR (DMSO-d₆) δ (ppm): 2.06-2.14 (2H, m), 2.23-2.33 (2H, m),3.20-3.30 (2H, m), 3.30-3.60 (4H, m), 4.90-4.98 (1H, m), 7.34-7.41 (1H,m), 7.66-7.82 (2H, m), 8.36-8.39 (2H, m), 9.53 (1H, s) MS (m/z): 240(MH+)

Example 2 Exemplary Compound No. 8-9

(Step A) (Intermediate 4)

A suspension of the hydrochloride of Exemplary Compound 8-1 (95.8 mg),and potassium carbonate (228 mg, Wako Pure Chemical Industries) inN,N-dimethylformamide (2.7 ml) was added with2-(2-bromoethoxy)tetrahydro-2H-pyran (181.2 μl, Aldrich), and stirred atroom temperature for 18 hours. The reaction mixture was added withacetone (10 ml), insoluble solids were removed by filtration, and thenthe solvent was evaporated under reduced pressure. The residue waspurified by silica gel column chromatography (chloroform/methanol mixedsolvent system) to obtain the title compound (91.3 mg).

(Step B)

According to the method of the Example 1, Step D, deprotection wasperformed by using Intermediate 4 (86.2 mg), and a 10% hydrochloricacid/methanol solution (5 ml) (room temperature, 2 hours). The solventwas evaporated under reduced pressure to obtain the compound ofExemplary Compound No. 8-9 (53.1 mg) as a hydrochloride (53.1 mg).

MS (m/z): 284 (MH+)

Example 3 Exemplary Compound No. 8-4

(Step A) (Intermediate 5)

A suspension of the hydrochloride of Exemplary Compound 8-1 (95.8 mg),and potassium carbonate (228 mg) in N,N-dimethylformamide (2.7 ml) wasadded with tert-butyl acrylate (174 μl, Aldrich), and stirred at roomtemperature for 40 hours. The reaction mixture was added with acetone(10 ml), insoluble solids were removed by filtration, and then thesolvent was evaporated under reduced pressure. The residue was purifiedby silica gel column chromatography (chloroform/methanol mixed solventsystem) to obtain the title compound (52.6 mg).

(Step B)

Intermediate 5 (47.3 mg) was added with a 4 N hydrochloric acid/dioxanesolution (3 ml, Kokusan Kagaku) at room temperature, and stirred for 4hours. After the reaction, the solvent was evaporated under reducedpressure to obtain the compound of Exemplary Compound No. 8-4 as ahydrochloride (18.5 mg).

MS (m/z): 312 (MH+)

Example 4 Exemplary Compound No. 8-6

A suspension of the hydrochloride of Exemplary Compound 8-1 (95.8 mg),and potassium carbonate (228 mg) in N,N-dimethylformamide (2.7 ml) wasadded with bromoacetonitrile (41.8 μl, Aldrich), and stirred at roomtemperature for 18 hours. The reaction mixture was added with acetone(10 ml), insoluble solids were removed by filtration, and then thesolvent was evaporated under reduced pressure. The residue was purifiedby silica gel column chromatography (chloroform/methanol mixed solventsystem), then added with a 10% hydrochloric acid/methanol solution (5ml), and stirred at room temperature for 2 hours. The solvent wasevaporated under reduced pressure to obtain the compound of ExemplaryCompound No. 8-6 as a hydrochloride (43.4 mg).

MS (m/z): 279 (MH+)

Example 5 Exemplary Compound No. 8-10

According to the method of Example 2, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran (Aldrich), and deprotection wereperformed by using the hydrochloride of Exemplary Compound 8-1 to obtainthe compound of Exemplary Compound No. 8-10 as a hydrochloride.

MS (m/z): 298 (MH+)

Example 6 Exemplary Compound No. 8-15

According to the method of Example 2, alkylation with tert-butylN-(2-bromoethyl)carbamate (Fluka), and deprotection were performed byusing the hydrochloride of Exemplary Compound 8-1 to obtain the compoundof Exemplary Compound No. 8-15 as a hydrochloride.

MS (m/z): 283 (MH+)

Example 7 Exemplary Compound No. 8-16

According to the method of Example 2, alkylation with tert-butylN-(3-bromopropyl)carbamate (Tokyo Kasei Kogyo), and deprotection wereperformed by using the hydrochloride of Exemplary Compound 8-1 to obtainthe compound of Exemplary Compound No. 8-16 as a hydrochloride.

MS (m/z): 297 (MH+)

Example 8 Exemplary Compound No. 8-3

According to the method of Example 3, alkylation with tert-butylbromoacetate (Aldrich), and deprotection were performed by using thehydrochloride of Exemplary Compound 8-1 to obtain the compound ofExemplary Compound No. 8-3 as a hydrochloride.

MS (m/z): 298 (MH+)

Example 9 Exemplary Compound No. 8-12

According to the method of Example 4, alkylation with 2-bromoethylmethyl ether (Tokyo Kasei Kogyo) was performed by using thehydrochloride of Exemplary Compound 8-1 to obtain the compound ofExemplary Compound No. 8-12 as a hydrochloride.

MS (m/z): 298 (MH+)

Example 10 Exemplary Compound No. 8-24

According to the method of Example 4, alkylation with 2-bromoacetamide(Aldrich) was performed by using the hydrochloride of Exemplary Compound8-1 to obtain the compound of Exemplary Compound No. 8-24 as ahydrochloride.

MS (m/z): 297 (MH+)

Example 11 Exemplary Compound No. 9-1

(Step A)4-(4-Bromo-5-isoquinolyl)amino-1-(tert-butoxycarbonyl)piperidine(Intermediate 6)

A mixture of 5-amino-4-bromoisoquinoline (3.00 g) obtained in ReferenceExample 1, and tert-butyl 4-oxo-1-piperidinecarboxylate (5.50 g,Aldrich) was added with titanium tetraisopropoxide (8.20 ml) at roomtemperature, and stirred at room temperature for 15 hours. Subsequently,the reaction mixture was added with methanol (60 ml) and sodiumborohydride (2.21 g), and stirred at room temperature for further 19hours. The reaction mixture was added with saturated aqueous sodiumhydrogencarbonate (100 ml) and ethyl acetate (100 ml), and theprecipitates were removed by filtration. Then, the organic layer wasseparated, and the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography(n-hexane:acetone:isopropylamine=150:10:2) to obtain the title compound(2.92 g).

(Step B)4-(4-Vinyl-5-isoquinolyl)amino-1-(tert-butoxycarbonyl)piperidine(Intermediate 7)

A suspension of Intermediate 6 (8.00 g), tri(n-butyl)vinyltin (8.63 ml),tetrakis(triphenylphosphine)palladium(0) (455 mg), and2,6-di-tert-butyl-p-cresol (8.7 mg) in toluene (120 ml) was stirred at110° C. for 2 hours. The reaction mixture was cooled to roomtemperature, then added with 10% aqueous potassium fluoride (120 ml),and stirred for 15 hours. After the precipitates were removed byfiltration, the organic layer was separated, and dried over anhydrousmagnesium sulfate. The solvent was evaporated under reduced pressure,and then the residue was purified by silica gel column chromatography(n-hexane:ethyl acetate=2:1) to obtain the title compound (6.72 g).(Step C) (Intermediate 8)

A suspension of Intermediate 7 (6.50 g), and potassium tert-butoxide(4.10 g) in tetrahydrofuran (92 ml) was stirred at 50° C. for 1 hour.The reaction mixture was added with water (100 ml), saturated aqueousammonium chloride (50 ml), and ethyl acetate (100 ml), and theprecipitates were removed by filtration. Then, the organic layer wasseparated, and dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure, and then the residue was purified bysilica gel column chromatography (n-hexane:ethyl acetate=1:2) to obtainthe title compound (4.45 g).

(Step D)

According to the method of the Example 1, step D, deprotection wasperformed by using Intermediate 8 (4.23 g), and a 10% hydrochloricacid/methanol solution (60 ml) (50° C., 2 hours). The solvent wasevaporated under reduced pressure to obtain the compound of ExemplaryCompound No. 9-1 as a hydrochloride (3.71 g).

¹H-NMR (DMSO-d₆) δ (ppm): 1.85-1.91 (2H, m), 2.03-2.12 (2H, m),3.05-3.20 (2H, m), 3.21-3.27 (2H, m), 3.37-3.42 (4H, m), 4.24-4.34 (1H,m), 7.45 (1H, d, J=8.1 Hz), 7.66 (1H, d, J=8.1 Hz), 7.78 (1H, t, J=8.1Hz), 8.35 (1H, s), 9.05 (1H, brs), 9.51 (1H, s) MS (m/z): 254 (MH+)

Example 12 Exemplary Compound No. 9-9

According to the method of Example 2, alkylation with2-(2-bromoethoxy)tetrahydro-2H-pyran, and deprotection were performed byusing the hydrochloride of Exemplary Compound 9-1 to obtain the compoundof Exemplary Compound No. 9-9 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.28-2.38 (2H, m),3.05-3.20 (6H, m), 3.35-3.45 (2H, m), 3.62-3.68 (2H, m), 3.79-3.85 (2H,m), 4.25-4.35 (1H, m), 7.43 (1H, d, J=8.1 Hz), 7.67 (1H, d, J=8.1 Hz),7.78 (1H, t, J=8.1 Hz), 8.36 (1H, s), 9.53 (1H, s) MS (m/z): 298 (MH+)

Example 13 Exemplary Compound No. 9-10

According to the method of Example 2, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran, and deprotection were performedby using the hydrochloride of Exemplary Compound 9-1 to obtain thecompound of Exemplary Compound No. 9-10 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.32-2.38 (2H, m),3.05-3.11 (2H, m), 3.15-3.21 (2H, m), 3.23-3.27 (2H, m), 3.36-3.44 (2H,m), 3.48-3.54 (2H, m), 3.57-3.61 (2H, m), 4.26-4.36 (1H, m), 7.43 (1H,d, J=8.1 Hz), 7.67 (1H, d, J=8.1 Hz), 7.79 (1H, t, J=8.1 Hz), 8.37 (1H,s), 9.53 (1H, s) MS (m/z): 312 (MH+)

Example 14 Exemplary Compound No. 9-15

According to the method of Example 2, alkylation with tert-butylN-(2-bromoethyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 9-1 to obtain the compound ofExemplary Compound No. 9-15 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.92-1.98 (2H, m), 2.33-2.39 (2H, m),3.20-3.80 (12H, m), 4.33-4.43 (1H, m), 7.45 (1H, d, J=8.1 Hz), 7.69 (1H,d, J=8.1 Hz), 7.80 (1H, t, J=8.1 Hz), 8.37 (1H, s), 8.59 (2H, brs), 9.56(1H, s) MS (m/z): 297 (MH+)

Example 15 Exemplary Compound No. 9-16

According to the method of Example 2, alkylation with tert-butylN-(3-bromopropyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 9-1 to obtain the compound ofExemplary Compound No. 9-16 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.08-2.14 (2H, m),2.38-2.44 (2H, m), 2.92-2.98 (2H, m), 3.19-3.60 (10H, m), 4.31-4.41 (1H,m), 7.46 (1H, d, J=8.1 Hz), 7.67 (1H, d, J=8.1 Hz), 7.79 (1H, t, J=8.1Hz), 8.22 (2H, brs), 8.37 (1H, s), 9.54 (1H, s) MS (m/z): 311 (MH+)

Example 16 Exemplary Compound No. 9-4

According to the method of Example 3, alkylation with tert-butylacrylate, and deprotection were performed by using the hydrochloride ofExemplary Compound 9-1 to obtain the compound of Exemplary Compound No.9-4 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.30-2.36 (2H, m),2.87-2.93 (2H, m), 3.20-3.30 (6H, m), 3.37-3.41 (2H, m), 3.57-3.61 (2H,m), 4.27-4.37 (1H, m), 7.47 (1H, d, J=8.1 Hz), 7.71 (1H, d, J=8.1 Hz),7.81 (1H, t, J=8.1 Hz), 8.38 (1H, s), 9.58 (1H, s) MS (m/z): 326 (MH+)

Example 17 Exemplary Compound No. 9-3

According to the method of Example 3, alkylation with tert-butylbromoacetate, and deprotection were performed by using the hydrochlorideof Exemplary Compound 9-1 to obtain the compound of Exemplary CompoundNo. 9-3 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.27-2.32 (2H, m),3.22-3.30 (2H, m), 3.32-3.40 (4H, m), 3.61-3.67 (2H, m), 4.17 (2H, s),4.24-4.34 (1H, m), 7.47 (1H, d, J=8.1 Hz), 7.69 (1H, d, J=8.1 Hz), 7.80(1H, t, J=8.1 Hz), 8.37 (1H, s), 9.55 (1H, s) MS (m/z): 312 (MH+)

Example 18 Exemplary Compound No. 9-6

According to the method of Example 4, alkylation with bromoacetonitrile,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 9-1 to obtain the compound of Exemplary CompoundNo. 9-6 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.94 (2H, m), 2.18-2.24 (2H, m),3.07-3.13 (2H, m), 3.23-3.29 (2H, m), 3.35-3.43 (4H, m), 4.19-4.29 (1H,m), 4.36 (2H, s), 7.51 (1H, d, J=8.1 Hz), 7.69 (1H, d, J=8.1 Hz), 7.80(1H, t, J=8.1 Hz), 8.37 (1H, s), 9.57 (1H, s) MS (m/z): 293 (MH+)

Example 19 Exemplary Compound No. 9-12

According to the method of Example 4, alkylation with 2-bromoethylmethyl ether, and formation of hydrochloride were performed by using thehydrochloride of Exemplary Compound 9-1 to obtain the compound ofExemplary Compound No. 9-12 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.32-2.38 (2H, m),3.20-3.45 (9H, m), 3.55-3.65 (2H, m), 3.72-3.82 (2H, m), 4.25-4.35 (1H,m), 7.45 (1H, d, J=8.1 Hz), 7.68 (1H, d, J=8.1 Hz), 7.79 (1H, t, J=8.1Hz), 8.37 (1H, s), 9.55 (1H, s) MS (m/z): 312 (MH+)

Example 20 Exemplary Compound No. 9-24

According to the method of Example 4, alkylation with 2-bromoacetamide,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 9-1 to obtain the compound of Exemplary CompoundNo. 9-24 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.88-1.95 (2H, m), 2.26-2.34 (2H, m),3.23-3.29 (2H, m), 3.35-3.43 (4H, m), 3.58-3.64 (2H, m), 4.24-4.34 (3H,m), 7.47 (1H, d, J=8.1 Hz), 7.68 (1H, d, J=8.1 Hz), 7.79 (1H, t, J=8.1Hz), 8.18 (2H, brs), 8.37 (1H, s), 9.55 (1H, s) MS (m/z): 311 (MH+)

Example 21 Exemplary Compound No. 2-2

(Step A) tert-Butyl N-benzyl-(4-oxo-cyclohexyl)carbamate (Intermediate9)

A solution of 1,4-cyclohexanedione monoethylene ketal (10 g, Tokyo KaseiKogyo) in 1,2-dichloroethane (65 ml) was added with benzylamine (7.69ml, Tokyo Kasei Kogyo), acetic acid (3.67 ml, Wako Pure ChemicalIndustries), and sodium triacetoxyborohydride (19.09 g, Aldrich) underice cooling, and stirred at room temperature for 0.5 hour. The reactionmixture was added with 1 N aqueous sodium hydroxide (80 ml), andextracted 5 times with chloroform (50 ml). The extract was dried overanhydrous magnesium sulfate, and the solvent was evaporated underreduced pressure. The obtained residue was added with tetrahydrofuran(90 ml) and 5 N aqueous hydrochloric acid (50 ml), and stirred at 100°C. for 15 hours. The reaction mixture was added with 2 N aqueous sodiumhydroxide (60 ml), and extracted with dichloromethane (150 ml). Theextract was dried over anhydrous magnesium sulfate, and the solvent wasevaporated under reduced pressure. The obtained residue was added withmethanol (100 ml), triethylamine (9.82 ml, Wako Pure ChemicalIndustries), and di-t-butyl dicarbonate (26.5 ml, Wako Pure ChemicalIndustries), and stirred at 60° C. for 2 hours. The solvent wasevaporated under reduced pressure, and then the residue was added with 1N aqueous hydrochloric acid (15 ml), and extracted twice withdichloromethane (50 ml). The extract was dried over anhydrous magnesiumsulfate, and then the solvent was evaporated under reduced pressure. Theresidue was added with isopropyl alcohol, and the precipitates weretaken by filtration to obtain the title compound (13.5 g).

(Step B) tert-ButylN-benzyl-[4-(4-vinyl-isoquinolin-5-ylamino)cyclohexyl]carbamate(Intermediate 10)

A solution of Intermediate 9 (5.73 g), Intermediate 1 (2.92 g), andpara-toluenesulfonic acid monohydrate (163 mg, Wako Pure ChemicalIndustries) in toluene (50 ml) was refluxed by heating for 1 hour. Thereaction mixture was cooled to room temperature, then added withmethanol (75 ml) and sodium borohydride (6.48 g), and stirred at roomtemperature for 1 hour. The reaction mixture was added with water (5ml), and then the solvent was evaporated under reduced pressure. Theresidue was added with ethyl acetate (100 ml), and the organic layer waswashed twice with water (50 ml), and dried over anhydrous magnesiumsulfate. Then, the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography (n-hexane:ethylacetate=2:1) to obtain the title compound (2.2 g of trans-isomer, 1.8 gof cis-isomer).(Step C) (Intermediate 11)

A suspension of the trans-isomer of Intermediate 10 (2.18 g), andpotassium tert-butoxide (1.07 g) in 1,4-dioxane (50 ml) was stirred at100° C. for 2 hours. After insoluble solids were removed by filtration,the solvent was evaporated under reduced pressure. The residue waspurified by silica gel column chromatography (n-hexane:ethylacetate=1:2) to obtain the title compound (1.82 g).(Step D) (Intermediate 12)

According to the method of the Example 1, Step D, deprotection wasperformed by using Intermediate 11 (789 mg), and a 10% hydrochloricacid/methanol solution (10 ml) (50° C., 2 hours). The reaction mixturewas cooled to room temperature to obtain the title compound,trans-benzyl-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]amine(687 mg), as a hydrochloride.

(Step E)

The hydrochloride of Intermediate 12 (500 mg) was added with 1 N aqueoussodium hydroxide (20 ml), and stirred for 0.5 hour. The reaction mixturewas added with chloroform (30 ml), and the organic layer was separated.The aqueous layer was further extracted twice with chloroform (30 ml foreach time), and the combined organic layer was dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure, andthen the residue was added with ethanol (30 ml) and 10% palladium/carbon(50 mg, Wako Pure Chemical Industries), and stirred at 70° C. for 14hours under hydrogen atmosphere. The reaction mixture was filteredthrough Cerite, and then the solvent was evaporated under reducedpressure. The residue was added with a 10% hydrochloric acid/methanolsolution (5 ml), and stirred at room temperature for 0.5 hour. Thesolvent was evaporated under reduced pressure to obtain the compound ofExemplary Compound No. 2-2 as a hydrochloride (240 mg).

¹H-NMR (DMSO-d₆) δ (ppm): 1.55-1.81 (6H, m), 2.06-2.10 (2H, m),3.00-3.16 (1H, m), 3.20 (2H, t, J=5.9 Hz), 3.40 (2H, t, J=5.9 Hz),3.85-3.89 (1H, m), 7.34 (1H, d, J=8.1 Hz), 7.61 (1H, d, J=8.1 Hz), 7.76(1H, t, J=8.1 Hz), 8.17 (2H, brs), 8.32 (1H, s), 9.49 (1H, s) MS (m/z):268 (MH+)

Example 22 Exemplary Compound No. 2-11

According to the method of Example 2, alkylation with2-(2-bromoethoxy)tetrahydro-2H-pyran, and deprotection were performed byusing the hydrochloride of Exemplary Compound 2-2 to obtain the compoundof Exemplary Compound No. 2-11 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.68-1.74 (4H, m), 1.82-1.88 (2H, m),2.20-2.26 (2H, m), 3.02-3.12 (3H, m), 3.19-3.23 (2H, m), 3.39-3.43 (2H,m), 3.70-3.74 (2H, m), 3.82-3.92 (1H, m), 7.34 (1H, d, J=8.1 Hz), 7.63(1H, d, J=8.1 Hz), 7.77 (1H, t, J=8.1 Hz), 8.17 (2H, brs), 8.33 (1H, s),9.02 (2H, brs), 9.51 (1H, s) MS (m/z): 312 (MH+)

Example 23 Exemplary Compound No. 2-12

According to the method of Example 2, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran, and deprotection were performedby using the hydrochloride of Exemplary Compound 2-2 to obtain ExemplaryCompound No. 2-12 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 24 Exemplary Compound No. 2-17

According to the method of Example 2, alkylation with tert-butylN-(2-bromoethyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 2-2 to obtain the compound ofExemplary Compound No. 2-17 as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.68-1.74 (4H, m), 1.82-1.88 (2H, m),2.20-2.26 (2H, m), 3.02-3.60 (9H, m), 3.91-3.99 (1H, m), 7.36 (1H, d,J=8.1 Hz), 7.62 (1H, d, J=8.1 Hz), 7.77 (1H, t, J=8.1 Hz), 8.33 (1H, s),8.45 (2H, brs), 9.02 (2H, brs), 9.50 (1H, s), 9.73 (1H, brs) MS (m/z):311 (MH+)

Example 25 Exemplary Compound No. 2-18

According to the method of Example 2, alkylation with tert-butylN-(3-bromopropyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 2-2 to obtain the compound ofExemplary Compound No. 2-18 as a hydrochloride.

MS (m/z): 325 (MH+)

Example 26 Exemplary Compound No. 2-6

According to the method of Example 3, alkylation with tert-butylacrylate, and deprotection were performed by using the hydrochloride ofExemplary Compound 2-2 to obtain the compound of Exemplary Compound No.2-6 as a hydrochloride.

MS (m/z): 340 (MH+)

Example 27 Exemplary Compound No. 2-5

According to the method of Example 3, alkylation with tert-butylbromoacetate, and deprotection were performed by using the hydrochlorideof Exemplary Compound 2-2 to obtain the compound of Exemplary CompoundNo. 2-5 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 28 Exemplary Compound No. 2-8

According to the method of Example 4, alkylation with bromoacetonitrile,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 2-2 to obtain the compound of Exemplary CompoundNo. 2-8 as a hydrochloride.

MS (m/z): 307 (MH+)

Example 29 Exemplary Compound No. 2-14

According to the method of Example 4, alkylation with 2-bromoethylmethyl ether, and formation of hydrochloride were performed by using thehydrochloride of Exemplary Compound 2-2 to obtain the compound ofExemplary Compound No. 2-14 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 30 Exemplary Compound No. 2-26

According to the method of Example 4, alkylation with 2-bromoacetamide,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 2-2 to obtain Exemplary Compound No. 2-26 as ahydrochloride.

MS (m/z): 325 (MH+)

Example 31 Exemplary Compound No. 3-2

(Step A) (Intermediate 13)

A solution of the cis-isomer of Intermediate 10 (2.18 g) obtained inExample 21, Step B, and potassium tert-butoxide (1.07 g) in 1,4-dioxane(50 ml) was stirred at 100° C. for 2 hours. After insoluble solids wereremoved by filtration, the solvent was evaporated under reducedpressure. The residue was purified by silica gel column chromatography(n-hexane:ethyl acetate=1:2) to obtain the title compound (155 mg).(Step B) (Intermediate 14)

According to the method of the Example 1, Step D, deprotection wasperformed by using Intermediate 13 (155 mg), and a 10% hydrochloricacid/methanol solution (1 ml) (50° C., 2 hours). The reaction mixturewas cooled to room temperature to obtain the title compound (102 mg).

(Step C)

The hydrochloride of Intermediate 14 (200 mg) was added with 1 N aqueoussodium hydroxide (10 ml), and stirred for 0.5 hour. The reaction mixturewas added with chloroform (15 ml), and the organic layer was separated.The aqueous layer was further extracted twice with chloroform (15 ml foreach time), and the combined organic layer was dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure, andthen the residue was added with ethanol (12 ml) and 10% palladium/carbon(20 mg), and stirred at 70° C. for 14 hours under hydrogen atmosphere.The reaction mixture was filtered through Cerite, and then the solventwas evaporated under reduced pressure. The residue was added with a 10%hydrochloric acid/methanol solution (2 ml), and stirred at roomtemperature for 0.5 hour. The solvent was evaporated under reducedpressure to obtain the compound of Exemplary Compound No. 3-2 as ahydrochloride (84 mg).

¹H-NMR (DMSO-d₆) δ (ppm): 1.60-1.64 (2H, m), 1.83-2.08 (6H, m),3.20-3.24 (1H, m), 3.37-3.39 (2H, m), 3.51 (2H, m), 3.92-3.98 (1H, m),7.33-7.36 (1H, m), 7.58-7.61 (1H, m), 7.72-7.77 (1H, m), 8.23 (2H, brs),8.31 (1H, s), 9.49 (1H, s) MS (m/z): 268 (MH+)

Example 32 Exemplary Compound No. 3-11

According to the method of Example 2, alkylation with2-(3-bromoethoxy)tetrahydro-2H-pyran, and deprotection were performed byusing the hydrochloride of Exemplary Compound 3-2 to obtain the compoundof Exemplary Compound No. 3-11 as a hydrochloride.

MS (m/z): 312 (MH+)

Example 33 Exemplary Compound No. 3-12

According to the method of Example 2, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran, and deprotection were performedby using the hydrochloride of Exemplary Compound 3-2 to obtain thecompound of Exemplary Compound No. 3-12 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 34 Exemplary Compound No. 3-17

According to the method of Example 2, alkylation with tert-butylN-(2-bromoethyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 3-2 to obtain the compound ofExemplary Compound No. 3-17 as a hydrochloride.

MS (m/z): 311 (MH+)

Example 35 Exemplary Compound No. 3-18

According to the method of Example 2, alkylation with tert-butylN-(3-bromopropyl)carbamate, and deprotection were performed by using thehydrochloride of Exemplary Compound 3-2 to obtain the compound ofExemplary Compound No. 3-18 as a hydrochloride.

MS (m/z): 325 (MH+)

Example 36 Exemplary Compound No. 3-6

According to the method of Example 3, alkylation with tert-butylacrylate, and deprotection were performed by using the hydrochloride ofExemplary Compound 3-2 to obtain the compound of Exemplary Compound No.3-6 as a hydrochloride.

MS (m/z): 340 (MH+)

Example 37 Exemplary Compound No. 3-5

According to the method of Example 3, alkylation with tert-butylbromoacetate, and deprotection were performed by using the hydrochlorideof Exemplary Compound 3-2 to obtain the compound of Exemplary CompoundNo. 3-5 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 38 Exemplary Compound No. 3-8

According to the method of Example 4, alkylation with bromoacetonitrile,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 3-2 to obtain the compound of Exemplary CompoundNo. 3-8 as a hydrochloride.

MS (m/z): 307 (MH+)

Example 39 Exemplary Compound No. 3-14

According to the method of Example 4, alkylation with 2-bromoethylmethyl ether, and formation of hydrochloride were performed by using thehydrochloride of Exemplary Compound 3-2 to obtain the compound ofExemplary Compound No. 3-14 as a hydrochloride.

MS (m/z): 326 (MH+)

Example 40 Exemplary Compound No. 3-26

According to the method of Example 4, alkylation with 2-bromoacetamide,and formation of hydrochloride were performed by using the hydrochlorideof Exemplary Compound 3-2 to obtain the compound of Exemplary CompoundNo. 3-26 as a hydrochloride.

MS (m/z): 325 (MH+)

Example 41 Exemplary Compound No. 2-3

(Step A) Intermediate 15

The hydrochloride of Intermediate 12 (100 mg) was added with 1 N aqueoussodium hydroxide (4 ml), and stirred for 0.5 hour. The reaction mixturewas added with chloroform (6 ml), and the organic layer was separated.The aqueous layer was further extracted twice with chloroform (6 ml foreach time), and the combined organic layer was dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure, andthen the residue was added with ethanol (2 ml), formalin (2 ml, WakoPure Chemical Industries), and 10% palladium/carbon (10 mg), and stirredat room temperature for 14 hours under hydrogen atmosphere. The reactionmixture was filtered through Cerite, and then the solvent was evaporatedunder reduced pressure to obtain the title compound (40.5 mg).

(Step B)

Intermediate 15 (40.5 mg) was added with ethanol (2 ml) and 10%palladium/carbon (4 mg), and stirred at 70° C. for 14 hours underhydrogen atmosphere. The reaction mixture was filtered through Cerite,and then the solvent was evaporated under reduced pressure. Then, theresidue was added with a 10% hydrochloric acid/methanol solution (1 ml),and stirred at room temperature for 0.5 hour. The solvent was evaporatedunder reduced pressure to obtain the compound of Exemplary Compound No.2-3 as a hydrochloride (22.3 mg).

¹H-NMR (DMSO-d₆) δ (ppm): 1.63-1.77 (4H, m), 1.83-1.90 (2H, m),2.17-2.22 (2H, m), 2.52 (3H, s), 2.93-3.06 (1H, m), 3.16-3.23 (2H, m),3.36-3.47 (2H, m), 3.83-3.93 (1H, m), 7.36 (1H, d, J=8.1 Hz), 7.64 (1H,d, J=8.1 Hz), 7.78 (1H, t, J=8.1 Hz), 8.34 (1H, s), 9.24 (1H, brs), 9.53(1H, s) MS (m/z): 282 (MH+)

Example 42 Exemplary Compound No. 9-51

The hydrochloride of Exemplary Compound No. 9-15 (50 mg) was added withdichloromethane (1 ml), N,N-diisopropylethylamine (110 μl, Tokyo KaseiKogyo), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(70.9 mg, Kokusan Kagaku), and acetic acid (7.8 μl, Wako Pure ChemicalIndustries), and stirred at room temperature for two hours. The reactionmixture was added with saturated aqueous sodium hydrogencarbonate (1ml), and stirred at room temperature for 10 minutes. Then, the organiclayer was separated, and the solvent was evaporated under reducedpressure. The residue was purified by silica gel column chromatography(chloroform:methanol=9:1), and the solvent was evaporated under reducedpressure to obtain the compound of Exemplary Compound No. 9-51 (28.6mg).

¹H-NMR (CDCl₃) δ (ppm): 1.86-1.90 (4H, m), 2.02 (3H, s), 2.15-2.24 (2H,m), 2.52-2.56 (2H, m), 3.05-3.16 (4H, m), 3.35-3.43 (4H, m), 3.72-3.82(1H, m), 6.02 (1H, brs), 6.78 (1H, d, J=8.1 Hz), 7.23 (1H, d, J=8.1 Hz),7.42 (1H, t, J=8.1 Hz), 8.16 (1H, s), 8.99 (1H, s) MS (m/z): 339 (MH+)

Example 43 Exemplary Compound No. 9-52

According to the method of Example 42, condensation with propionic acidwas performed by using the hydrochloride of Exemplary Compound No. 9-15to obtain the compound of Exemplary Compound No. 9-52.

MS (m/z): 353 (MH+)

Example 44 Exemplary Compound No. 9-53

According to the method of Example 42, condensation with butyric acidwas performed by using the hydrochloride of Exemplary Compound No. 9-15to obtain the compound of Exemplary Compound No. 9-53.

MS (m/z): 367 (MH+)

Example 45 Exemplary Compound No. 9-54

According to the method of Example 42, condensation with isobutyric acidwas performed by using the hydrochloride of Exemplary Compound No. 9-15to obtain the compound of Exemplary Compound No. 9-54.

MS (m/z): 367 (MH+)

Example 46 Exemplary Compound No. 9-55

According to the method of Example 42, condensation with pivalic acidwas performed by using the hydrochloride of Exemplary Compound No. 9-15to obtain the compound of Exemplary Compound No. 9-55.

MS (m/z): 381 (MH+)

Example 47 Exemplary Compound No. 9-56

According to the method of Example 42, condensation with acetic acid wasperformed by using the hydrochloride of Exemplary Compound No. 9-41 toobtain the compound of Exemplary Compound No. 9-56.

MS (m/z): 353 (MH+)

Example 48 Exemplary Compound No. 9-57

According to the method of Example 42, condensation with propionic acidwas performed by using the hydrochloride of Exemplary Compound No. 9-41to obtain the compound of Exemplary Compound No. 9-57.

MS (m/z): 367 (MH+)

Example 49 Exemplary Compound No. 9-58

According to the method of Example 42, condensation with butyric acidwas performed by using the hydrochloride of Exemplary Compound No. 9-41to obtain the compound of Exemplary Compound No. 9-58.

MS (m/z): 381 (MH+)

Example 50 Exemplary Compound No. 9-59

According to the method of Example 42, condensation with isobutyric acidwas performed by using the hydrochloride of Exemplary Compound No. 9-41to obtain the compound of Exemplary Compound No. 9-59.

MS (m/z): 381 (MH+)

Example 51 Exemplary Compound No. 9-60

According to the method of Example 42, condensation with pivalic acidwas performed by using the hydrochloride of Exemplary Compound No. 9-41to obtain the compound of Exemplary Compound No. 9-60.

MS (m/z): 395 (MH+)

Example 52 Exemplary Compound No. 9-2

A solution of the compound of Exemplary Compound No. 9-1 (53 mg) inethanol (1.5 ml) and 37% formalin (1.5 ml, Wako Pure ChemicalIndustries) was added with 10% palladium/carbon (5 mg), and stirred at70° C. for 8 hours under hydrogen atmosphere. The reaction mixture wasfiltered through Cerite, and then the solvent was evaporated underreduced pressure. The residue was purified by silica gel columnchromatography (chloroform:methanol=9:1), and the solvent was evaporatedunder reduced pressure to obtain the title compound (35 mg).

MS (m/z): 268 (MH+)

Example 53 Exemplary Compound No. 2-123

A solution of the compound of Exemplary Compound No. 2-2 (100 mg) inethanol (2.5 ml) and 37% formalin (2.5 ml) was added with 10%palladium/carbon (10 mg), and stirred at 70° C. for 12 hours underhydrogen atmosphere. The reaction mixture was filtered through Cerite,and then the solvent was evaporated under reduced pressure. The residuewas purified by silica gel column chromatography(chloroform:methanol=9:1), and the solvent was evaporated under reducedpressure to obtain the title compound (70 mg).

MS (m/z): 296 (MH+)

Example 54 Exemplary Compound No. 9-79

According to the method of Example 1, the title compound was obtainedfrom Intermediate 1 and tert-butyl3-fluoro-4-oxo-1-piperidinecarboxylate prepared according to the methodof Collins et al. (J. Med. Chem., 42, 12, 1999, 2087).

¹H-NMR (DMSO-d₆) δ (ppm): 1.90 (1H, d, J=13 Hz), 2.45 (1H, m), 3.0-3.7(8H, m), 4.54 (1H, m), 5.27 (1H, d, J=48 Hz), 7.45 (1H, d, J=7.8 Hz),7.71 (1H, d, J=7.8 Hz), 7.78 (1H, t, J=7.8 Hz), 8.37 (1H, s), 9.53 (1H,s) MS (m/z): 272 (MH+)

Example 55 Exemplary Compound No. 2-12

According to the method of Example 2, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran, and deprotection were performedby using the hydrochloride of Exemplary Compound No. 2-2 to obtain thetitle compound as a hydrochloride.

MS (m/z): 326 (MH+)

Example 56 Exemplary Compound No. 2-35

According to the method of Example 53, the title compound was obtainedfrom the compound of Exemplary Compound No. 2-2.

MS (m/z): 326 (MH+)

Example 57 Exemplary Compound No. 9-18

A solution of the hydrochloride of Exemplary Compound No. 9-1 (3 g) inN,N-dimethylformamide (100 ml) was added with bromoacetaldehydedimethylacetal (4.35 ml, Tokyo Kasei Kogyo) and potassium carbonate(7.62 g), and stirred at 30° C. for 48 hours. The reaction mixture wascooled to 0° C., added with water (100 ml), and extracted twice withethyl acetate (200 ml for each time). The combined organic layer waswashed three times with saturated brine (200 ml for each time), anddried over anhydrous sodium sulfate. The solvent was evaporated underreduced pressure, and the residue was purified by silica gel columnchromatography (chloroform:methanol=19:1). Subsequently, the resultantwas added with 5 N hydrochloric acid (50 ml), and stirred at roomtemperature for 72 hours. The reaction mixture was cooled to 0° C.,neutralized with 2 N aqueous sodium hydroxide (pH 7.5), and extractedthree times with ethyl acetate (100 ml for each time). The combinedorganic layer was dried over anhydrous sodium sulfate, and the solventwas evaporated under reduced pressure. The residue was dissolved inmethanol (15 ml) and methylene chloride (30 ml), added with 40%methylamine/methanol solution (30 ml, Tokyo Kasei Kogyo), and stirred atroom temperature for one hour. Then, the reaction mixture was added withsodium borohydride (121 mg), and stirred at room temperature for 16hours. The reaction mixture was cooled to 0° C., added with water (100ml), and extracted twice with methylene chloride (200 ml for each time).The combined organic layer was dried over anhydrous sodium sulfate, andthe solvent was evaporated under reduced pressure. The residue waspurified by silica gel column chromatography(chloroform:methanol:isopropylamine=92.0:7.9:0.1) to obtain the titlecompound (962 mg).

MS (m/z): 311 (MH+)

Example 58 Exemplary Compound No. 9-21

According to the method of Example 53, the title compound was obtainedfrom the compound of Exemplary Compound No. 9-18.

MS (m/z): 325 (MH+)

Example 59 Exempiary Compound No. 9-71

According to the method of Example 42, condensation with acetic acid wasperformed by using the compound of Exemplary Compound No. 9-18 to obtainthe title compound.

MS (m/z): 353 (MH+)

Example 60 Exemplary Compound number No. 9-73

A solution of the compound of Exemplary Compound No. 9-15 (364 mg) andtert-butyl acrylate (450 μl, Tokyo Kasei Kogyo) in N,N-dimethylformamide(12 ml) was added with potassium carbonate (849 mg), and stirred at roomtemperature for 72 hours. The reaction mixture was cooled to 0° C.,added with water (30 ml), and extracted three times with ethyl acetate(50 ml for each time). The combined organic layer was washed three timeswith saturated brine (50 ml for each time), and dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure, andthe residue was purified by silica gel column chromatography (ethylacetate:methanol:isopropylamine=95:4.9:0.1). Subsequently, the resultantwas added with 4 N hydrogen chloride/1,4-dioxane solution (4 ml, KokusanKagaku), and stirred at room temperature for 1.5 hours. The solvent wasevaporated under reduced pressure, and a suspension of the residue inmethylene chloride (12 ml) was added with 2-chloro-1-methylpyridiniumiodide (64 mg, Aldrich) and triethylamine (138 μl) and stirred at roomtemperature for 48 hours. The solvent was evaporated under reducedpressure, and the residue was purified by silica gel columnchromatography (ethyl acetate:methanol:isopropylamine=95:4.9:0.1).Subsequently, the resultant was added with 4 N hydrogenchloride/1,4-dioxane solution (0.2 ml), and stirred at room temperaturefor 0.5 hour. The solvent was evaporated under reduced pressure toobtain the title compound as a hydrochloride (15 mg).

¹H-NMR (DMSO-d₆) δ (ppm): 1.93 (2H, m), 2.24 (2H, m), 2.89 (2H, m),3.1-3.7 (14H, m), 4.19 (1H, m), 7.06 (1H, d, J=7.8 Hz), 7.36 (1H, d,J=7.8 Hz), 7.51 (1H, t, J=7.8 Hz), 8.19 (1H, s), 9.06 (1H, s) MS (m/z):351 (MH+)

Example 61 6-Chloro-1-(piperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalene

(Step A) 5-Nitro-4-vinylisoquinoline

A suspension of 4-bromo-5-nitroisoquinoline (52 g) obtained in ReferenceExample 1, Step A, tri(n-butyl)vinyltin (105 g),tetrakis(triphenylphosphine)palladium(0) (4.8 g), and2,6-di-tert-butyl-p-creosol (11.3 mg) in toluene (300 ml) was stirred at110° C. for three hours. The reaction mixture was cooled to roomtemperature, then added with 10% aqueous potassium fluoride (400 ml),and stirred for 0.5 hour. The reaction mixture was added with ethylacetate (250 ml), and the precipitates were removed by filtration. Then,the organic layer was separated, and dried over anhydrous magnesiumsulfate. The solvent was evaporated under reduced pressure, and then theresidue was purified by silica gel column chromatography (n-hexane/ethylacetate) to obtain the title compound (24 g).

¹H-NMR (CDCl₃) δ (ppm): 5.48 (1H, d, J=11 Hz), 5.63 (1H, d, J=17 Hz),6.87 (1H, dd, J=11 Hz, 17 Hz), 7.68 (1H, t, J=8.1 Hz), 7.94 (1H, d,J=8.1 Hz), 8.20 (1H, d, J=8.1 Hz), 8.64 (1H, s), 9.28 (1H, s)

(Step B) 5-Nitro-4-vinylisoquinoline N-oxide

The 5-nitro-4-vinylisoquinoline (23 g) obtained in Step A mentionedabove was dissolved in dichloromethane (400 ml), then slowly added withm-chloroperbenzoic acid (43 g, Tokyo Kasei Kogyo), and stirred for 3.5hours. The reaction mixture was cooled on ice, and then neutralized byaddition of saturated aqueous sodium hydrogencarbonate. Then, theorganic layer was separated, and dried over anhydrous magnesium sulfate.The solvent was evaporated under reduced pressure to obtain the titlecompound (27 g).

(Step C) 1-Chloro-5-nitro-4-vinylisoquinoline

The 5-nitro-4-vinylisoquinoline N-oxide (27 g) obtained in Step Bmentioned above was suspended in chloroform (300 ml), and added dropwisewith phosphorus oxychloride (22.3 ml, Wako Pure Chemical Industries)under ice cooling. After the addition, the reaction mixture was warmedto 60° C., and stirred at the same temperature for one hour. Thereaction mixture was poured into in ice water, and neutralized with 2 Nsodium hydroxide with stirring. The organic layer was separated, anddried over anhydrous magnesium sulfate. The solvent was evaporated underreduced pressure to obtain the title compound (15 g).

¹H-NMR (CDCl₃) δ (ppm): 5.49 (1H, d, J=11 Hz), 5.63 (1H, d, J=17 Hz),6.81 (1H, dd, J=11 Hz, 17 Hz), 7.77 (1H, t, J=8.1 Hz), 7.97 (1H, d,J=8.1 Hz), 8.36 (1H, s), 8.64 (1H, d, J=8.1 Hz)

(Step D) 5-Amino-1-chloro-4-vinylisoquinoline

The 1-chloro-5-nitro-4-vinylisoquinoline (15 g) obtained in Step Cmentioned above was dissolved in ethyl acetate (700 ml), added withstannous chloride dihydrate (72 g), and stirred for two hours. Thereaction mixture was poured on ice, and then added with 5 N aqueoussodium hydroxide. The organic layer was separated, and dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure, and then the residue was purified by silica gel columnchromatography (n-hexane:ethyl acetate=3:1) to obtain the title compound(10 g).

¹H-NMR (CDCl₃) δ (ppm): 5.54 (1H, dd, J=1.5, 10.8 Hz), 5.65 (1H, dd,J=1.5, 17.1 Hz), 6.92 (1H, d, J=7.8 Hz), 7.41-7.64 (2H, m), 7.77 (1H, d,J=8.7 Hz), 7.94 (1H, s) MS (m/z): 205 (MH+)

(Step E)4-(1-Chloro-4-vinylisoquinolin-5-yl)aminopiperidine-1-carbonxylic acidtert-butyl ester

According to the method of Example 1, Step B, the5-amino-1-chloro-4-vinylisoquinoline mentioned above was reacted andcondensed with tert-butyl 4-oxo-1-piperidinecarboxylate instead oftert-butyl 3-oxo-1-pyrrolidinecarboxylate to obtain the title compound.

MS (m/z): 388 (MH+)

(Step F)4-(6-Chloro-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carbonxylicacid tert-butyl ester

According to the method of Example 11, Step C, the4-(1-chloro-4-vinylisoquinolin-5-yl)aminopiperidine-1-carbonxylic acidtert-butyl ester mentioned above was cyclized to obtain the titlecompound.

MS (m/z): 388 (MH+)

(Step G) 6-Chloro-1-(piperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalene

The4-(6-chloro-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carbonxylicacid tert-butyl ester (12.1 g) mentioned above was added with 4 Nhydrogen chloride/1,4-dioxane solution (155 ml), and stirred for 1.5hours. The precipitated solid was taken by filtration to obtain thetitle. compound as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.87 (2H, m), 2.08 (2H, m), 3.07-3.18 (4H, m),3.30-3.41 (4H, m), 4.23 (1H, m), 7.19 (1H, d, J=8.3 Hz), 7.45 (1H, d,J=8.3 Hz), 7.59 (1H, t, J=8.3 Hz), 7.96 (1H, s)

MS (m/z): 288 (MH+)

Example 62 Exemplary Compound No. 9-26

The4-(6-chloro-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidine-1-carbonxylicacid tert-butyl ester obtained Example 61, Step F was added withconcentrated hydrochloric acid, and stirred at 90° C. for 17 hours.After the reaction, the solvent was concentrated under reduced pressureto obtain the title compound as a hydrochloride.

¹H-NMR (DMSO-d₆) δ (ppm): 1.81 (2H, m), 2.03 (2H, m), 2.77 (2H, m),3.00-3.25 (4H, m), 3.36 (2H, d, J=12 Hz), 4.15 (1H, m), 6.82 (1H, s),7.13 (1H, d, J=7.8 Hz), 7.29 (1H, t, J=7.8 Hz), 7.47 (1H, d, J=7.8 Hz)MS (m/z): 270 (MH+)

Example 63 Exemplary Compound No. 9-34

According to the method of Example 2, Step A, alkylation was performedby using the hydrochloride obtained in Example 61, and then the reactionmixture was added with concentrated hydrochloric acid, and stirred at90° C. for 17 hours. After the reaction, the solvent was concentratedunder reduced pressure to obtain the title compound as a hydrochloride.

MS (m/z): 314 (MH+)

Example 64 Exemplary Compound No. 9-35

According to the method of Example 2, Step A, alkylation with2-(3-bromopropoxy)tetrahydro-2H-pyran was performed by using thehydrochloride obtained in Example 61, and then the reaction mixture wasadded with concentrated hydrochloric acid, and stirred at 90° C. for 17hours. After the reaction, the solvent was concentrated under reducedpressure to obtain the title compound as a hydrochloride.

MS (m/z): 328 (MH+)

Example 65 Exemplary Compound No. 9-40

According to the method of Example 2, Step A, alkylation with tert-butylN-(2-bromoethyl)carbamate was performed by using the hydrochlorideobtained in Example 61, and then the reaction mixture was added withconcentrated hydrochloric acid, and stirred at 90° C. for 17 hours.After the reaction, the solvent was concentrated under reduced pressureto obtain the title compound as a hydrochloride.

MS (m/z): 313 (MH+)

Example 66 Exemplary Compound No. 9-41

According to the method of Example 2, Step A, alkylation with tert-butylN-(3-bromopropyl)carbamate was performed by using the hydrochlorideobtained in Example 61, and then the reaction mixture was added withconcentrated hydrochloric acid, and stirred at 90° C. for 17 hours.After the reaction, the solvent was concentrated under reduced pressureto obtain the title compound as a hydrochloride.

MS (m/z): 327 (MH+)

Example 67 Exemplary Compound No. 9-61

According to the method of Example 42, condensation with acetic acid wasperformed by using the hydrochloride obtained in Exemple 65 to obtainthe title compound.

MS (m/z): 355 (MH+)

Example 68 Exemplary Compound No. 9-62

According to the method of Example 42, condensation with propionic acidwas performed by using the hydrochloride obtained in Exemple 65 toobtain the title compound.

MS (m/z): 369 (MH+)

Example 69 Exemplary Compound No. 9-63

According to the method of Example 42, condensation with butyric acidwas performed by using the hydrochloride obtained in Exemple 65 toobtain the title compound.

MS (m/z): 383 (MH+)

Example 70 Exemplary Compound No. 9-64

According to the method of Example 42, condensation with isobutyric acidwas performed by using the hydrochloride obtained in Exemple 65 toobtain the title compound.

MS (m/z): 383 (MH+)

Example 71 Exemplary Compound No. 9-65

According to the method of Example 42, condensation with pivalic acidwas performed by using the hydrochloride obtained in Exemple 65 toobtain the title compound.

MS (m/z): 397 (MH+)

Example 72 Exemplary Compound No. 9-66

According to the method of Example 42, condensation with acetic acid wasperformed by using the hydrochloride obtained in Exemple 66 to obtainthe title compound.

MS (m/z): 369 (MH+)

Example 73 Exemplary Compound No. 9-67

According to the method of Example 42, condensation with propionic acidwas performed by using the hydrochloride obtained in Exemple 66 toobtain the title compound.

MS (m/z): 383 (MH+)

Example 74 Exemplary Compound No. 9-68

According to the method of Example 42, condensation with butyric acidwas performed by using the hydrochloride obtained in Exemple 66 toobtain the title compound.

MS (m/z): 397 (MH+)

Example 75 Exemplary Compound No. 9-69

According to the method of Example 42, condensation with isobutyric acidwas performed by using the hydrochloride obtained in Exemple 66 toobtain the title compound.

MS (m/z): 397 (MH+)

Example 76 Exemplary Compound No. 9-70

According to the method of Example 42, condensation with pivalic acidwas performed by using the hydrochloride obtained in Exemple 66 toobtain the title compound.

MS (m/z): 411 (MH+)

Example 77 Exemplary Compound No. 2-53

(Step A) tert-Butyltrans-N-benzyl-[4-(1-chloro-4-vinylisoquinolin-5-yl)aminocyclohexyl]carbamate

A solution of 5-amino-1-chloro-4-vinylisoquinoline (0.6 g) andIntermediate 9 (1.8 g) in dichloromethane (13 ml) was added withtitanium tetraisopropoxide (1.7 ml) at room temperature, and stirred atroom temperature for 22 hours. The reaction mixture was added withmethanol (13 ml), and sodium borohydride (444 mg), and stirred at roomtemperature for two hours. The reaction mixture was added with saturatedaqueous sodium hydrogencarbonate (60 ml), and ethyl acetate (60 ml), andthe precipitates were removed by filtration. Then, the organic layer wasseparated, and the solvent was evaporated under reduced pressure. Theresidue was purified by silica gel column chromatography(n-hexane:acetone=5:4) to obtain the title compound (890 mg).

MS (m/z): 492 (MH+)

(Step B) tert-Butyltrans-N-benzyl-[4-(6-chloro-2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]carbamate

According to the method of Example 21, Step C, the tert-butyltrans-N-benzyl-[4-(1-chloro-4-vinylisoquinolin-5-yl)aminocyclohexyl]carbamateobtained in Step A mentioned above was used for the cyclization insteadof the trans-isomer of Intermediate 10 to obtain the title compound.

MS (m/z): 492 (MH+)

(Step C)Trans-1-(4-benzylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol

Concentrated hydrochloric acid was added with tert-butyltrans-N-benzyl-[4-(6-chloro-2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]carbamate,and stirred at 90° C. for 17 hours. After the reaction, the solvent wasconcentrated under reduced pressure to obtain the title compound as ahydrochloride.

MS (m/z): 374 (MH+)

(Step D) (Exemplary Compound No. 2-53)

According to the method of Example 21, Step E, thetrans-1-(4-benzylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-olobtained in Step C mentioned above was subjected to the debenzylationreaction instead of Intermediate 12 to obtain the title compound.

¹H-NMR (DMSO-d₆) δ (ppm): 1.60-1.80 (6H, m), 1.81 (2H, m), 2.74 (2H, m),3.02 (1H, m), 3.18 (2H, m), 3.71 (1H, m), 6.79 (1H, s), 6.98 (1H, d,J=8.1 Hz), 7.28 (1H, t, J=8.1 Hz), 7.43 (1H, d, J=8.1 Hz) MS (m/z): 284(MH+)

Example 78 Exemplary Compound No. 2-62

According to the method of Example 63, alkylation and deprotection wereperformed by using the compound obtained in Example 77 to obtain thetitle compound as a hydrochloride.

MS (m/z): 328 (MH+)

Example 79 Exemplary Compound No. 2-63

According to the method of Example 64, alkylation and deprotection wereperformed by using the compound obtained in Example 77 to obtain thetitle compound as a hydrochloride.

MS (m/z): 342 (MH+)

Example 80 Exemplary Compound No. 2-68

According to the method of Example 65, alkylation and deprotection wereperformed by using the compound obtained in Example 77 to obtain thetitle compound as a hydrochloride.

MS (m/z): 327 (MH+)

Example 81 Exemplary Compound No. 2-69

According to the method of Example 66, alkylation and deprotection wereperformed by using the compound obtained in Example 77 to obtain thetitle compound as a hydrochloride.

MS (m/z): 341 (MH+)

Example 82 Exemplary Compound No. 2-113

According to the method of Example 42, condensation with acetic acid wasperformed by using the hydrochloride obtained in Exemple 80 to obtainthe title compound as a hydrochloride.

MS (m/z): 369 (MH+)

Example 83 Exemplary Compound No. 2-114

According to the method of Example 42, condensation with propionic acidwas performed by using the compound obtained in Exemple 80 to obtain thetitle compound as a hydrochloride.

MS (m/z): 383 (MH+)

Example 84 Exemplary Compound No. 2-115

According to the method of Example 42, condensation with butyric acidwas performed by using the compound obtained in Exemple 80 to obtain thetitle compound as a hydrochloride.

MS (m/z): 397 (MH+)

Example 85 Exemplary Compound No. 2-116

According to the method of Example 42, condensation with isobutyric acidwas performed by using the compound obtained in Exemple 80 to obtain thetitle compound as a hydrochloride.

MS (m/z): 397 (MH+)

Example 86 Exemplary Compound No. 2-117

According to the method of Example 42, condensation with pivalic acidwas performed by using the compound obtained in Exemple 80 to obtain thetitle compound as a hydrochloride.

MS (m/z): 411 (MH+)

Example 87 Exemplary Compound No. 2-118

According to the method of Example 42, condensation with acetic acid wasperformed by using the hydrochloride obtained in Exemple 81 to obtainthe title compound as a hydrochloride.

MS (m/z): 383 (MH+)

Example 88 Exemplary Compound No. 2-119

According to the method of Example 42, condensation with propionic acidwas performed by using the compound obtained in Exemple 81 to obtain thetitle compound as a hydrochloride.

MS (m/z): 397 (MH+)

Example 89 Exemplary Compound No. 2-120

According to the method of Example 42, condensation with butyric acidwas performed by using the compound obtained in Exemple 81 to obtain thetitle compound as a hydrochloride.

MS (m/z): 411 (MH+)

Example 90 Exemplary Compound No. 2-121

According to the method of Example 42, condensation with isobutyric acidwas performed by using the compound obtained in Exemple 81 to obtain thetitle compound as a hydrochloride.

MS (m/z): 411 (MH+)

Example 91 Exemplary Compound No. 2-122

According to the method of Example 42, condensation with pivalic acidwas performed by using the compound obtained in Exemple 81 to obtain thetitle compound as a hydrochloride.

MS (m/z): 425 (MH+)

Test Example 1 Action on Amount of Phosphorylated Myosin RegulatoryLight Chain in the Cells

A volume of 50 to 100 ml of peripheral blood collected from healthyvolunteers was centrifuged by using Mono-Poly separator solution(Dainippon Pharmaceutical) to prepare a neutrophil containing fraction.The neutrophils were washed with PBS(−) and resuspended in Hanks'Balanced Salt Solution (HBSS+, Gibco) to prepare a cell suspension(8×10⁶/ml). The cell suspension was diluted to 5×10⁶/ml, introduced intoEppendorf tubes in a volume of 0.4 ml each, then 0.1 ml each ofsolutions of a test compound at various concentrations were added to thesuspension and allowed to react at 25° C. for 5 minutes. After thereaction, 0.1 ml of trichloroacetic acid solution was added to eachreaction, the reaction mixture was gently shaken and centrifuged at12,000 rpm (4° C., 5 minutes), and the supernatant was removed.Subsequently, 3 μl of 1 M Tris solution was added to the residue, themixture was further mixed with 50 μl of extraction buffer (8 M urea,0.02% 2-mercaptoethanol, 0.002% bromophenol blue) and left stand at roomtemperature for 1 hour. Then, the reaction mixture was loaded on a spincolumn (0.45 μm, Millipore) to remove the insoluble solids and a samplebuffer for SDS polyacrylamide gel electrophoresis (25 mM, Tris-HCl pH6.8, 2.5% 2-mercaptoethanol, 2% sodium dodecylsulfate, 5% sucrose,0.002% bromophenol blue as final concentrations) was added, and 10 μl ofeach sample was subjected to electrophoresis.

The gel after the electrophoresis was blotted on a nitrocellulosemembrane (BioRad), blocked with 5% skim milk, and reacted successivelywith antibodies pLC1 (Sakurada K. et al, Am. J. Physiol., 274,C1563-C1572 (1998)), which specifically recognize the phosphorylatedmyosin regulatory light chain, and donkey anti-mouse IgG (Chemicon)conjugated with horseradish peroxidase. The band of the phosphorylatedmyosin regulatory light chain was detected on a film by using ECL PlusKit (Amersham Pharmacia Biotech). This band was subjected toquantification using a densitometer. By using this value, the inhibitoryratio (%) for phosphorylation of the myosin regulatory light chain wascalculated by using the following equation. Phosphorylation inhibitionratio (%)=1-(Band intensity of phosphorylated myosin regulatory lightchain with addition of the test compound/Band intensity ofphosphorylated myosin regulatory light chain without addition of thetest compound)×100

Further, the phosphorylation inhibition ratio was calculated withchanging the concentrations of the test compound, and a compoundconcentration providing an inhibition ratio of 50% was obtained as IC₅₀.

The compounds of the present invention obtained in Examples 1, 11, 12,13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24, 31, 41 42, 47, 52, 53, 54,55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73,74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, and91 inhibited the phosphorylation of myosin regulatory light chain at aconcentration of 40 μM or less, and further, the compounds of Examples11, 12, 13, 14, 15, 21, 22, 24, 31, and 41 inhibited the phosphorylationof myosin regulatory light chain at a concentration of 10 μM or less.Further,trans-benzyl-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]amineinhibited the phosphorylation of myosin regulatory light chain at aconcentration of 40 μM or less.

Test Example 2 Vasoconstriction Inhibitory Action

Rats (Wistar, 11-week old) were bleeded to death and laparotomized totake out the thoracic aorta. That aorta was cut into a ring of a lengthof about 3 mm in a conventional manner (Asano, T., et al., J. Pharmacol.Exp. Ther., 241, pp. 1033-1040 (1987)) and hung in 10-ml organ bathfilled with Krebs-Hensright nutrient solution bubbled with a mixed gasof 95% O₂ and 5% CO₂. One end of the blood vessel was connected to anisometric transducer (FD Pickup TB-912T, Nihon Kohden) and applied with2.5 g of resting tension, and constriction and relaxation reactions ofthe aorta were recorded.

The aorta was constricted with phenylephrine (1 μM, Sigma) and thenadded with a test compound (1 μM), and the vasoconstriction inhibitoryaction thereof was observed. The vasoconstriction inhibitory actions ofthe test compounds were calculated as relaxation ratios, which werebased on the vasoconstriction with phenylephrine observed immediatelybefore the addition of the test compounds taken as 100%.

The compounds of the present invention obtained in Examples 16, 17, 19,20, 24, and 41 exhibited significant vasoconstriction inhibitory action.

Thus, it was confirmed that the compounds of the present invention wereuseful as medicaments for prophylactic and/or therapeutic treatment ofdiseases relating to cell contraction.

Test Example 3 Respiratory Tract Constriction Suppressing Action

Four-week old Hartley guinea pigs (male) were immunized byintraperitoneal administration of ovalbumin (Sigma, Grade V) in amountsof 1 mg for each animal on the day on which the experiment was started,3 mg for each animal after 2 days, and 10 mg for each animal after 4days.

Twelve to fourteen days after the final immunization, theovalbumin-immunized guinea pigs were anesthetized by intraperitonealadministration of about 40 mg/kg of pentobarbital (Somnopentyl), and thetracheas were taken out. Subsequently, a cannula (SP-110, Natsume) wasinserted into each trachea, and one end of the cannula was connected toan artificial respirator (Model-b83, Harvard). The aeration conditionswere set at 6 ml per kilogram and 60 times per 1 minute. Further, acannula for medicament administration (JMS wing needle 23G 3/4) wasinserted into a hind leg vein. Myoblock (Organon Technica) wasadministered in an amount of 0.5 mg/kg from the cannula inserted intothe hind leg vein to stop the spontaneous breathing, and after 2 or 3minutes, 0.3 mg/kg of ovalbumin was administered to induce constrictionof respiratory tract. The increase of airway resistance value 2 minutesafter the induction (measurement apparatuses: pressure transducerTR-603T, respiratory amplifier AR-601G, and recorder RTA-3100, NihonKohden Corp.) was confirmed to be above 80 cm H₂O or higher, and then, asolution of a test medicament was administered from the cannula insertedinto the hind leg vein, and the airway resistance value was continuouslymeasured for 15 minutes after the administration to determine theeffect. As a result, the compounds of the present invention obtained inExamples 11, 14, 15, 17, 20, and 24 significantly improved theconstriction of respiratory tract.

Further, the respiratory tract constriction suppression action of thetest compounds was also evaluated by inhalation. Twelve to fourteen daysafter the final sensitization, 10 mg/kg of pyrilamine (Sigma), 5 mg/kgof indomethacin (Wako), or 0.1 mg/kg of propranolol (Sigma) wasintraperitoneally administered. Then, 30 minutes after theadministration, a 0.1% ovalbumin aqueous solution was inhaled by using apressurization type nebulizer (PARI-IS2) to induce constriction of therespiratory tract. Ten minutes after the induction, 2 ml of a solutionof a test compound prepared at various concentrations was filled in theaforementioned nebulizer, and administered by inhalation over 5 minutes.After the administration of pyrilamine and other drugs, airwayresistance value was continuously measured to determine effectiveness.As a result, the compounds of the present invention obtained in Examples11, 14, 15, 17, 20, and 24 significantly improved the constriction ofrespiratory tract.

Therefore, it was confirmed that the compounds of the present inventionwere useful as medicaments for prophylactic and/or therapeutic treatmentof bronchial asthma and/or chronic obstructive pulmonary disease (COPD).

Test Example 4 Intraocular Pressure Reducing Action

A Japanese white rabbit having a body weight of about 2 kg was placed ina positioner and naturalized for one week before the experiment. Anophthalmologic local anesthesant (Benoxil) was administered to the lefteye, and then intraocular pressure was measured by using a tonometer(Classic 30, Solan). The initial value of the intraocular pressure wasmeasured, then 50 μl of an aqueous solution of a test compound wasdropped to the left eye at various concentrations, and the intraocularpressure was measured with passage of time. As a result, the compoundsof the present invention obtained in Examples 1, 11, 12, 13, 14, 15, 16,18, 19, 20, 21, 22, 31, 41, 42, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60,62, 63, 64, 67, 68, 69, 72, 73, 76, 77, 78, 79, 82, 83, 84, 87, 88, and91 exhibited significant intraocular pressure reducing action.

Thus, it was confirmed that the compounds of the present invention wereuseful as medicaments for prophylactic and/or therapeutic treatment ofglaucoma.

Test Example 5 Neurite Outgrowth Action

From 18 day-old Sprague-Dawley rats, cerebral hippocampal neurons wereprepared according to the method of Neuman et al. (Neuman, H. R. et al.,J. Neurosci., 22, pp. 854-862, 2002). The prepared neurons were culturedfor 24 hours according to the method of Tanaka et al. (Tanaka, H. etal., J. Cell Biol., 158 (2), pp. 321-329, 2002), then the medium wasexchanged with fresh medium, and test medicaments of variousconcentrations or equivalent amounts of vehicle were added. Twenty-fourhours after the addition of the medicaments, neurite length of eachneuron was measured for the medicament-added group and the no-additiongroup, and compared. The neurite length was evaluated according to themethod of Neuman et al. (Neuman, H. R. et al., J. Neurosci., 22, pp.854-862, 2002).

As a result, the compounds of the present invention obtained in Examples16, 17, 19, 20, 24, and 41 induced significant neurite outgrowth axisextension.

Thus, it was confirmed that the compounds of the present invention wereuseful as medicaments for prophylactic and/or therapeutic treatment ofspinal cord injury.

Test Example 6 Neutrophil Migration Inhibitory Action

Neutrophils were isolated from 50 to 100 ml of peripheral bloodcollected from healthy human donors by the method described in TestExample 1 to obtain a cell suspension (8×10⁶/ml). Subsequently,solutions of a test compound at various concentrations were introducedinto wells of a 96-well plate in a volume of 125 μl per well, the cellsuspension of an equivalent volume was added to it and the plate waspreincubated at room temperature for 5 minutes. During thepreincubation, FMLP (1 μM, Sigma) solution was added to the lowerchamber to set Boyden Chamber, the preincubated cell suspension wasadded to the upper chamber in a volume of 200 μl per well, and the cellswere allowed to migrate at 37° C. under 5% carbon dioxide for 30minutes. The filter after the migration was collected, and thenon-migrated cells adhered to the surface that faced the upper chamberwere carefully wiped off. Then, the migrated cells on the back surfacewere stained with DifQuick dye solution (International Reagents), washedwith water and dried, and then absorbance was measured at 595 nm. Theinhibition ratio against migration (%) of a test compound was calculatedby using the following equation:Migration inhibition ratio (%)=(1−Absorbance of the group with additionof test compound/Absorbance of the group without addition of testcompound)×100

Further, the migration inhibitory ratio was calculated with changing thetest compound concentration, and a compound concentration providing aninhibition ratio of 50% was obtained as IC₅₀. The compounds of thepresent invention obtained in Examples 1, 11, 12, 13, 14, 15, 16, 18,19, 20, 21, 22, 24, 31, 41, 42, 47, 52, 53, 54, 55, 56, 57, 58, 59, 60,62, 63, 64, 65, 66, 67, 68, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82,83, 84, 87, 88, 89, 90, and 91 inhibited the migration of neutrophils ata concentration of 40 μM or less, and further, the compounds of Examples1, 11, 12, 13, 14, 15, 19, 21, 22, 24, 31, and 41 inhibited themigration of neutrophils at a concentration of 10 μM or less. Further,trans-benzyl-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]amineinhibited the migration of neutrophils at a concentration of 40 μM orless.

Thus, it was confirmed that the compounds of the present invention wereuseful for prophylactic and/or therapeutic treatment of diseasesrelating to cell migration.

Test Example 7 Respiratory Tract Inflammation Suppressing Action

According to Henderson, W. R., et al., Am. J. Respir. Cric. Care Med.,165(1), 108-116 (2002), suppressing action on bronchial inflammation wasconfirmed. BALB/c female mice (7-week old) were used for the test, eachgroup consisting of 7 mice, and the control group consisting of 11 or 12mice. The mice were intraperitoneally administered with ovalbumin (OVA,100 ng, Sigma) and 1 mg of aluminum hydroxide for initial immunization,and after 2 weeks, they are subcutaneously administered with 10 ng ofOVA as additional immunization. After further 1 week, a test compoundwas dissolved in water containing 0.5% carboxymethylcellulose and orallyadministered (30 mg/kg) to the test animals once a day for 5 days. Thecontrol group was similarly given only with water containing 0.5%carboxymethylcellulose. After 1 hour, the mice were orally inhaled with2% OVA for 10 minutes to induce a respiratory tract inflammation.Further, the control group, in which the mice were not given with thetest compound, was divided into a positive control group (n=7), in whichthe mice were inhaled with 2% OVA to induce the reaction, and a negativecontrol group (n=4 or 5), in which the mice were similarly inhaled withphysiological saline. After 24 hours, alveoli in the lungs of the testanimals were washed with physiological saline, and the total infiltratedwhite blood cells (WBC) were counted.

As a result, the compounds of the present invention significantlyimproved the pathological conditions.

Thus, it was confirmed that the compounds of the present invention wereuseful as medicaments for prophylactic and/or therapeutic treatment ofbronchial asthma.

Further, no abnormality was observed in the test animals (mice) in a 5consecutive day administration test of these compounds, and thus theywere safe compounds.

Test Example 8 Pulmonary Inflammation Suppressing Action

According to Gonzales de Moraes, V L., et al., Br. J. Pharmacol., 123,pp. 631-6, 1998, suppressing action on pulmonary inflammation wasstudied. BALB/c female mice (7-week old) were used for the test, as thecompound administration group and positive control group, eachconsisting of 7 mice, as well as the negative control group consistingof 5 mice. For induction of inflammation, a 0.03% physiological salinesolution of a lipopolysaccharide (LPS, a mixture derived fromEscherichia coli O55 and B5 strains, Sigma) was used. A test compoundwas dissolved in physiological saline to prepare solutions of variousconcentrations. The test animals were first inhaled with theaforementioned lipopolysaccharide solution for 10 minutes by using apressurization type nebulizer (PARI-IS2) to induce inflammation. Then, 1minute after the completion of the inhalation of the lipopolysaccharidesolution, the animals were administered with a solution of test compoundat various concentrations over 10 minutes by inhalation using theaforementioned nebulizer. The mice of the positive control group wereadministered with the same volume of physiological saline instead of thetest compound solution over 10 minutes by inhalation. Three hours afterthe administration of the test compound, pulmonary cavities of the testanimals were washed with physiological saline, and the total infiltratedleucocyte (WBC) number was counted. As a result, the compounds of thepresent invention obtained in Examples 17, 19, 20, 24, and 41significantly improved the pathological condition.

Thus, it was confirmed that the compounds of the present invention wereuseful as medicaments for prophylactic and/or therapeutic treatment ofpneumonia.

Test Example 9 Action on Increase of Intracellular Calcium Concentration

According to the method described in Test Example 1, a neutrophilcontaining fraction was prepared. Fura2-AM (Sigma) at a finalconcentration of 3 μM was added to the human neutrophil fraction and themixture was incubated at 37° C. for 1 hour. After centrifugation (250 gfor 5 minutes), the supernatant was discarded, and the neutrophils wereresuspended in Hanks' Balanced Salt Solution (HBSS, Gibco) to prepare acell suspension (8×10⁶/ml) for measurement of intracellular calciumconcentration. The cell suspension for measurement of intracellularcalcium concentration was left stand at room temperature for 30 minutes.Then, 490 μl of the cell suspension for measurement of intracellularcalcium concentration was placed in a cuvette, 10 μl of calcium chloridesolution at a final concentration of 1 μM was added to it and thecuvette was set in an intracellular calcium concentration analyzer(CAF110, Nippon Bunko). FMLP (Sigma) solution at a final concentrationof 1 μM was added to the cell suspension, and F340 and F380, which arefluorescence intensity at 340 nm and 380 nm, respectively, were measuredto obtain an R value (F340/F380) as an index of the intracellularcalcium concentration. A test compound (1 μM) was added 3 minutes beforethe addition of fMLP, and the action on the intracellular calciumconcentration was observed. The ratios of the maximum R value obtainedwith addition of each test compound relative to the maximum R valueobtained without addition of test compound and taken as 100% wereobtained.

It was revealed that the compounds of the present invention had almostno effect on the increase of the intracellular calcium concentrationcaused by the fMLP stimulation.

Test Example 10 Action on Myosin Light Chain Kinase (MLCK) Activity

A myosin light chain kinase (MLCK) was purified from chicken gizzardsmooth muscle by a conventional method (Yoshida, M., et al., J.Biochem., 99, 1027-1036 (1986)). The myosin regulatory light chain as asubstrate was purified from the chicken gizzard smooth muscle by aconventional method (Grand, R. J., et al., Biochem. J., 211, 267-272(1983)). The MLCK activity was measured by ELISA (Sakurada, K., et al.,J. Biochem., 115, 18-21 (1994)) using anti-phosphorylated myosinregulatory light chain-recognizing antibodies (Sakurada, K., et al., Am.J. Physiol., 274, C1563-C1572, 1998). The myosin regulatory light chainwas diluted in phosphate-buffered saline (PBS, Sigma) to a concentrationof 5.0 g/ml, added to 96-well Immunoplate (Nunc) in a volume of 100 μlper well and left stand overnight at 4° C. Each well was washed withPBS, and 25 mM Tris/HCl buffer containing 100 μM ATP, 3 mM MgCl₂, 1 mMCaCl₂, 100 ng/ml of calmodulin (Sigma) and 100 ng/ml of MLCK (pH 7.4,Buffer A) was added to each well and incubated at 30° C. for 10 minutes.In a volume of 100 μl each of 20% aqueous phosphoric acid solution wasadded to each well to terminate the enzymatic reaction. Each well waswashed with 25 mM Tris/HCl buffer (TTBS) containing 0.1% Tween 20, andthen 100 μl of antibodies specifically recognizing phosphorylated myosinregulatory light chain (Sakurada, K., et al., Am. J. Physiol., 274,C1563-C1572, 1998) was added to each well and incubated at roomtemperature for 90 minutes.

Each well was washed with TTBS, and then 100 μl of the HRP-labeledanti-mouse IgG antibodies (Bio-Rad) were added to each well andincubated at room temperature for 90 minutes. Each well was washed withTTBS, and then 25 mM citrate buffer (pH 5.0) containingorthophenylenediamine (Sigma) as a substrate of HRP and aqueous hydrogenperoxide (0.03%) was added in a volume of 100 μl per well and incubatedat room temperature for 5 minutes. 50 μl of 4 N sulfuric acid was addedto each well to terminate the reaction, and then absorbance was measuredby using an immunoplate reader (Bio-Rad). The MLCK activity inhibitionratio was calculated by adding the test compound to Buffer A at variousconcentrations to obtain a compound concentration providing aninhibition ratio of 50% as IC₅₀.

It was revealed that the compounds of the present invention had almostno inhibitory effect on MLCK.

INDUSTRIAL APPLICABILITY

The compounds of the present invention represented by the formula (1)have an inhibitory action on phosphorylation of myosin regulatory lightchain, and are useful as active ingredients of medicaments forprophylactic and/or therapeutic treatment of, for example, diseasesrelating to contraction of various cells, diseases relating tomorphological change of various cells, diseases relating to migration ofvarious cells, diseases relating to release of various cells, diseasesrelating to aggregation of various cells, diseases relating to apoptosisof various cells, and diseases relating to abnormality of geneexpression in various cells.

1. A compound represented by the following formula (1) or a saltthereof:

wherein R¹ represents hydrogen atom, chlorine atom, or hydroxyl group;X¹ . . . X² represents —CH(R²)—CH(R³)—, —CH(R²)—CH(R³)—CH(R⁴)—,—C(R²)═C(R³)—, or —C(R²)═C(R³)—CH(R⁴)—; R², R³, and R⁴ independentlyrepresent hydrogen atom, or an alkyl group; A¹, A¹¹, A², and A²¹independently represent hydrogen atom, or an alkyl group; Y represents—CH(A³)-, —CH(A³)-C(A⁴)(A⁴¹)-, —CH(A³)-C(A⁴)(A⁴¹)-C(A⁵)(A⁵¹)-, or asingle bond; A³, A⁴, A⁴¹, A⁵, and A⁵¹ independently represent hydrogenatom, or an alkyl group; Z represents hydroxyl group, or —N(A⁶)(A⁶¹); A⁶represents hydrogen atom, or an alkyl group, A⁶¹ represents hydrogenatom, an alkyl group, an aralkyl group, an alkyl group substituted withcarboxyl group, an alkyl group substituted with cyano group, an alkylgroup substituted with hydroxyl group, an alkyl group substituted withan alkoxyl group, an alkyl group substituted with an amino group, analkyl group substituted with aminocarbonyl group, or an alkyl group ofwhich end is substituted with N(A⁷)(-X³-A⁷¹), where —X³— representscarbonyl group, A⁷ represents hydrogen atom, or an alkyl group, and A⁷¹represents an alkyl group, an aralkyl group, or an aryl group, or A⁷ andA⁷¹ may together become an alkylene group, or an alkylene groupsubstituted with an alkyl group to form a ring; and groups in each ofone or more combinations selected from the group consisting ofcombinations of A⁶ and A³, A⁶ and A⁴, A⁶ and A¹, A⁶ and A², A² and A³,A² and A⁴, A⁶ and A⁵, A³ and A¹, and A⁵ and A¹ may bind to each other toform a 5- or 6-membered ring.
 2. The compound represented by the formula(1) or salt thereof according to claim 1, wherein A⁶¹ is hydrogen atom,an alkyl group, an aralkyl group, an alkyl group substituted withcarboxyl group, an alkyl group substituted with cyano group, an alkylgroup substituted with hydroxyl group, an alkyl group substituted withan alkoxyl group, an alkyl group substituted with an amino group, or analkyl group substituted with aminocarbonyl group.
 3. The compoundrepresented by the formula (1) or salt thereof according to claim 1,wherein X¹ . . . X² is —CH(R²)—CH(R³)—.
 4. The compound represented bythe formula (1) or salt thereof according to claim 1, wherein R¹ ishydrogen atom.
 5. The compound represented by the formula (1) or saltthereof according to claim 1, wherein R¹ is hydroxyl group.
 6. Thecompound represented by the formula (1) or salt thereof according toclaim 1, wherein Y is a single bond, Z is —N(A⁶)(A⁶¹), and the groups ofA⁶ and A¹ bind to each other to form a 5- or 6-membered ring.
 7. Thecompound represented by the formula (1) or salt thereof according toclaim 1, wherein Y is —CH(A³)-, Z is —N(A⁶)(A⁶¹), and the groups of A⁶and A³ bind to each other to form a 6-membered ring.
 8. The compoundrepresented by the formula (1) or salt thereof according to claim 1,wherein Y is —CH(A³)-C(A⁴)(A⁴¹)-, Z is —N(A⁶)(A⁶¹), and the groups of A²and A³ bind to each other to form a 6-membered ring.
 9. The compoundaccording to claim 1, which is selected from the group consisting of thefollowings: (1) 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine;(2) N-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]-N-methylamine;(3) [4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]acetic acid;(4) 3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]propionicacid; (5)2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]ethanol; (6)3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]propanol; (7)N-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]ethylenediamine; (8)N-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]propane-1,3-diamine;(9)N-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]-N′-methylpropane-1,3-diamine;(10)N-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]-N-methylethylenediamine;(11)N′-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]-N,N-dimethylethylenediamine;(12)2-{[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]methylamino}ethanol;(13) 1-(4-aminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol; (14)1-(4-methylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol; (15)[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]aceticacid; (16)3-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamino]propionicacid; (17)1-[4-(2-hydroxyethylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(18)1-[4-(3-hydroxypropylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(19)1-[4-(2-aminoethylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(20)1-[4-(3-aminopropylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(21)1-[4-(2-(methylamino)ethylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(22)1-[4-(3-(methylamino)propylamino)cyclohexyl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(23)1-{4-[(2-hydroxyethyl)methylamino]cyclohexyl}-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(24)1-{4-[(3-hydroxypropyl)methylamino]cyclohexyl}-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(25) 1-(3-pyrrolidinyl)-2,3-dihydro-1H-1,5-diazaphenalene; (26)[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]acetic acid; (27)3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propionic acid;(28) 2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethanol;(29) 3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propanol;(30)2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethylamine;(31)3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propane-1,3-diamine;(32)N-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}-N-methylamine;(33)N-{3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propyl}-N-methylamine;(34) 1-(3-pyrrolidinyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol; (35)[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]aceticacid; (36)3-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propionicacid; (37)1-[1-(2-hydroxyethyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(38)1-[1-(3-hydroxypropyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(39)1-[1-(2-aminoethyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(40)1-[1-(3-aminopropyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(41)1-[1-(2-methylaminoethyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(42)1-[1-(3-methylaminopropyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(43)1-[1-(2-dimethylaminoethyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(44)1-[1-(3-dimethylaminopropyl)pyrrolidin-3-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(45)N-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}acetamide;(46)N-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}propionamide;(47)N-{3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propyl}acetamide;(48)N-{3-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propyl}propionamide;(49)N-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}acetamide;(50)N-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}propionamide;(51)N-{3-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propyl}acetamide;(52)N-{3-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]propyl}propionamide;(53) 1-(4-piperidinyl)-2,3-dihydro-1H-1,5-diazaphenalene; (54)[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]acetic acid; (55)3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propionic acid;(56) 2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethanol;(57) 3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propanol;(58) 2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethylamine;(59)3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propylamine;(60)N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}-N-methylamine;(61)N-{3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propyl}-N-methylamine;(62) 1-piperidin-4-yl-2,3-dihydro-1H-1,5-diazaphenalen-6-ol; (63)[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]aceticacid; (64)3-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propionicacid; (65)1-[1-(2-hydroxyethyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(66)1-[1-(3-hydroxypropyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(67)1-[1-(2-aminoethyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(68)1-[1-(3-aminopropyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(69)1-[1-(2-methylaminoethyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(70)1-[1-(3-methylaminopropyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(71)1-[1-(2-dimethylaminoethyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(72)1-[1-(3-dimethylaminopropyl)piperidin-4-yl]-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(73)N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}acetamide;(74)N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}propionamide;(75)N-{3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propyl}acetamide;(76)N-{3-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propyl}propionamide;(77)N-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}acetamide;(78)N-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}propionamide;(79)N-{3-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propyl}acetamide;(80)N-{3-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]propyl}propionamide;(81)trans-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexyl]dimethylamine;(82)trans-1-(4-dimethylaminocyclohexyl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol;(83)N-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}N-methylacetamide;(84)N-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}-N-methylacetamide;(85)1-{2-[3-(2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}azetidin-2-one;(86)1-{2-[3-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)pyrrolidin-1-yl]ethyl}azetidin-2-one;(87)N-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}-N-methylacetamide;(88)N-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}-N-methylacetamide;(89)1-{2-[4-(2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}azetidin-2-one;(90)1-{2-[4-(6-hydroxy-2,3-dihydro-1,5-diazaphenalen-1-yl)piperidin-1-yl]ethyl}azetidin-2-one;(91) 1-(3-fluoropiperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalene; and(92) 1-(3-fluoropiperidin-4-yl)-2,3-dihydro-1H-1,5-diazaphenalen-6-ol.10. A medicament comprising a compound represented by the formula (1) ora physiologically acceptable salt thereof according to claim 1 as anactive ingredient, and further comprising a pharmaceutical additive asrequired.
 11. The medicament according to claim 1, which is forinhibiting phosphorylation of myosin regulatory light chain.
 12. Themedicament according to claim 1, which is for inhibiting Rho/Rho kinasepathway.
 13. The medicament according to claim 1, which is used forprophylactic and/or therapeutic treatment of glaucoma.
 14. Themedicament according to claim 1, which is used for prophylactic and/ortherapeutic treatment of bronchial asthma and/or chronic obstructivepulmonary disease.
 15. The medicament according to claim 1, which isused for prophylactic and/or therapeutic treatment of a nervedysfunction.
 16. An inhibitor of the phosphorylation of myosinregulatory light chain, which comprises a compound represented by theformula (1) or a salt thereof according to claim
 1. 17. An inhibitor ofthe Rho/Rho kinase pathway, which comprises a compound represented bythe formula (1) or a salt thereof according to claim 1.